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Synopsis: In the Overview section of this supplement, recovering
drug user Harry L. Simpson delivers a moving call to pharmacists for com-
passion, cooperation, and care for injection drug users (IDUs). Describing
his years of addiction following service in the Vietnam War, Simpson puts
a human face on the real challenges and dilemmas faced each day by the
hundreds of thousands of IDUs in cities and towns across America.
Analysis: Pharmacists can be key players in reducing epidemics of
HIV and hepatitis B and C among IDUs, supplement guest editors T.
Stephen Jones and Phillip O. Coffin explain in their overview. To help
pharmacists, several obstacles must be addressed, including pharmacists’
attitudes, state laws and regulations, and education of IDUs.
See pages S6 and S10.
Synopsis: If pharmacists are to sell sterile syringes and needles to
IDUs, a primary concern is legality. This survey of laws and regulations
shows that such sales are clearly legal in 20 states and can be reasonably
interpreted as legal in 22 other states. Such sales are clearly illegal in 11
states, including three states where such sales are illegal even with a pre-
scription.
Analysis: A comprehensive public policy of ensuring syringe access
for IDUs who cannot or will not abstain from drug use requires eliminat-
ing legal barriers to the sale, possession, and disposal of syringes. Equally
important, however, is educating pharmacists and law enforcement offi-
cials about the value of sterile syringe access in the effort to reduce the
transmission of HIV and other blood-borne diseases.
See page S13.
Synopsis: Two state boards of pharmacy have dealt directly with the
issue of pharmacists’ sales of sterile syringes and needles to IDUs. The
Washington State and Maine boards took the position that selling syringes
to IDUs to help prevent blood-borne infections was a legitimate medical
and pharmacy practice and worked with the state legislatures to pass new
laws.
Analysis: Cooperation among the boards, pharmacy professional
associations, and schools of pharmacy was essential in these efforts.
Similar board of pharmacy activities in other states may help increase
syringe availability and reduce transmission of blood-borne infections.
See pages S23 and S24.
Synopsis: In addition to improving options for IDUs, expanded
pharmacy access to syringes benefits patients with other health care needs.
New York State’s Expanded Syringe Access Demonstration Program
(ESAP) has worked with patients with diabetes in its outreach efforts,
including educational programs and promotional materials.
Analysis: ESAP offers a model for other states seeking to reduce the
transmission of blood-borne diseases among IDUs and increase access for
patients of all types who need sterile syringes and needles. With ESAP and
improved access programs in Seattle and New Mexico, pharmacists’
awareness of this public health need and their own participation in mak-
ing sterile syringes available increased following education and outreach
efforts.
See pages S26, S28, S29, and S32.
Continued on page S5.
In This Issue …
[Drug users are] people like us.
They’re our brothers, our sisters,
our mothers, our fathers, our
friends, our lovers. They are 
people like you and people like me.
Legality of Sale of Syringes by a Person Who Knows the
Syringes Will Be Used to Inject Illegal Drugs, 2002
Reasonable Claim
Clearly Legal to Legality Clearly Illegal
(n = 20) (n = 22) (n = 11)
aSale clearly legal or has a reasonable claim to legality in pharmacy only.
AK, CT,a HI,a IN, a
LA,a ME,a MN,a
MT,a NH,a NM,a
NY,a OH,a OR, PR,
RI,a SC,a TN,a WV,a
WA,a WI
AL,a AR, AZ, CO, FL,
ID, IA, KY, MD,a MI,
MO, MS, NE, NV,a NC,
ND, OK, SD, TX, UT,
VA,a WY
CA, DE, DC, GA,
IL, KS, MA, NJ,
PA, VT, VI
A 1999 Maine pharmacy
board ruling affirmed that sell-
ing sterile syringes to IDUs is a
legitimate medical and pharmacy
practice.
[Patients with diabetes] can
now purchase up to 10 syringes
at a time, without a prescription,
and they benefit from new,
improved options for safe syringe
disposal.
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Synopsis: As ESAP was implemented, support for the program
increased among pharmacists in high-drug-use neighborhoods of New
York City. Compared with opinions just after the enabling law was passed,
larger proportions of supporters of the law viewed benefits more positive-
ly and indicated that potential problems were not as important as previous-
ly believed.
Analysis: The full spectrum of pharmacists’ and pharmacy students’
opinions about IDUs and syringe access and disposal are illustrated in the
articles in the Pharmacists’ Attitudes section of the Journal. Written sur-
veys, focus groups, and interviews were conducted in a pharmacy school
and among pharmacists in Atlanta, Denver, Colorado, Connecticut,
Kentucky, Missouri, and Rhode Island.
See pages S34, S40, S46, S52, S58, and S62.
Synopsis: ESAP began on January 1, 2001, and IDUs quickly rec-
ognized participating pharmacies as important sources of sterile syringes
and needles. In the research shown here, more IDUs attempted to purchase
syringes in pharmacies after ESAP was implemented, and more of those
attempting purchases were successful. In another study designed to mea-
sure syringe access, 69% of purchase attempts at participating pharmacies
were successful, although not all ESAP elements were provided routinely.
No differences in success of syringe purchases were observed based on the
customer’s age, gender, or race/ethnicity.
Analysis: The studies in this section show that pharmacies can and
do serve as HIV-prevention service providers and sources of sterile
syringes for IDUs.
See pages S68, S73, S77, S83, S88, and S92.
Synopsis: Going hand in hand with improved syringe access are
better systems of sharps disposal. As illustrated by the quantity of
sharps that were diverted from household waste in Brown County,
Wisconsin, large amounts of used syringes and needles are generated in
the community. Green Bay-area pharmacies have provided convenient
locations where sharps can be collected for pick-up. In fact, 19 of 31
(61%) collection stations are pharmacies.
Analysis: Their number and convenience make pharmacies
prime sites for sharps disposal. Patients with diabetes and other con-
ditions that require injections—who frequent pharmacies—use this
disposal option in those areas where programs have been established.
IDUs need to have access to these disposal options as well, if public
health benefits of safe disposal are to be realized.
See pages S113 as well as S108, S109, S111, S114, S116, and
S117.
Synopsis: For IDUs, a key disincentive to the use of safe dispos-
al options are the laws of many states and U.S. territories, which make
possession of drug paraphernalia illegal. As shown here, most jurisdic-
tions have laws making it illegal to possess syringes for injecting ille-
gal drugs and laws forbidding possession of the residual drug in used
syringes. Only two states, Hawaii and Rhode Island, have no legal bar-
riers that deter IDUs from safely disposing of used syringes.
Analysis: Pharmacists can be effective advocates for removal of
legal barriers so that workers and others are not exposed to used
syringes in household garbage and in public places. In states with
either or both types of these laws, IDUs understandably fear arrest,
and this leads to unsafe disposal habits, endangering the public and
sanitation workers in particular.
See pages S94 and S99.
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Statistically Significant Changes in Law Supporters’
Opinions Before and After Implementation of ESAP in
New York City
Baseline After Law Change
% Respondents % Respondents 
Opinion Topic (n = 27) (n = 50)
Benefits
Important part of 
HIV prevention 63.0 91.7
Decrease HIV transmission 51.9 77.5
Detriments
Increase other 
customers’ discomfort 40.7 23.3
Increase drug use 40.7 24.1
IDUs’ Attempts and Purchases of Syringes from
Pharmacies, New York City, 2001-2002
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Pharmacists can play a key role in preventing the major blood-
borne infections caused by human immunodeficiency virus (HIV),
hepatitis C virus, and hepatitis B virus. Specifically, pharmacists
are able to contribute to community-level disease prevention ini-
tiatives by providing patient counseling (including information on
safe needle disposal and substance abuse treatment) and by selling
condoms, sterile syringes, and HIV treatment medications.
Pharmacists, by increasing access to sterile syringes, can also help
reduce the risk for transmission of blood-borne infections among
injection drug users (IDUs) and, by participating in community
needle disposal programs, decrease the chance that others will be
infected through needle-stick injuries.
Stopping drug use and entering substance abuse treatment are
recommended for all IDUs.1 For IDUs who continue to inject, the
use of new, sterile syringes is recommended to help prevent blood-
borne infections.1,2 Pharmacies can be reliable sources of sterile
syringes for IDUs, particularly compared with “street” syringe
sellers who, at times, sell repackaged, previously used syringes.3,4
However, laws and regulations limit access to sterile syringes.5 For
example, Georgia state pharmacy board regulations prohibit sell-
ing syringes for an “illegal purpose,”6 making Georgia 1 of 10
states in which it is clearly illegal for a pharmacist to sell syringes
to an IDU.5 This regulation affects pharmacists’ decisions about
selling syringes to persons who may be IDUs.6,7
In New Hampshire, New York, Rhode Island, and Washington,
attempts to pass syringe deregulation bills were defeated in sever-
al sessions of the legislatures before being passed and becoming
law.8,9 The ultimately successful passage of deregulation legisla-
tion in these states can be attributed to broad cooperation and
active support from professional organizations (particularly phar-
macists and physicians), boards of pharmacy, HIV prevention
groups, health departments, schools of public health, and sub-
stance abuse treatment programs. These collaborations have con-
tinued with the new goal of promoting widespread acceptance of
the new laws.
Pharmacists’ Attitudes and Practices
Differ
Surveys and in-depth studies of the attitudes of pharmacists and
pharmacy students about selling syringes without a prescription to
IDUs have repeatedly found pharmacists to be divided into three
groups: one that strongly favors such sales, a second that vigor-
ously opposes such sales, and a third that is unsure.6,10–13 These
positions result from an interaction of individual factors (e.g.,
beliefs that selling syringes conflicts with efforts to reduce drug
use) and structural issues (e.g., regulations that limit syringe
sales).6
To increase pharmacy syringe sales to IDUs, the Maine and
Washington state boards of pharmacy clearly stated that preven-
tion of blood-borne infections was a legitimate medical purpose
for such sales.9,14 In four states that deregulated syringe sales
(Minnesota, New Mexico, New York, and Washington), depart-
ments of public health led multipronged, multiyear efforts to pro-
mote pharmacy sales of syringes without a prescription.12,15–17 The
partners in the successful deregulation efforts joined in the sus-
tained efforts to promote acceptance of the new laws. Parallel out-
reach efforts informed IDUs about the new laws and about which
pharmacies were selling syringes without a prescription.15–17 Such
Preventing Blood-Borne
Infections Through Pharmacy
Syringe Sales and Safe
Community Syringe Disposal
This supplement to the November–December 2002
issue of JAPhA highlights pharmacy and public
health cooperation to increase pharmacy syringe
sales to injection drug users and to promote safe
community syringe disposal.
T. Stephen Jones and Phillip O. Coffin
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sustained promotional efforts may be needed for pharmacists and
IDUs because the reluctance to sell syringes to IDUs and to buy
them from pharmacies is deeply ingrained from decades of restric-
tive laws and regulations.
IDUs would prefer to obtain syringes from pharmacies and, at
least in some locations, do so.18,19 Removing legal and regulatory
barriers to IDUs purchasing and possessing syringes has helped
change the attitudes and practices of pharmacists and IDUs in sev-
eral states. When syringe laws and regulations were deregulated in
New York, Minnesota, and New Hampshire, pharmacists’ will-
ingness to sell syringes and the number of pharmacy syringe sales
without prescriptions increased, and IDUs purchased more
syringes from pharmacies.8,15,20,21 Minnesota researchers docu-
mented a reduction in HIV risk behaviors among IDUs 1 year after
the law change.22
In Minnesota, New Hampshire, and New York, the deregulation
bills included provisions mandating evaluation of the impact of the
legal changes. Systematic evaluation of these syringe deregulation
“natural experiments” will substantially expand our understanding
of the effects of changing syringe laws. The extensive evaluation
of the New York Expanded Syringe Access Demonstration
Program (ESAP), supported by the National Institutes of Health
and the Centers for Disease Control and Prevention, will be par-
ticularly valuable. Four papers in this supplement examine the
effects of ESAP.20,21,23,24
People with Diabetes Benefit From
Syringe Deregulation and Safer
Syringe Disposal
The primary goal of syringe deregulation is to prevent blood-
borne infections by increasing the number of sterile syringes avail-
able to IDUs. Brochures provided by pharmacists to persons pur-
chasing syringes without a prescription are usually written with
IDUs in mind, providing information about substance abuse treat-
ment and safer injecting practices.15,17,25 In New York, however,
HIV prevention program staff realized that ESAP also benefited
people who used insulin to treat their diabetes (e.g., they may not
have easy access to a physician to obtain prescriptions for
syringes26). The New York health department programs for HIV
prevention and diabetes brought in diabetes educators and diabetes
groups to help adapt ESAP options for people using insulin.27
People with diabetes made it clear that they saw ESAP as useful
for themselves but found the ESAP materials written for IDUs to
be offensive. Therefore, the health department designed new mate-
rials and promotional matter to address the issues of people who
use insulin. The New York experience demonstrates that syringe
deregulation can benefit people who are not IDUs and that adapt-
ing the messages and outreach may increase use of deregulated
syringe access and broaden public support.
Syringe Deregulation Catalyzes Safe
Community Syringe Disposal
IDUs and people who use insulin account for several billion
injections a year in the United States.28,29 Most of these needles
and syringes presumably end up in household trash. Concern about
unsafe syringe disposal by IDUs was often raised during legisla-
tive consideration of syringe deregulation bills.8,15,30 The concern
was that increasing the number of syringes in the hands of IDUs
could lead to increases in unsafely discarded syringes, raising the
specter of children picking up these discarded syringes. That con-
cern led to including syringe disposal elements in the deregulation
bills.15,30 As a result, public health departments and HIV preven-
tion organizations became actively involved in improving dispos-
al options.17,30 In addition to the states where syringe deregulation
efforts helped stimulate syringe disposal programs,8,12,15,17,30 inter-
est in community-level safe syringe disposal has been heightened
by concerns about worker (particularly those working with trash)
safety31–34 and changes in state laws affecting syringe disposal.35,36
Expanded Community-Generated
Syringe Disposal Programs are
Needed
While disposal of syringes from medical care facilities is exten-
sively regulated, disposal of community-generated syringes has
generally been exempted from regulation and not given a high
public health priority. Disposal of syringes in household trash is
recommended by the Environmental Protection Agency.37 This
option, however, puts solid waste workers, workers who hand pick
recyclable materials out of trash, and custodial workers (e.g., those
who collect trash from public restrooms)34 at risk for needle-stick
injuries and, potentially, blood-borne infections.38 To ensure safe-
ty for these workers, the public health goal is no syringes and other
sharps in trash.
Disposal programs described in this supplement typically
involve collaborations of multiple community sectors, including
local government, pharmacists, environmental health agencies,
solid waste authorities, diabetes groups, health care facilities,
infectious waste haulers, and fire departments.30–33,36 The environ-
mental health or solid waste public agencies often organize the
efforts. Donations and contributions from involved agencies33,36
and funding from the local solid waste management budget
finance them.32,33,36
Because pharmacists sell many of the syringes used outside of
health care settings, they are well positioned to help their patients
by (1) providing advice and information on safe disposal, (2) pro-
viding sharps containers for sale or free, (3) accepting used
syringes for safe disposal, or (4) referring patients to sites for safe
syringe disposal. Pharmacists have proven to be central players in
designing and maintaining most community disposal pro-
grams.15,30,32,33,36 More importantly, pharmacy-based “take back”
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programs can recover substantial numbers of used syringes (e.g.,
an estimated 900,000 syringes per year in Brown County,
Wisconsin and 2 million per year in San Francisco).32,36
However, most programs appear to recover only a relatively
small proportion of all syringes used outside health care facilities.
To reach the goal of no syringes and other sharps in trash and
unsafely discarded in the community, major changes in both pub-
lic attitudes and the scale of safe disposal options are needed. New
personal and social norms must be promoted so that placing used
syringes in residential trash or other unsafe locations becomes
socially unacceptable. Easy-to-use, inexpensive, inconspicuous
disposal options must be readily available. Placing syringe dispos-
al units in public places (e.g., in pharmacies30,31 and in airport bath-
rooms34) is likely to increase public consciousness of safe syringe
disposal. In addition, greater consistency of syringe disposal regu-
lations among the states could substantially reduce confusion
about how to safely dispose of syringes.38
IDUs Risk Arrest If They Safely
Dispose of Syringes
Because syringe exchange programs (SEPs) usually have
some legal or informally agreed-upon protection for clients,
IDUs use SEPs to obtain new syringes. Since SEPs usually
require that used syringes be turned in to receive new ones, these
programs capture millions of used syringes a year (e.g., 19 mil-
lion in 1998).40 However, IDUs may face substantial legal threats
if they attempt safe syringe disposal in other ways. Because of
the nearly ubiquitous drug paraphernalia and drug possession
laws, an IDU can be at risk for arrest for possession of a syringe,
particularly one that might contain even minute quantities of
drug residue.41 These penalties make IDUs cautious, if not fear-
ful, about collecting and then transporting their used syringes to
a safe disposal site.42 For community syringe disposal efforts to
be successful and to gain full participation by IDUs, disposal
programs must be available and accessible to IDUs and the legal
obstacles must ultimately be addressed.
Conclusion
Several conclusions emerge from the reports in this supplement.
First, the efforts to change laws to deregulate syringes, promote
acceptance of the new laws, and develop systems to keep sharps
out of solid waste appear to have been most successful when they
involved wide community coalitions. Second, pharmacists usually
play important roles in these coalition efforts. Third, these efforts
must be available to IDUs. Finally, we must continue to evaluate
these efforts to ensure that they are achieving the intended public
health outcomes.
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American Pharmaceutical Association Policies on Syringe Access
and Syringe Disposal
1999 APhA encourages state legislatures and boards of pharmacy to revise laws and regulations to permit the unrestricted
sale or distribution of syringes and needles by or with the knowledge of a pharmacist in an effort to decrease the
transmission of blood-borne diseases.
2001 APhA supports collaboration with other interested health care organizations, public health and environmental health
groups, waste management groups, syringe manufacturers, health insurers and patient advocacy groups to develop and
promote safer systems and procedures for the disposal of used needles and syringes by patients outside of healthcare
facilities.
P O L I C Y  S T A T E M E N T
FEATURE
Injection Drug Users and
Pharmacists: A Call for
Compassion, Cooperation, 
and Care
A recovering injection drug user calls on
pharmacists to help.
Harry L. Simpson
Based on a talk delivered to a meeting co-sponsored by the
American Pharmaceutical Association, the Centers for Disease
Control and Prevention, and the National Association of Boards
of Pharmacy on HIV Prevention and the Role of Pharmacists in
the Sale of Sterile Syringes, San Antonio, Texas, March 3–4, 1999.
As the executive director of the largest minority-operated
acquired immunodeficiency syndrome (AIDS) service organiza-
tion in Michigan and a person who has wrestled with the issue of
access to sterile syringes from both personal and professional per-
spectives, I will attempt to represent both active drug injectors and
the community-based providers who work with them. In doing so,
I hope to (1) provide a better understanding of what it’s like to be
in the grip of addiction, (2) describe what it’s like for a drug injec-
tor to try to buy syringes from a pharmacist, and (3) enlist your
assistance in preventing further spread of human immunodeficien-
cy virus (HIV).
Syringe Access: A Legal Framework
Michigan law allows an individual to purchase syringes and
needles (referred to hereafter as “syringes”) from pharmacies with-
out a prescription. Under Michigan law, pharmacists make the
final decision about selling syringes, and often refuse to sell to per-
sons who do not appear to have a “legitimate medical need.” State
law also criminalizes syringe possession and possession of “drug
paraphernalia” for the injection of any illegal substance.
Each county in Michigan has the option of regulating the sale of
drug paraphernalia. Some have enacted restrictions that specify
that individuals cannot purchase syringes without a prescription.
Others have no enforced restrictions. Since the 1960s, a local para-
phernalia ordinance in Detroit, which makes drug paraphernalia
possession a crime, has been rigorously enforced. This restriction
on syringe access was estimated to have contributed to as many as
3,000 AIDS cases in Detroit between 1986 and 1996 (George
Gaines, MPH, written communication, July 1997).
Because pharmacy syringe sales without a prescription are legal
in Michigan, people often assume that drug users in the state have
adequate access to sterile injection equipment. In 1997 colleagues
and I surveyed pharmacy syringe sale practices in Detroit. We
sought to verify information from drug injectors stating that one
must convince a pharmacist that one is not an injection drug user
to purchase a syringe. We randomly selected 60 Detroit pharma-
cies. Study staff made two attempts to purchase syringes at each
pharmacy. The study staff included African American and white
men and African American and white women. At each pharmacy,
the study staff making the two buy attempts were either an African
American man and a white woman or an African American
woman and a white man. Fifty-eight percent of the attempts were
successful (Peter Lurie, MD, written communication, September
1998). Our study demonstrated that, despite state law, syringes are
difficult to purchase from Detroit pharmacies.
Even if users are able to purchase them in pharmacies, syringes
become “drug paraphernalia” the instant they leave the store, and
users can then be arrested for possessing these legally purchased
syringes. Thus drug users, fearing prosecution under Michigan’s
paraphernalia law, often turn to easier methods of acquiring
syringes—easier, but riskier from a health standpoint.
If not from pharmacies, where else do drug users get syringes?
They rent them from “shooting galleries” where many users go to
inject drugs. They get them from drug houses when they purchase
drugs. They get them from illegal, unlicensed stores in homes
located near known drug-selling areas. These stores sell syringes,
pipes for smoking crack, stems, and other drug paraphernalia.
Drug users may purchase them from “street sellers,” often users
themselves, who are able to obtain large quantities of syringes.
There’s no guarantee that these rented or purchased syringes are
new; in fact, they have likely been used.1
Obtaining syringes from pharmacies is difficult because many
S10 Supplement to the Journal of the American Pharmaceutical Association November/December 2002    Vol. 42, No. 6, Suppl. 2
Detroit pharmacists—while rightfully exercising their discretion
about selling syringes—require proof of illness, ask intrusive ques-
tions, require photo identification, or deny sales to persons who do
not appear to have a “legitimate medical need.” These barriers may
appear small to the pharmacist but are significant for users and are
likely to limit substantially the number of drug users who attempt
to buy syringes from pharmacies.
“Drug Users Are People Like Us”
What about the drug users whose lives we are trying to save?
Who are these “addicts”? What are their lives like? Why do they
do what they do?
They are people like us. They’re our brothers, our sisters, our
mothers, our fathers, our friends, our lovers. They are people like
you and people like me.
I began using drugs during the summer of 1968 as an 18-year-
old tank crewman serving my country in the Republic of Vietnam.
When I returned from that country a year later, I had a Purple Heart
for wounds received in battle, an Army Commendation Medal for
Valor, and a heroin addiction that controlled my life for the next
14 years.
Every hour, every minute, every second of every day for those
14 years I was consumed with an overpowering need to feed the
monkey that was on my back. It was no longer a matter of getting
“high”—it was about survival. Every ounce of me wanted to avoid
the horrible pain of withdrawal. I felt like I would die if I didn’t get
that next fix.
In the vernacular of the street, I was a “junkie.” Not an addict, not
a user—a junkie. According to the code of the streets, junkies, unlike
users and addicts, couldn’t hold down jobs, had little or no family
support, and would kill for heroin. I was a junkie. I had no job, no
support, no home, nowhere to go, no hope, no future, nothing but
this huge habit that had to be fed at least three times each day.
I shot dope each and every day, several times a day. Some days
were better than others. On those days, I would shoot up maybe
seven or eight times. The more drugs I could get my hands on, the
more drugs I would shoot. Most days I would cop (purchase drugs)
and then go to the shooting gallery to inject. It was on the same
block where I bought my dope, so it was convenient. The needles
and syringes that they rented were never new. They sat on a table
in the middle of the room in a glass of pink-tinted water. They
weren’t in very good shape either. You had to look to find a set that
wasn’t clogged. The needles were always dull and, more often
than not, had burrs on them from being used so many times.
I was busted once for carrying syringes, so after that, I never
carried them. The time I was busted, the police beat me pretty
badly. After they stopped me, they asked if I was carrying syringes
and I, of course, said “no.” I was afraid to say “yes” because they
would have taken me to jail. After I said “no,” they searched me,
found the syringes, beat me, and then took me to jail. So I stopped
carrying syringes, and I got them from wherever I could: shooting
galleries, another user, whatever. Most of the time the syringes I
used to inject were shared with someone else or had been used
before by someone else. I knew this was dangerous; I had heard
about hepatitis and abscesses, but these were not high on my list of
things to worry about.
Recovery from addiction was something that other people did. I
wanted to kick this habit but didn’t know how. My first treatment
experience was in a 16-week residential program that specialized
in treating alcoholism. I had to say I was an alcoholic to get in,
even though I didn’t think I was, because they wouldn’t treat you
if you were only a heroin addict. I relapsed in the 16th week and,
of course, they threw me out because it was an abstinence-based
program. If you couldn’t abstain, you were out, period.
There were many more treatment experiences after that—
methadone maintenance, outpatient, inpatient, therapeutic com-
munities, hospitals, medical detoxification, and psych wards. You
name it, I tried it. None of them worked for me—at least not then.
I entered treatment the final time on September 8, 1984, and I
became the Executive Director of Community Health Awareness
Group in Detroit, one of Michigan’s oldest and largest HIV-pre-
vention agencies. I led a staff of 26 people, nearly one-half of them
recovering drug users themselves, and managed an annual operat-
ing budget of more than $1 million.
Curbing Blood-Borne Diseases
Among Injection Drug Users
I tell you this story—my story—so that you can put a face on
the suffering users  we are trying to help. Although it is a face that
truly only a mother could love, it is the face of drug users all over
this country: users whose lives are in grave danger because they
are injecting heroin or cocaine with used and possibly HIV- or
hepatitis-contaminated syringes. Those are the lives that I am ask-
ing pharmacists to help save.
We must recognize and accept that the dual epidemics of
HIV/AIDS and substance abuse call for an approach much broad-
er than making absolute abstinence the only measure of success.
Abstinence from drugs is a life-long commitment that is fraught
with both successes and failures. Treatment seldom works the first
time, and success varies from individual to individual. We must
also recognize that drug addiction is a chronic, relapsing, but treat-
able disorder. Most drug addicts relapse or “slip” after they try to
stop using drugs, start recovery, and attempt to remain abstinent
for the rest of their lives. Many users will go through multiple
treatment experiences and multiple relapses. Thus, access to ster-
ile syringes will always be necessary, even if drug treatment pro-
grams are universally available, because relapses are common
among drug users and because many people in drug treatment con-
tinue to inject drugs.
Particularly damaging to our efforts to curb the spread of injec-
tion-related AIDS and hepatitis B and C is the perception that pro-
viding sterile needles to active drug users undermines efforts to
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prevent the use of illegal drugs in our communities. Some insist
that providing sterile syringes promotes drug use, drug-related 
violence, gang wars, and chaos. Others suggest that funds for clean
needle programs might be better spent on drug treatment, as
though a choice must be made between stopping AIDS and treat-
ing addiction. These perceptions have never been supported by
science: no studies have ever demonstrated that access to sterile
syringes promotes the use of illegal drugs. But the fears raised by
these perceptions have prevented many of us from implementing
strategies that, according to exhaustive research, will save tens of
thousands of lives.2 Clearly, more funding needs to be directed to
drug treatment efforts, and the availability of drug treatment needs
to be expanded greatly. But the current restrictions on syringe
access seriously hamper our efforts to stop the spread of HIV, and
expose far too many injection drug users, their sexual partners, and
their children, to AIDS.
In May 1997, the U.S. Public Health Service published the HIV
Prevention Bulletin: Medical Advice for Persons Who Inject Illicit
Drugs.3 The bulletin, a joint effort of several federal agencies,
summarized the latest information on preventing the transmission
of HIV and other blood-borne infections among injection drug
users. According to the bulletin, “Drug injectors who are unable or
unwilling to stop or enter a drug treatment program…can reduce
their risks of blood-borne transmission and other serious health
problems by never reusing or ‘sharing’ syringes.”3 This text makes
clear one very important fact: for active drug injectors, sterile
syringes are indeed a legitimate medical need.
Increased access to sterile syringes is not the total solution, but
rather a critical part of a comprehensive approach that includes
repeal of restrictive paraphernalia laws, federal funding of harm-
reduction programs, and increased access to, and expansion of,
substance abuse treatment. Nonetheless, if we’re going to stop the
spread of these diseases, we’ve got to be open to new ideas and
new solutions, even if they run counter to our beliefs. For active
injection drug users, preventing HIV and other blood-borne
pathogen transmission is a legitimate medical purpose for phar-
macy sale of syringes. It is not a political issue…it is not a moral
issue…it is not a criminal justice issue…it is a public health issue.
I implore each of you to make a strong statement that the
American Pharmaceutical Association (APhA) and pharmacists
everywhere have decided to support selling syringes to drug users
as a legitimate medical practice to prevent disease transmission.
Editor’s note: At its March 1999 Annual Meeting, APhA adopted the
following policy:
APhA encourages state legislatures and boards of pharmacy to
revise laws and regulations to permit the unrestricted sale or distri-
bution of syringes and needles by or with the knowledge of a
pharmacist in an effort to decrease the transmission of blood-borne
diseases.
Harry L. Simpson is a consultant in Detroit. At the time of this talk, Mr.
Simpson was Executive Director, Community Health Awareness Group,
Detroit. He was National Community Relations Manager, Agouron
Pharmaceuticals, Inc., 2000–2002.
Correspondence: Harry L. Simpson, 3028 East Grand Blvd., Detroit,
MI 48202. Fax: 248-543-8511. E-mail: Harry1081@aol.com.
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American Medical Association Policy on Syringe Access
That the AMA encourage the extensive application of needle and syringe exchange and distribution programs and the modi-
fication of restrictive laws and regulations concerning the sale and possession of needles and syringes to maximize the avail-
ability of sterile syringes and needles, while ensuring continued reimbursement for medically necessary needles and syringes.
The need for such programs and modification of laws and regulations is urgent, considering the contribution of injection drug
use to the epidemic of HIV infection.
Policy approved by the American Medical Association House of Delegates in June 1997.
Lundberg GD. New winds blowing for American drug policies [editorial]. JAMA. 1997;278:946–7.
P O L I C Y  S T A T E M E N T
RESEARCH
The Legality of Selling or Giving
Syringes to Injection Drug Users
Scott Burris, Jon S. Vernick, Alyssa Ditzler, and Steffanie Strathdee
Public health authorities recommend that injection drug users
(IDUs) who continue to inject use a new, sterile syringe for every
injection1 as an important part of a comprehensive approach to reduc-
ing the transmission of viral and bacterial infections.2 Laws and reg-
ulations prohibiting the sale or distribution of syringes to IDUs have
proven to be a significant obstacle to this public health goal.3–8
Although the legality of providing syringes to IDUs has been fre-
quently assessed,8–15 a new analysis is helpful for two reasons.
First, the law continues to change. Since 1987, 11 states have
deregulated the sale or possession of at least some number of
syringes.13,16–18 Second, previous analyses have usually used as
their main outcome measure whether or not a state had certain gen-
eral types of syringe access regulation.8,10,11,15,19,20 They have not
addressed significant differences in the precise wording of these
laws from state to state, nor analyzed how these laws differ in their
application to specific classes of sellers (most notably pharmacists),
modes of delivery (sale or free distribution), or distribution outlets
(such as pharmacies or syringe exchange programs [SEPs]).
Objectives
This study sought to determine the legality under state law of
three basic modes of syringe distribution to IDUs: retail sale with-
out a prescription, retail sale with a prescription, and free syringe
exchange or distribution.
Design
Earlier studies identified syringe prescription laws, drug para-
phernalia laws, and pharmacy regulations governing the sale of
syringes to IDUs in the 50 states, the District of Columbia, Puerto
Rico, and the Virgin Islands.13,21 The research was updated in
Objectives: Laws limiting access to sterile syringes impede the public health goal that injection drug users (IDUs) use a new, sterile
syringe for every injection to reduce blood-borne disease transmission. We sought to determine the legality of selling or giving syringes
to IDUs to prevent disease. Design: We used standard legal research methods to identify and analyze laws and regulations influenc-
ing the distribution of syringes in the 50 states, the District of Columbia, Puerto Rico, and the Virgin Islands. Results: A total of 51 juris-
dictions had drug paraphernalia laws; 14 had syringe prescription laws or regulations; 11 required purchasers to show identification;
13 had legislation authorizing syringe exchange programs (SEPs). Since the beginning of the human immunodeficiency virus epidem-
ic, 11 states have fully or partially deregulated syringe sales. Nonprescription retail syringe sales to IDUs for disease prevention pur-
poses are clearly legal in 20 states, and have a reasonable claim to legality in 22 more. Sales to IDUs with a prescription are clearly ille-
gal in only 3 jurisdictions. SEPs can operate legally in at least 21 states. Conclusion: Syringe access laws in most states may reason-
ably be interpreted to allow pharmacists to sell syringes to IDUs to prevent disease. In practice, however, unclear laws and pharmacist
uncertainty as to their interpretation may constitute continuing barriers to syringe access for IDUs. A comprehensive public policy of
ensuring syringe access for IDUs requires eliminating legal barriers to the sale, possession, and disposal of syringes, and educating
pharmacists and law enforcement officials about the legality and public health importance of sterile syringe access.
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2001 using standard legal research methods, and results were
cross-checked against the most recent survey of pharmacy law
conducted by the National Association of Boards of Pharmacy.22
Laws whose applicability was not clear were interpreted using
conventional methods of statutory and case law analysis.
Results
Current Status of Drug Paraphernalia Laws,
Syringe Prescription Laws, and Other
Pharmacy Regulations
All jurisdictions studied except Alaska and Puerto Rico current-
ly have a drug paraphernalia law. Most of these laws were passed
in the 1970s and 1980s to regulate an increasing retail trade in
drug-use equipment, and closely followed a model paraphernalia
law drafted by the U.S. Department of Justice.10 The typical statute
defines drug paraphernalia to include all equipment, products, and
materials of any kind, which are used, intended for use, or
designed for use to “manufacture, inject, ingest, inhale, or other-
wise introduce into the human body a controlled substance” in vio-
lation of law.23 It then provides a list of items that could be con-
sidered drug paraphernalia in some intended uses. In the majority
of states, this list includes “[h]ypodermic syringes, needles, and
other objects used…in parenterally injecting controlled substances
into the human body.”23 Paraphernalia laws usually create two
basic offenses: “manufacturing or distributing” and “possessing”
paraphernalia. Not every state has created both offenses. Although
the definition of paraphernalia is broad enough to cover many
common items that have legal uses, there is no violation unless the
person selling or possessing the item knows of its intended use
with illegal drugs. For both sellers and possessors, the crime is typ-
ically a misdemeanor.24
A significant minority of states currently have paraphernalia
laws that, at least on paper, make it legal under some circum-
stances for a seller knowingly to dispense a syringe to an IDU.
These exemptions, set out in Table 1, take several forms: exclusion
of syringes in at least some quantity; exemption of pharmacists
and other health care providers; and omission of references to
injection or syringes in the text of the law, suggesting syringes may
not be covered. In states that have both paraphernalia and pre-
scription laws, the interaction of the two must be assessed to deter-
mine which laws apply to syringe sale and possession.
Thirteen states and the Virgin Islands currently impose some
form of syringe prescription requirement by statute or regulation.
The requirement stands as a substantial barrier to syringe access in
only seven of these jurisdictions (CA, DE, IL, MA, NJ, PA, VI).
Some states require prescriptions only for minors (FL, VA), or
waive the prescription requirement for syringes used in the treat-
ment of asthma or diabetes, which practically vitiates the require-
ment (NV). The remaining four prescription-law states, shown in
Table 1, have partially deregulated syringes and now allow non-
prescription sale and possession of syringes in limited numbers.
Five other types of restriction on the sale of syringes, called here
“subprescription” limits, appear in state law, usually but not
always as regulations within the pharmacy code. These include
rules confining syringe sales to pharmacies, requiring sellers to get
information concerning the intended use of the syringe from the
buyer, requiring sellers to maintain various records, requiring pur-
chasers to present identification, and limiting the locations or man-
ner in which syringes may be displayed in the store. These are also
listed in Table 1.
Analysis: Legality of Selling or Giving
Syringes to IDUs
The determination of the legality of a mode of syringe access in
a particular state is ultimately a matter of professional legal judg-
ment taking into consideration statutory language, legislative
intent, case decisions, and social factors. Although generally sim-
ilar, the various types of laws set out in Table 1 often differ from
state to state in their wording. Moreover, with the exception of
syringe exchange and deregulation laws, syringe and drug para-
phernalia laws were not written with disease prevention in mind,
nor always intended to apply to pharmacists or others who are dis-
tributing syringes to IDUs for public health reasons. Even laws
that unambiguously prohibit some forms of syringe access may
authorize others: syringe prescription laws generally prohibit sales
without a prescription, but do not in most instances prohibit physi-
cians from prescribing syringes to IDUs or pharmacists from fill-
ing those prescriptions. The legality of syringe distribution to
IDUs to prevent disease therefore differs depending on the word-
ing of the law, the legal status of the person providing the syringe
(e.g., pharmacist or unlicensed person), the location of distribution
(e.g., SEP or pharmacy), and whether the syringe is being sold or
given away. The conclusions below should be understood as pro-
fessionally defensible predictions about how a judge—the legal
official ultimately empowered to say what the law is—would
interpret the law in a state. This is reflected by our use of three cat-
egories of legality: “clearly legal” and “clearly illegal,” both indi-
cating that the plain text of laws or case decisions would be
deemed by most lawyers to authorize or bar the activity, and “rea-
sonable claim to legality,” indicating that an attorney could ethi-
cally advise a client that the law, while unclear, could be interpret-
ed to allow the conduct at issue. This legal uncertainty is a charac-
teristic and important aspect of syringe access policy and practice.
Retail Syringe Sale Without a Prescription
In states without a prescription requirement, the main legal
influences on the retail sale of syringes are statutes or regulations
requiring the buyer to demonstrate a legitimate medical purpose
for the purchase and drug paraphernalia laws. Legitimate-purpose
rules place a duty on the seller (usually a pharmacist) to require the
buyer to state the proper purpose; the seller is not obliged to inde-
pendently verify its truth. Under a paraphernalia law, a seller who
does not know of the intended use, and is not being willfully blind
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Table 1. Requirements of State Syringe Statutes (S) and Regulations (R), and 
Drug Paraphernalia Laws (P), 2002
Syringe Prescription and Other Syringe-Specific Statutes and Regulations Paraphernalia Law Exemptions
Information Record Exempts Exempts Omits
Sale from on Buyer’s Keeping by ID of Limits on Some Some Reference Other
State or Pharmacy Prescription Purpose Pharmacists Purchaser Syringe or all Types of to Syringes Significant
Territory Only Requireda Required Requiredb Required Display Syringesc Sellersd or Injection Exemptione
(n = 22) (n = 14) (n = 9) (n = 15) (n = 11) (n = 11) (n = 9) (n = 9) (n = 5) (n = 3)
AL S
AK
AZ
AR
CA S S 3 S 1,2,3 S: non- S P 1,2
Rx only
CO P 
CT S S 1 S 4,7 S P 1
DE S S 1,2,4 S  S
FL S 2
GA R R    R P2
HI P 1,2,3
ID
IL S S S1,2 S
IN R R 1,2,3 R P2
IA P 1
KS
KY S S1,2,5,6 S S
LA R R R 1,2,3 R R P 2
ME S S 1,5 S P
MD R R R 1,2,3 R
MA S S S 1,2,3 S S
MI P
MN S P
MS
MO
MT P 1,2
NE
NV S S 4 P
NH S S 1,2 S 1,2,7 P
NJ S S S 1
NM P 2   
NY S S 1,2 S & R 1,3,7 P 3
NC
ND           
OH S  S S P 1,2
OK
OR P
PA R
PR
RI S S P
Table 1 continued on next page
No paraphernalia law
No paraphernalia law
to clear indications of the user’s intention, does not violate the law.
It is likely that many IDUs obtain syringes from sellers who are not
aware of the intended use.
Table 2 addresses the harder legal question of whether it is legal
to sell when the seller knows the purchaser will use the syringe for
injecting illegal drugs. Paraphernalia laws in some states explicitly
exempt pharmacists or contain other exemptions that would allow
at least some retail sales where the seller was aware that the
syringes would be used for injecting illegal drugs. Moreover, near-
ly all state paraphernalia laws were passed before the human
immunodeficiency virus (HIV) epidemic, and were aimed at the
sale of nonmedical equipment in stores catering to recreational drug
users (e.g., “head shops”). In many of these states, it is reasonable
to conclude that paraphernalia laws were not intended to prohibit
sales of a medical device such as a syringe in retail establishments
not primarily catering to drug users, as part of an effort to reduce
HIV transmission. This argument is generally not reasonable, how-
ever, where legislatures have subsequently amended paraphernalia
laws to allow SEPs. Amending a paraphernalia law to allow SEPs
would not be necessary unless the legislature believed that syringe
sales were generally limited by the paraphernalia law.
Retail Syringe Sale with Prescription
Physicians generally have broad discretion to prescribe drugs
and devices that they believe will be medically beneficial for
patients.25–27 For their part, pharmacists are authorized to dispense
medications ordered by a valid prescription and are ordinarily
expected to do so in the absence of good reason to refuse. An ear-
lier study examined the legality of physician prescription of injec-
tion equipment to patients as a means of preventing disease trans-
mission as a consequence of injection drug use.21,28 The findings
were updated for this article. The practice is clearly legal in 49
jurisdictions, while dispensing the prescribed syringes in pharma-
cies is clearly legal in 28 (see Table 3). The legal difference
between prescribing and dispensing lies chiefly in the fact that
writing a prescription does not entail the actual transfer of posses-
sion of a syringe—the act the law most commonly regulates. In
many states, therefore, physicians and pharmacists, by virtue of
their professional status, have the discretion to make syringes
available to IDUs that is not afforded lay people, such as needle
exchange operators.
Syringe Distribution Through Syringe Exchange
Programs
SEPs continue to increase their role as important providers of
syringe access. Twelve states and the District of Columbia have
affirmatively authorized SEPs (see Table 4). Nine jurisdictions
(CT, DC, HI, ME, MD, NH, NM, RI, VT) have done so by pass-
ing laws establishing programs. In Maryland, SEPs are authorized
in Baltimore only. In New Hampshire, one program is authorized.
In Vermont, no SEP has actually been approved to operate by the
health department. Two states—California and Massachusetts—
SYRINGE LAWS    Legality of Selling or Giving Syringes to IDUs
S16 Supplement to the Journal of the American Pharmaceutical Association November/December 2002    Vol. 42, No. 6, Suppl. 2
Table 1. Requirements of State Syringe Statutes (S) and Regulations (R), and 
Drug Paraphernalia Laws (P), 2002 (continued)
Syringe Prescription and Other Syringe-Specific Statutes and Regulations Paraphernalia Law Exemptions
Information Record Exempts Exempts Omits
Sale from on Buyer’s Keeping by ID of Limits on Some Some Reference Other
State or Pharmacy Prescription Purpose Pharmacists Purchaser Syringe or all Types of to Syringes Significant
Territory Only Requireda Required Requiredb Required Display Syringesc Sellersd or Injection Exemptione
(n = 22) (n = 14) (n = 9) (n = 15) (n = 11) (n = 11) (n = 9) (n = 9) (n = 5) (n = 3)
SC S R R 2 R P P 3
SD
TN R R R P 1,2
TX
UT
VT
VA S S 2 S S 1,2 S R
VI S S S1       
WA S P 2   
WV R P 2,3
WI P
WY P
SEP = Syringe exchange program.
a1 = for >10; 2 = <18 years old; 3 = except for use with insulin/adrenaline; 4 = except for asthma/diabetes; 5 = no sales to <18 years old.
b1= date of sale; 2 = type, price, and/or quantity of syringe; 3 = signature or name of seller; 4 = prescription on file; 5 = purchaser name/address;
6 = purpose of purchase; 7 = for prescription sales only.
c1 = < 31; 2 = items customarily used to inject lawful substances; 3 = legally obtained from pharmacy or SEP.
d1= physicians; 2 = pharmacists; 3 = other licensed providers.
e1 = does not include items for medical use; 2 = does not include syringes sold for “lawful purposes”; 3 = does not cover items for heroin use.
have delegated the decision to allow SEPs by passing legislation
authorizing local governments to approve them. In New York,
SEPs are authorized by the commissioner of health exercising
power granted in the paraphernalia law to waive its application.29
In Washington State, local health officials secured a declaratory
judgment from the state supreme court holding that the parapher-
nalia law did not prohibit them from authorizing SEPs,30 a ruling
that was later codified by the legislature.
SEPs in three states presently operate by authority of local gov-
ernment alone. In Philadelphia, Pittsburgh, and Cleveland, local
officials determined that their public health authority extended to
authorizing SEPs, despite the existence of state laws otherwise lim-
iting syringe access to IDUs. In Chicago, local law enforcement
and health officials interpreted a “research” exemption from the
paraphernalia law to encompass SEPs. While these interpretations
are legally debatable, they are also legally reasonable and have
proven a politically expedient way to operate SEPs in states unlike-
ly to change their law. In five states, the law does not regulate the
free distribution of syringes, and therefore does not prohibit SEPs.
As of 1998, SEPs were operating without a specific claim to
legality in 19 states (including states where other SEPs are legally
authorized). The law in these states may or may not clearly forbid
SEPs, but these SEPs nevertheless are able to operate through
more or less tacit arrangements with law enforcement authorities.
The fact that a given SEP operates without a clear legal basis does
not necessarily mean that such a basis could not be identified. In
Colorado, for example, local governments have substantial
authority to deal with local health threats, and so a city would have
a reasonable basis for authorizing a SEP under its own authority.
No research has been published on the legal authority of most
cities to authorize syringe exchange.
Limitations
This study analyzed syringe and paraphernalia laws as they
apply to distribution of syringes by a pharmacist, SEP, or other
legitimate source. The effect of these laws on the legality of syringe
possession by an IDU is addressed elsewhere in this issue.24 “Law
on the books” may differ from law as it is actually applied by police
officers, prosecutors, and judges. A study of statutes and regula-
tions as written cannot therefore replace research on the actual
implementation of law in specific jurisdictions.
Conclusion
Syringe access laws in most states may reasonably be interpret-
ed to allow pharmacists to sell syringes under at least some cir-
cumstances to IDUs to prevent disease. A state-by-state analysis
shows that nonprescription retail syringe sales in pharmacies or
other authorized outlets are clearly legal in 20 states and have a
reasonable claim to legality in 22 more. Sale with a prescription is
clearly illegal in only 3 jurisdictions. SEPs can operate legally in
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Table 2. Legality of Sale of Syringes by a Person
Who Knows the Syringes Will Be Used to Inject
Illegal Drugs, 2002
Reasonable Claim
Clearly Legal to Legality Clearly Illegal
(n = 20) (n = 22) (n = 11)
aSale clearly legal or has a reasonable claim to legality in pharmacy only.
AK, CT,a HI,a IN, a
LA,a ME,a MN,a
MT,a NH,a NM,a
NY,a OH,a OR,
PR, RI,a SC,a TN,a
WV,a WA,a WI
AL,a AR, AZ, CO,
FL, ID, IA, KY, MD,a
MI, MO, MS, NE,
NV,a NC, ND, OK,
SD, TX, UT, VA,a
WY
CA, DE, DC, GA,
IL, KS, MA, NJ,
PA, VT, VI
Table 3. Legality of Prescription and Sale by Prescription of Syringes with Knowledge of Intention to
Use for Illegal Drug Injection, 2002
Physician Prescription of Sterile Syringes Pharmacy Sale of Prescribed Syringes
Reasonable Claim Reasonable Claim 
Clearly Legal to Legality Clearly Illegal Clearly Legal to Legality Clearly Illegal 
(n = 49) (n = 2) (n = 2) (n = 28) (n = 22) (n = 3)
DE, GA, KSAL, AR, AZ, DC,
FL, ID, IA, KY,
MD, MS, MO,
NE, NC, ND, OH,
OK, SD, TX, UT,
VT, VI, WY
AK, CA, CO, CT,
HI, IL, IN, LA,
ME, MA, MI,
MN, MT, NV,
NH, NJ, NM,
NY, OR, PA, PR,
RI, SC, TN, VA,
WA, WV, WI
DE, KSOH, OKAL, AK, AR, AZ,
CA, CO, CT,
DC, FL, GA, HI,
ID, IL, IN, IA,
KY, LA, ME,
MD, MA, MI,
MN, MS, MO,
MT, NE, NV,
NH, NJ, NM,
NY, NC, ND,
OR, PA, PR, RI,
SC, SD, TN,
TX, UT, VT, VA,
VI, WA, WV,
WI, WY
at least 21 states. Since the beginning of the HIV epidemic, more
than a fifth of the states—11—have fully or partially deregulated
syringe sales as a measure to reduce blood-borne disease.
These laws are only part of the story. Actual practice may differ
from what legal theory might allow. Pharmacists exercise consid-
erable discretion to sell or not to sell, and their willingness to do so
may be influenced by uncertainty or misinformation about the law.
Moreover, the purchaser may remain in legal jeopardy for pos-
sessing the syringe even if the seller is not at legal risk.24 A com-
prehensive public policy of ensuring syringe access for IDUs who
cannot or will not abstain from drug use requires eliminating legal
barriers to the sale, possession, and disposal of syringes. Equally
important, however, is educating pharmacists and law enforce-
ment officials about the value of sterile syringe access in the effort
to reduce the transmission of HIV and other blood-borne diseases.
The authors declare no conflicts of interest or financial interests in any
product or service mentioned in this article. This article is based on a
review of syringe access poilicy commissioned by the Substance Abuse
Policy Research Program of the Robert Wood Johnson Foundation.The
data and conclusions presented here are solely those of the authors.
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Table 4. Legal Status of Syringe Exchange Programs in the United States, 2002
SEP Authorized by Local SEP(s) Operating Without
SEP Authorized by Government Based on its Free Distribution of Syringes Specific Claim to 
State Law Interpretation of State Law Not Restricted by State Law Legality in 1998 
(n = 13) (n = 3) (n = 5) (n = 19)
CA, CT, DC, HI, ME, MA, MD, IL, OH, PA AK, LA, OR, RI, WI AZ, CO, GA, IN, KS, MA, MI,
NH, NM, NY, RI, a VT, WA MN, MT, NJ, NY, NC, OK, 
PA, PR, TN, TX, UT, WA
SEP = Syringe exchange program.
aState law no longer restricts free distribution.
Source: Reference 31.
Deregulation of Syringe Sale
and Possession in New
Hampshire, 1991–2000
William Kassler and David Ayotte
On April 20, 2000, two decades into the human immunodeficien-
cy virus (HIV) epidemic and nearly a decade after it was first intro-
duced, the New Hampshire senate passed a bill allowing drug users
to buy and possess syringes without a prescription. This legislation
had been repeatedly introduced since 1991 and on two occasions
was passed by the house and senate but vetoed by previous gover-
nors. In 2000 Governor Jeanne Shaheen signed the bill.
HIV/AIDS Among IDUs
Injection drug users (IDUs) accounted for 19% (128/657) of all
adult acquired immunodeficiency virus (AIDS) cases in New
Hampshire from 1991 to 1999. New Hampshire’s geographic
location in the northeastern United States suggested substantial
risk of introduction of HIV from the neighboring states that have
much higher rates of HIV among IDUs.
Although there are only an estimated 6,000 IDUs in the state,
HIV, hepatitis B, and hepatitis C are passed to sexual partners and
children who then can spread these infectious diseases in the com-
munity. Reducing the risk of disease transmission among IDUs,
and thus the broader community, was a legitimate public health
rationale for increasing access to sterile syringes.
Showing the toll of HIV on individuals and families made the
problems more compelling. When individuals who worked in
community-based organizations testified about their experiences,
legislators paid attention. The most compelling testimony came
from individuals in recovery who talked about their past drug use
and who did not conform to stereotypes of “street addicts.”
One of the most effective voices in focusing the legislature’s
attention on the problem was an octogenarian member of the
house, Representative Cecilia Kane, who introduced her deregula-
tion bill year after year. She is a retired nurse whose son was 34
years old when he died of AIDS. The eventual success of the bill
can be attributed to her commitment.
Deregulating Sale and Possession of
Syringes
The deregulation bill that was introduced in 1991 and was ulti-
mately enacted permits persons 18 years of age and older to pur-
chase up to 10 syringes per transaction, without a prescription, at
pharmacies that voluntarily participate in the initiative. The bill
also modified the existing drug paraphernalia laws, decriminaliz-
ing possession, and initiated a program to educate syringe users on
safe disposal.
Opponents argued that there was no evidence that the bill would
reduce HIV transmission, that drug users from large neighboring
states like Massachusetts would travel to New Hampshire to
escape strict regulations and buy syringes for illegal drug use, and
that increased syringe availability in New Hampshire would bring
in more IDUs.
As the scientific evidence in support of deregulation grew, the
political dialogue shifted. Studies cited in well-respected sources
such as the Journal of the American Medical Association and
National Academy of Sciences publications lent credibility to the
argument that increasing access to sterile syringes would reduce
HIV transmission and would not lead to increases in the number of
IDUs.1–5 It thus became difficult to oppose syringe deregulation
based on arguments of harm or ineffectiveness.
Local police and emergency medical technicians (EMTs) ini-
tially argued that increased access to syringes would attract more
drug users and result in more crime. When those concerns were
defused by research in other localities, their arguments shifted to
safety concerns: decriminalizing possession could lead to an
increased risk of needle sticks for police, firefighters, and EMTs.
Findings in Connecticut that needle-stick injuries to police officers
were lower after that state legalized selling syringes without a pre-
scription deflected some of this concern.6 However, law enforce-
ment never fully supported the policy.
Syringe Disposal
Additional concerns focused on how IDUs would dispose of
their syringes. Lawmakers debated how people with diabetes cur-
rently dispose of their syringes and if drug users would do so safe-
ly. The hospital association polled its members and several health
facilities indicated that they provide sharps disposal for the public.
People with diabetes explained how they place their used syringes
in plastic bottles and dispose of them in household trash.
Legislators thus determined that, with effective community educa-
tion on disposal and disposal sites in hospitals, safe syringe dis-
posal was feasible.
For some legislators, it did not matter what the evidence
showed; the idea of government establishing a program that was
perceived to facilitate or enable drug use amounted to tacit legit-
imization of illegal and unethical behavior. This conflict was best
illustrated by one senator, who, as a former registered nurse, val-
ued the scientific evidence, yet felt that syringe access enabled
drug use. During a critical vote, this legislator left the room, thus
allowing the bill to pass without having to violate her own ethics.
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SEP Authorized but Not
Implemented
Throughout the decade, proponents debated the relative merits
of deregulation versus syringe exchange programs (SEPs). Some
opponents of increased access viewed SEPs as less objectionable.
In 1997, legislation was enacted allowing a 2-year pilot SEP in one
community in the state, but only after a compromise sponsors of
deregulation withdrew their legislation. The legislation required
local political and local police endorsement before a SEP could be
established. Since the law was passed, no community has estab-
lished a SEP.
In October 1999, the month the deregulation bill was heard in
the statehouse, five leading national health organizations released
a joint policy statement urging states to remove legal barriers to
obtaining sterile syringes through pharmacies. These joint and
individual statements by the American Medical Association,
American Pharmaceutical Association, Association of State and
Territorial Health Officials, National Association of State and
Territorial AIDS Directors, and National Association of Boards of
Pharmacy clearly supported deregulation and influenced the legis-
lature.7
By 1999 a broad coalition of state health officials, the medical
society, the pharmacy association, the hospital association, and
AIDS service organizations gave sufficient political support to
reassure lawmakers. Pharmacists supported HIV prevention, but
were concerned that this law would be implemented as an unfund-
ed mandate, resulting in new administrative burdens and increased
costs. Thus pharmacists supported a voluntary program in which
they could choose to participate.
Finally, the legislature felt quite strongly that if enacted, the law
must be evaluated and the health department agreed to conduct
such an evaluation. Preliminary results show that the program has
raised very little controversy. There have been no complaints from
law enforcement or local officials, and the network of participat-
ing pharmacists is extensive.
Conclusion
New Hampshire’s history of political conservatism made it dif-
ficult for decision makers to support any policy that appeared to be
“soft on drugs.” However, the state also has a strong tradition of
libertarian political thought, which facilitated acceptance of a pol-
icy that consisted of voluntary efforts on the part of pharmacists
and pharmacy owners, and that did not involve implementation of
a new government program. The policy ultimately prevailed when
three dynamics converged: the persistence of a legislator who kept
the issue alive; the emergence of a clear scientific consensus that
deregulation was effective and did not promote increased drug use;
and a political alliance of advocates, pharmacists, physicians,
elected officials, and the boards of pharmacy, nursing, and
medicine that demonstrated broad political support.
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The Minnesota Pharmacy
Syringe Access Initiative: A
Successful Statewide
Program to Increase Injection
Drug User Access to Sterile
Syringes
Gary A. Novotny, Niki U. Cotton-Oldenburg, Bill
Bond, and Bob Tracy
As of December 2001, injection drug use and sex with injection
drug users (IDUs) accounted for 14% of cumulative non–acquired
immunodeficiency syndrome (AIDS) cases of human immunode-
ficiency syndrome (HIV) infection in Minnesota.1 On July 1,
1998, new Minnesota laws went into effect legalizing pharmacy
sale without a prescription and individual possession of as many as
10 syringes. These new laws were intended to reduce HIV trans-
mission among IDUs and their sex partners by increasing access to
sterile syringes. The legislation required the Minnesota
Department of Health (MDH) to develop, implement, promote,
and evaluate a new public health program called the Minnesota
Pharmacy Syringe Access Initiative (SAI).
A few months before SAI went into effect, MDH conducted two
surveys of pharmacy managers to identify possible barriers and
incentives to participation in SAI. In the first survey, we inter-
viewed a convenience sample of 29 chain pharmacists who gener-
ally supported SAI. In the second, we mailed a short questionnaire
to 918 Minnesota retail pharmacy managers. Of the 648 (70%)
managers who responded, 421 (65%) reported that they would par-
ticipate in SAI, 130 (20%) reported that they would not participate,
and 97 (15%) were undecided. Of the 227 pharmacy managers
who were undecided or who would not participate, 111 (49%) had
concerns about having IDUs in the pharmacy, and about possibly
supporting an illegal activity, or felt that there was no need for SAI
in their town. Only 15 of these 227 pharmacists reported factors
that would increase their likelihood of participating, including
availability of home needle disposal systems, referral of customers
to substance abuse treatment, and educational materials for cus-
tomers. More than 60% (265/421) of the pharmacists likely to par-
ticipate in SAI were concerned about syringe disposal. They
requested more syringe disposal options, such as state- or county-
sponsored disposal systems or a $0.25 surcharge to syringe sales
to help fund disposal. They indicated that the availability of edu-
cational materials on syringe disposal and HIV transmission
would facilitate their participation in SAI.
Promoting Pharmacist Participation
in SAI
The success of SAI depended on the active, voluntary partici-
pation of pharmacists and IDUs. In an effort to increase pharma-
cists’ willingness to sell up to 10 new syringes to any customer
requesting them, MDH solicited the support of the Minnesota
Board of Pharmacy and Minnesota Pharmacists Association
(MPhA), which had been involved in crafting the laws, as well as
collaborations with chain and independent pharmacies. The
Minnesota pharmacy board provided a list of community pharma-
cies that was used for outreach and to evaluate the program.
MPhA, in conjunction with MDH, published articles supporting
SAI in the January 1998 and April 1998 issues of the pharmacy
board’s newsletter. In August 1998, the Minnesota Society of
Health-System Pharmacists issued a policy statement supporting
SAI.
At MPhA’s 1998 annual meeting, Minnesota AIDS Project
(MAP) and MDH staff promoted pharmacist participation in SAI.
MAP had provided leadership in the passage of the authorizing
legislation. MDH made a similar presentation to MPhA in 2000.
Between March 1998 and May 2000, MDH staff mailed three let-
ters to all community pharmacy managers in Minnesota soliciting
participation in SAI. In May 2000, 47% (430/918) of community
pharmacies reported they were participating in SAI and, in May
2001, 49% (505/1,025) were participating.
MDH promoted use of pharmacies as a source of syringes
among IDUs. In 1998 MDH staff held focus groups of IDUs and
HIV educators from community-based organizations to identify
ways to raise IDU awareness of SAI. Focus group findings aided
MDH in developing and distributing: (1) pocket size “law cards”
that stated the new statute language allowing the sale and posses-
sion of 10 or fewer new syringes without a prescription; (2)
brochures on safer home disposal of used syringes; and (3) pock-
et-size cards with the MAP hotline (Minnesota AIDSLine) phone
number for information on disposal sites and pharmacies partici-
pating in SAI.
Promoting Safe Syringe Disposal
Safe syringe disposal was a priority for the Legislature, MDH,
IDUs, and pharmacists. To participate in SAI, pharmacies were
required to certify their participation in one of the following
syringe disposal activities: (1) distribution of educational materials
about safe personal disposal of syringes: (2) participation in a
sharps container distribution and collection program; (3) referring
customers to a medical facility that accepts home-generated
sharps; (4) referring customers to the Minnesota AIDSLine to
identify syringe exchange programs they could use for safe syringe
disposal; (5) collecting used syringes from customers; or (6) some
other syringe disposal activity (with a description). Pharmacists
signed and returned a form to MDH. The original name of the
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form, “Syringe Disposal Certification” was changed to
“Participation Form” because the word “certification” raised con-
cerns about pharmacists being required to do something as part of
this voluntary program. MDH entered the pharmacy’s information
from the completed form into a database used by the Minnesota
AIDSLine and community-based organizations serving IDUs.
Participating pharmacies were sent any MDH-generated HIV and
disposal educational materials they requested.
We consulted the Minnesota Pollution Control Agency, the
Minnesota Chapter of the American Diabetes Association, waste
management companies, and Access Works (www.accessworks.
org; formerly known as Women With A Point), an HIV/sexually
transmitted disease prevention program serving IDUs in
Minneapolis, about their approaches to promoting safe communi-
ty syringe disposal. The Access Works approach, distributing a
hand-carry, plastic container (FitPak) to IDUs, was considered
appropriate for MDH involvement. FitPak has two compartments:
one holds 10 new syringes and the other locks in 10 used syringes.2
MDH provided funding to Access Works from April 1999 to
March 2001 to conduct a needs assessment about syringe disposal
and to pilot test FitPak distribution at four pharmacies in the
Minneapolis and St. Paul metropolitan area. The results of this pro-
ject are currently being analyzed.
Increased Syringe Sales and Fewer
Risky Behaviors
In May 1999, after 1 year of SAI we telephoned a convenience
sample of 19 participating pharmacies in areas with high levels of
injection drug use in the Twin Cities. None reported incidents of
unsafe syringe disposal in or around their pharmacies as a result of
participating in SAI. Park police did not report any incident of
syringes discarded in public areas. An MDH study showed that
nearly all IDUs disposed of their syringes in a manner that did not
pose a risk to the general public.4
MDH staff conducted two outcome evaluation studies to assess
the impact of SAI on IDU syringe-related behaviors and pharma-
cy syringe sales. We recruited cross-sectional samples of IDUs
over 3-month periods before (March through June, 1998) and 1
year after (March through June, 1999) SAI went into effect. We
also conducted a 12-month prospective surveillance of monthly
syringe sales by community pharmacies with a stratified random
sample of chain and independent pharmacies.
The pharmacy evaluation found that pharmacies in the Twin
Cities, which had a higher concentration of IDUs, experienced a
significantly higher number of individual syringe sales made with-
out a prescription for an accompanying drug than other pharmacies
in the metropolitan area or greater Minnesota (P < .01). IDUs
reported that (1) their pharmacy syringe purchases increased sig-
nificantly within 1 year of when the laws went into effect; (2) phar-
macies replaced street locations, friends, or pimps as their primary
source of syringes; and (3) syringe sharing decreased by 17%.3
MDH has continued to enroll new pharmacies and to retain and
express gratitude to enrolled pharmacies. Community pharmacy
services in Minnesota have been expanding through new pharma-
cy services in grocery and department stores and construction of
new branches of pharmacy chains, opening further opportunities
for SAI expansion.
Conclusion
The Minnesota SAI partnership among the community groups,
public health agencies, and the pharmacy profession may be a
model for public programs to prevent blood-borne disease trans-
mission among IDUs, their sex partners, and children by increas-
ing IDU access to sterile syringes.
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Increasing Legal and
Regulatory Support for
Pharmacy Syringe Sales to
Injection Drug Users,
Washington State, 1999–2002
Donald H. Williams
In 1999 the Centers for Disease Control and Prevention (CDC),
the American Pharmaceutical Association (APhA), and the
National Association of Boards of Pharmacy co-sponsored a con-
ference in San Antonio to examine blood-borne disease transmis-
sion and state policies on pharmacy syringe sales. The presenters
provided convincing evidence of the need to modify laws, rules,
and policies at the state level to allow the sale of sterile syringes
to injection drug users (IDUs) to reduce blood-borne disease
transmission. The evidence demonstrated that drug injection with
previously used injecting equipment contributes substantially to
human immunodeficiency virus (HIV) transmission among
IDUs, their sex partners, and their children, and selling sterile
syringes addresses a legitimate public health concern by decreas-
ing the reuse of syringes.
Since 1991, the Washington State Board of Pharmacy
(“Board”) has supported syringe distribution through syringe
exchange programs (SEPs). In a lawsuit about the legality of a
proposed SEP, the Board filed an amicus brief supporting the
local public health department proposal. A 1992 Washington
court decision found that Washington public health officials had
extraordinary power and broad authority to control the spread of
infectious disease
.
The court stated, “Moreover, we are persuad-
ed the broad powers given local health boards and officers under
(Washington State) Const. Art 11, § 11 and RCW 70.05 authorize
them to institute needle exchange programs in an effort to stop the
spread of HIV and AIDS [acquired immunodeficiency syn-
drome].” 1 The Supreme Court ruling did not mention pharmacy
involvement in IDU access to sterile syringes.
Since 1981, two state laws have governed the distribution
(including sale) of syringes in Washington State. First, the Drug
Injection Device Law, chap. 70.115.050 RCW,2 required that
when selling syringes “the retailer must satisfy himself or herself
that the device will be used for the legal use intended.” Second,
the drug paraphernalia section of the Uniform Controlled
Substances Act3 listed various items that may be considered drug
paraphernalia, including “hypodermic syringes, needles, and
other objects used, intended for use, or designed for use in par-
enterally injecting controlled substances into the human body.”
Therefore, a syringe used to illegally inject a controlled substance
clearly met the legal definition of drug paraphernalia.
In 1998 the legislature passed a new drug paraphernalia law,
chap. 69.50.4121 RCW,4 that provided civil penalties. Before
approval, public health officials convinced legislators to add an
amendment protecting the legal status of SEPs: “Nothing in sub-
section (1) of this section prohibits legal distribution of injection
syringe equipment through public health and community-based
HIV prevention programs.”
Board Support for Pharmacy Sale of
Syringes to IDUs
Based upon the information presented at the 1999 CDC/APhA
conference, the 1992 Washington Supreme Court decision, and
the 1998 amendment to the civil drug paraphernalia law, the
Board determined that it would reinterpret the syringe laws. The
Board reasoned that it would be legal for a pharmacy to distribute
(sell) syringes to IDUs within the context of an HIV-prevention
program.
The Board examined the laws affecting the sale of syringes:
70.115.050 RCW and 69.50.102 RCW.1–4 In May 1999, the
Board adopted the following resolution, declaring that the term
“legal use” in 70.115.050 RCW included the sale of sterile
syringes for the purpose of reducing blood-borne disease trans-
mission.
Whereas: Recent studies by the Centers for Disease
Control and Prevention (CDC) and by various states have
found that a large number of new cases of HIV/AIDS, 
hepatitis and other sexually transmitted diseases are found
in persons who either are injection drug users (IDU’s) or
who have had sexual relationships with IDU’s. A recent
meeting co-sponsored by CDC, National Association of
Boards of Pharmacy, and the American Pharmaceutical
Association demonstrated that revisions in state laws and
rules to permit the unrestricted sale or distribution of ster-
ile needles and syringes would reduce the transmission of
blood-borne diseases.
Now Therefore be it Resolved: that the Washington State
Board of Pharmacy has determined that the term, “legal
use” as used in 70.115.050 RCW—Hypodermic Syringes
includes, the distribution of sterile hypodermic syringes
and needles for the purpose of reducing the transmission 
of blood-borne diseases. Such distribution shall be 
performed through public health and community based
HIV prevention programs.
The Board communicated this resolution to the state board of
health, pharmacists, pharmacies, and county public health depart-
ments and is converting the resolution into a formal rule. The rule
will be codified in the Pharmacy Law book. Based on this reso-
lution, the Seattle/King County and Kitsap County Health
Departments developed agreements with pharmacies that formal-
ly incorporated pharmacy-based syringe sales into the health
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departments’ disease prevention programs.5
During the 2001 and 2002 legislative sessions, the Washington
State Legislature considered bills changing the legal status of
syringe sales, distribution, and possession. During 2001, a state
representative introduced a bill to allow the possession of syringes
by persons over the age of 18 for the purpose of reducing blood-
borne diseases. The bill included pharmacies in the sale of syringes
for public health programs, and defined such sales and use as
“legal use.” The bill was controversial and was amended so that
only single-use, difficult-to-reuse (DTR) syringes could be sold
and possessed. Because of concerns that DTR syringes might
increase blood-borne transmission risk among IDUs,6,7 the spon-
sor withdrew the bill.
During the 2002 legislative session, the original 2001 bill was
reintroduced, without the DTR requirement. The legislature
approved the bill with amendments requiring pharmacists to sell
syringes only in exchange for syringes turned in by the consumer,
to provide printed materials about disease prevention, substance
abuse treatment and safe needle disposal techniques at the point of
sale and to handle “biomedical waste,” presumably syringes, as
defined in the legislation. These amendments were in a single sec-
tion of the bill. At the request of public health agencies, the gover-
nor used line item veto authority to approve the bill while vetoing
the amendments.8 The new law went into effect on June 13, 2002.
Conclusion
Based on scientific research, local experiences, and statements
from public health agencies, first the Board established that, under
pharmacy regulations, pharmacy syringe sales to IDUs were legit-
imate because they could help prevent blood-borne disease trans-
mission. Then, the state legislature passed new laws that such sales
and carrying syringes were legal. The strong support of the Board,
pharmacy professional associations, and schools of pharmacy
were essential to making these changes.
J Am Pharm Assoc. 2002;42(suppl 2):S23–4.
Received June 10, 2002, and in revised form September 3, 2002. Accepted
for publication September 18, 2002.
Donald H. Williams, FASHP, is executive director, Washington State Board
of Pharmacy, Olympia.
The author declares no conflicts of interest or financial interests in any
product or service mentioned in this article.
Correspondence: Donald H. Williams, FASHP, Executive Director,
Washington State Board of Pharmacy, P.O. Box 47863, Olympia, WA
98504-7863. Fax: 360-586-4359. E-mail: don.williams@doh.wa.gov.
References
1. Spokane County Health District v Brockett, 120 Wash. 2d. 140 839
P2d324 (1992).
2. Wash Rev Code chap. 70.115.050.
3. Wash Rev Code chap. 69.50.
4. Wash Rev Code chap. 69.50.4121.
5. Marks RW, Hanrahan M, Williams DH, et al. Encouraging pharmacy sale
and safe disposal of syringes in Seattle, Washington. J Am Pharm
Assoc. 2002;42(suppl 2):S26–7.
6. Des Jarlais DC. “Single-use” needles and syringes for the prevention of
HIV infection among injection drug users. J Acquir Immune Defic Syndr
Hum Retrovirol. 1998;18(suppl 1):S52–6.
7. Caulkins JP, Kaplan EH, Ahn SH. Can difficult-to-reuse syringes reduce
the spread of HIV among injection drug users? Operations Res.
1998;28:23–33.
8. Washington Laws of 2002 chap. 213.
Maine Board of Pharmacy
Strongly Supports
Unrestricted Sale of Sterile
Syringes
Barbara Ginley, Sally-Lou Patterson, Nathan
Nickerson, Joe Bruno, and John Grotton
The Portland Needle Exchange Program (PNE) is the only
syringe exchange program (SEP) in Maine. Although Maine law
allows anyone over 18 years of age to buy syringes without a pre-
scription and without showing identification, during summer
1999, several PNE participants complained that they had not been
able to purchase syringes from pharmacies. PNE participants
reported that pharmacists had either refused to sell syringes or dis-
couraged persons asking to purchase syringes by requiring photo
identification and/or a signature.
The state of Maine has taken several steps to improve public
access to sterile syringes to prevent the transmission of human
immunodeficiency virus (HIV) and other blood-borne diseases. In
1993 Public Law 394 removed the prescription requirement for
syringe sales.1 In 1997 legislation was passed legalizing syringe
exchange and amending the Maine drug paraphernalia law to
legalize possession of as many as 10 syringes.2,3 The Maine SEP
law requires the SEP to receive one used syringe for every new
syringe provided to a SEP participant (“one-for-one exchange”).4
To use a Maine SEP, a participant must obtain the initial syringes
to turn in (“starter” syringes) from a source other than the SEP.
Pharmacies are the only legal source of “starter” syringes.
Problem in Practice
In July 1999, the Portland Public Health Division (PPHD) staff
met with central office staff of the chain pharmacies that had not
sold syringes to PNE participants. PPHD staff provided the phar-
macy chain staff with information about the Injection Drug User
(IDU) HIV Prevention Program, reviewed the laws passed in
1997, and discussed the difficulties reported by consumers. The
pharmacists believed that questions about pharmacy-based syringe
sales had implications for all Maine pharmacists. At their request,
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the Maine Pharmacy Association (MPA) requested an advisory
ruling from the Maine Board of Pharmacy. MPA posed four ques-
tions for the board to consider at its September 1999 meeting:
1. Must a pharmacist sell a hypodermic apparatus without a pre-
scription, or can a pharmacist exercise his/her own judgment or
policy?
2. Should a pharmacist require identification when selling a
hypodermic apparatus over the counter?
3. What is the pharmacy board’s opinion regarding civil liability
for selling a hypodermic apparatus over the counter?
4. Is the board aware of any “potential conflict” between 32
MRSA §13787-A (the 1997 legislative amendment) and regula-
tions of the Drug Enforcement Administration?
Board of Pharmacy’s Response
The board responded to the first two questions posed by the
association. The board did not rule on question 3, because the lia-
bility issue was outside the board’s jurisdiction, or on question 4,
because the Drug Enforcement Administration was the authority
on its policies.
The ruling on question 1 expressed definitive support for the
intent of the state legislation to increase access to sterile syringes
to prevent disease:
The Legislature enacted 32 MRSA §13787-A as a prophy-
lactic against the spread of AIDS, hepatitis, and other
blood-borne diseases. The Board unanimously endorses
that effort and believes implementation … to be wholly con-
sistent with the highest principles of pharmacy.
The board stated that any pharmacist refusing to sell syringes
must be ready to “justify that decision in light of both the statute’s
broad sweep and its salutary intent.”
The ruling on question 2 outlined legitimate reasons for a phar-
macist to request photo identification (e.g., if the pharmacist
believed the purchaser was younger than 18 years old). The ruling
stated, “arbitrary imposition of other criteria including an unjusti-
fied request for identification, would clearly run contrary to
Legislative intent.”
The 1999 pharmacy board ruling affirmed that selling sterile
syringes to IDUs is legitimate medical and pharmacy practice.
This ruling clearly affirmed the legitimacy of public and individu-
al health reasons for the recommendation that IDUs use sterile
syringes and board support for unrestricted syringe sales to per-
sons over 18.
We hoped that the unanimous board ruling would prompt all phar-
macists to sell syringes. However, after the ruling, the PNE continued to
receive reports of pharmacists refusing to sell syringes to IDUs. In
response, PNE began giving SEP participants copies of the board ruling
confirming their legal right to purchase syringes. If a consumer ade-
quately documented a pharmacist’s refusal to sell syringes and filed a
complaint with the board, the pharmacist involved could face disciplinary
action. No formal complaints have been filed against pharmacists. The
isolated reports of pharmacists’ refusals to sell syringes appear to be indi-
vidual pharmacists’ interpretations of state law and professional obliga-
tion rather than the policies of pharmacy chains. PPHD has contacted a
small number of pharmacists who reportedly refused to sell syringes and
given them copies of the board’s 1999 ruling.
Conclusion
The 1999 Maine pharmacy board ruling clarified an important
public policy issue for consumers, public health professionals, and
pharmacists. The ruling assured pharmacists that the board regu-
lating their professional practice strongly supports selling syringes
to IDUs. It also affirmed that drug users over 18 years old can pur-
chase sterile syringes from Maine pharmacies.  Similar board of
pharmacy rulings in other states may help increase the availability
of sterile syringes and help prevent transmission of blood-borne
infections.
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PROMOTING PHARMACY SYRINGE SALES
Encouraging Pharmacy Sale
and Safe Disposal of
Syringes in Seattle,
Washington
Robert W. Marks, Michael Hanrahan, Donald H.
Williams, Gary Goldbaum, Hanne Thiede, and
Robert W. Wood
In Seattle and King County, Washington, human immunodefi-
ciency virus (HIV) seroprevalence among injection drug users
(IDUs) has remained at 2% to 3% for more than 8 years.1 More
than 80% of King County IDUs, however, are infected with the
hepatitis C virus, and more than 20% of the uninfected become
infected each year.1,2  These blood-borne infections mostly result
from the reuse and shared use of drug injection equipment,
including needles and syringes, drug cookers, water, and cotton
filters.3
Access to sterile injection equipment is associated with lower
frequency of unsafe injection practices and reduced risk of infec-
tion4–6 and does not appear to increase drug use by increasing
injection frequency or the number of injectors.7–9 In 2001, King
County syringe exchange programs (SEPs) exchanged more than
2 million syringes. Even with extensive SEP operations, some
King County IDUs continue to share syringes. Approximately
62% of recently arrested IDUs revealed that they had injected
with a syringe used by someone else in the previous 6 months,10
in part because of the limited hours, limited locations, and the lack
of confidentiality of SEPs. Moreover, based on an estimated
15,000 IDUs in King County injecting 3 times per day, SEPs
alone cannot provide the approximately 17 million syringes need-
ed countywide per year so that IDUs would have access to a ster-
ile syringe for every injection.1
Washington State syringe access laws and regulations were
amended in the years 1999–2002.11 In 1999 the Washington State
Board of Pharmacy determined that legal use “includes the distri-
bution of sterile hypodermic syringes and needles for the purpose
of reducing the transmission of blood-borne diseases.” Based on
the Washington Supreme Court’s interpretation of the State’s
drug paraphernalia law, the pharmacy board specified that phar-
macy syringe sales should “be performed through public health
and community-based HIV prevention programs.”12 In 2002,
Washington State amended its drug paraphernalia law to further
clarify legal restrictions regarding syringes (RCW 69.50.4121
and 1998 c 317 s 1 and RCW 69.50.412 and 1981 c 48 s 2). The
revised statute specifically exempts pharmacies from any penal-
ties associated with syringe sale and allows individuals over the
age of 18 to possess hypodermic syringes for the purpose of
reducing blood-borne infections. Although pharmacists may now
legally sell syringes, the pharmacy board continues to recom-
mend that pharmacies enter into a programmatic relationship with
public health agencies for this activity.
Public Health and Pharmacy
Collaboration
In March 2001, Public Health–Seattle & King County (Public
Health) began collaborating with community pharmacists to
increase voluntary syringe sales to help prevent blood-borne infec-
tions. For each pharmacy, a pharmacy representative and the pub-
lic health director sign a memorandum of understanding (MOU).
The MOU recognizes the pharmacy as Public Health’s “commu-
nity partner” providing access to sterile syringes for disease pre-
vention. Public Health agrees to provide (1) written materials for
free distribution to customers, (2) free anonymous/confidential
HIV and hepatitis counseling and testing at nearby sites, and (3)
free training for pharmacy staff on blood-borne disease preven-
tion. Participating pharmacies agree to (1) offer retail sale of ster-
ile syringes to persons who use drugs by injection; (2) provide ver-
bal and written information to customers concerning syringe dis-
posal, blood-borne disease prevention, substance abuse treatment,
and HIV counseling and testing; and (3) if needed, to request train-
ing from Public Health on blood-borne infection prevention. In
2001, in addition to community pharmacy activities, Public Health
pharmacies began to sell syringes to anyone who requested them.
As of August 2002, Public Health had contacted 48 King
County community pharmacies about collaborating in selling
syringes to IDUs. Twenty-eight (58%) enrolled as Public Health
partners. One has closed, and the remainder report that the col-
laboration has been positive and successful.
The response of pharmacy corporations has been mixed. One
director of pharmacy, a national leader in increasing syringe
access, instructed his King County district managers to assist
Public Health. Another director, concerned about having her
pharmacies advertised to IDUs, declined to participate stating that
she would nevertheless educate individual pharmacy managers to
sell to anyone requesting syringes. Staff of community pharma-
cies that declined participation expressed concerns that partici-
pating would attract IDUs who might be safety and security
threats. Some pharmacists were not comfortable signing an MOU
without consent from their corporate offices. One pharmacist
adamantly opposed increasing syringe access, stating that provid-
ing access condoned drug use.
The Washington State Board of Pharmacy and the Washington
State Pharmacist Association have assisted Public Health’s
recruitment efforts. One pharmacy manager personally recruited
fellow managers and wrote a letter to King County pharmacists
recommending participation.
Anecdotal reports from participating pharmacists and IDU sug-
gest that pharmacies are selling syringes to IDUs. Public Health
proposes to recruit 50 additional pharmacies by spring 2003 and
plans to assess pharmacy syringe sale practices by systematic
attempts to purchase syringes from pharmacies.
Syringe Disposal
Public Health also established a program to help reduce the
number of used syringes in the trash and solid waste. Individuals
may give any quantity of used syringes to staff at 10 Public Health
clinics and 7 SEPs for safe disposal as medical waste. Secure, steel
syringe drop boxes have been installed outside 3 Public Health
clinics and, through collaborative initiatives, outside 1 private
Community Health Center. These enable individuals to discretely
and safely dispose of syringes 24 hours a day. Public Health is
considering placing a drop box at each of its other seven health
clinics and at other Community Health Centers.
Public Health clinic managers have been overwhelmingly sup-
portive, but some clinic staff were initially ambivalent about
accepting used syringes for disposal. Through education focused
on health promotion and disease prevention, by providing educa-
tion about blood-borne infections, by challenging staff perceptions
about IDUs, and by giving staff members the authority to coordi-
nate syringe disposal procedures at their clinic, most staff became
less fearful and embraced syringe disposal. Early indicators sug-
gest that syringe disposal drop boxes installed in Public Health and
Community Health Center clinics have been used properly. No
adverse events have been reported from any of the clinics where
drop boxes were installed.
Conclusion
Seattle and King County are served by active SEPs that
exchange more than 2 million syringes a year. However, because
some IDUs continued to share syringes, and because of the mil-
lions of additional syringes needed for IDUs to have a new, sterile
syringe for each injection, Public Health wanted to expand phar-
macy syringe sales to IDUs. The new policy of the Washington
Board of Pharmacy and new state laws allowed pharmacists to
expand syringe sales to IDUs. Public Health staff established
working relationships with practicing pharmacists to promote such
sales. The support of pharmacy leaders and institutions (the Board
of Pharmacy and the Washington Pharmacy Association) have
promoted pharmacist participation.
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Additional information about pharmacy sale of syringes and
safe syringe disposal in Seattle and King County, Washington
is available at the Harm Reduction and Drug Use section on the
HIV/AIDS Program Web site at www.metrokc.gov/health/apu.
■ Syringe disposal at http://www.metrokc.gov/health/apu/
resources/disposal.htm.
■ Syringe access at http://www.metrokc.gov/health/apu/
harmred/syringe_campaign.htm.
Mobilizing Public and Private
Partners to Support New
York’s Expanded Syringe
Access Demonstration
Program
Susan J. Klein, Alma R. Candelas,
and Guthrie S. Birkhead
Improved access to hypodermic needles and syringes (hereafter
referred to as “syringes”) through pharmacy sales without a prescrip-
tion can help prevent blood-borne disease transmission among injec-
tion drug users (IDUs), their sex partners, and their children, as well as
others who self-inject medications.1–3 On January 1, 2001, the
Expanded Syringe Access Demonstration Program (ESAP) went into
effect in New York State.4,5 ESAP offered to register pharmacies,
health care facilities, and health care practitioners with the New York
State Department of Health (NYSDOH) to sell or furnish up to 10
syringes without a prescription to persons at least 18 years of age.6
ESAP was authorized through March 31, 2003, as a demonstration
program. The legislation required an extensive independent evaluation.
Beginning in 2000, NYSDOH developed and implemented
extensive outreach to promote and explain ESAP to secure the
cooperation of agencies and organizations that could maximize
ESAP’s success.
This report provides a brief description of outreach to some key
organizations.
Objectives
To communicate accurate information and promote ESAP in
New York State.
Methods
We used a social marketing approach to identify goals, priority
groups, and approaches for mobilizing partners from diverse sec-
tors. We sought to tailor messages and methods of communication
and to obtain feedback so that program strategies could be adjust-
ed to meet the specific needs of others, such as pharmacists.
We aimed to (1) provide basic program information, (2) gather
recommendations on how to structure regulations and program
requirements pertaining to syringe access, safe disposal, and registra-
tion of eligible providers, (3) encourage referrals to participating
ESAP providers, (4) engage local agencies and organizations in com-
munity-level systems of improved syringe access and safe disposal,
(5) offer training, and (6) ensure access to information for program
evaluation. Not all goals were pertinent to each sector. For example,
goals related to suggestions on regulations and provider registration
were particularly relevant to pharmacies and other eligible providers.
Our priorities for outreach included pharmacies, health care
facilities, health care practitioners, legal/law enforcement agen-
cies, local public health departments, human immunodeficiency
(HIV)/acquired immunodeficiency syndrome (AIDS) prevention
providers, diabetes educators and associations,7 DOH planning or
advisory bodies, and state agencies.
We conducted two mailed surveys, one to gather pharmacists’
perspectives on ESAP regulations and requirements8 and a second
to gather information about syringe disposal from health care facil-
ities required to operate sharps disposal programs.9
Results
Pharmacists
Pharmacists and pharmacy organizations were key ESAP part-
ners. We collaborated with the New York State Education
Department (SED), which licenses pharmacists, and the
Pharmacists Society of the State of New York (PSSNY), and we
met with pharmacy leadership. The SED, the PSSNY, and New
York State-based schools of pharmacy supported ESAP and com-
municated to individual pharmacists.
Comments from the NYSDOH survey of 4,395 licensed phar-
macies in New York State, which was conducted in July and
August 2000,8 were considered in developing the ESAP regula-
tions that became effective March 7, 2001. Every corporation
operating pharmacies in the state was contacted concerning poten-
tial participation in ESAP. NYSDOH developed a streamlined
registration process for corporately owned pharmacies and provid-
ed personalized assistance to those seeking to register multiple
pharmacies in ESAP.
State Agencies
Outreach to state agencies, individually and through such mech-
anisms as the Governor’s Interagency Task Force on AIDS, result-
ed in a high level of interagency collaboration. Ten other New York
State government agencies (in addition to NYSDOH) were
involved in ESAP implementation. Involvement of other state
agencies as avenues for active outreach to, for example, law
enforcement was particularly valuable. New York State’s Division
of Criminal Justice Services (DCJS) and the New York State
Commission of Corrections, and the New York State Police pro-
vided law enforcement officials with written guidance on the
amendments to the Public Health Law that created ESAP. They
also explained how ESAP interfaces with provisions of the Penal
Law, which was not modified by ESAP legislation. In addition, the
DCJS agreed to provide criminal activity data for ESAP evaluation.
Local Health Departments
NYSDOH contacted local health departments directly and
through the New York State Association of County Health
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Officials. Many local health departments promoted ESAP within
their communities, providing information about ESAP to local res-
idents and health and human service providers through news
releases, fliers, brochures, presentations, and county-specific
ESAP “resource directories” for syringe access and safe disposal.
Some expanded options for safe syringe disposal. Several reached
out to other local government agencies and providers (similar to
the outreach by NYSDOH to other state agencies).
Discussion
Our approach involved multiple outreach strategies. We identi-
fied relevant sectors, actively solicited recommendations, engaged
professional organizations, employed multiple methods of com-
munication, reached out to corporate contacts for pharmacy
chains, and developed training and technical assistance to meet
specific needs.
Mobilizing public and private partners for optimal public health
impact of ESAP is a continuing priority for NYSDOH. We built
upon these early experiences and expanded outreach even further.
We also employed multiple strategies to inform consumers about
ESAP and initiated several projects to promote safe disposal of
syringes used outside of health care settings.9
Conclusion
NYSDOH began an extensive outreach program to engage pub-
lic and private sector organizations in maximizing ESAP’s success.
These efforts offer models for other states implementing expanded
syringe access initiatives and similar public health programs.
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Maximizing the Benefits of
Expanded Syringe Access and
Safe Disposal for Persons
with Diabetes
Susan J. Klein, Maureen S. Spence, Rita A. Fahr,
and Hope A. Plavin
Increasing access to sterile syringes is a well established inter-
vention to prevent transmission of human immunodeficiency virus
(HIV) and other blood-borne infections among injection drug
users (IDUs).1 The additional benefits of syringe access initiatives
to individuals who are not IDUs are less well documented. The
Expanded Syringe Access Demonstration Program (ESAP) is a
New York State initiative to prevent the spread of blood-borne dis-
eases, particularly HIV and hepatitis B and C, by providing access
to sterile hypodermic needles and syringes (hereafter referred to as
“syringes”) without a prescription and improving options for safe
disposal of used syringes.2,3 Consistent with legislative intent, the
New York State Department of Health (NYSDOH) prioritized the
development of messages, materials, and methods to promote
syringe access and safe disposal to IDUs. During program imple-
mentation, the benefits of ESAP to other syringe users became
apparent.
New York State PROMOTING PHARMACY SYRINGE SALES
Vol. 42, No. 6, Suppl. 2    November/December 2002 Supplement to the Journal of the American Pharmaceutical Association S29
◆
Syringe Access and Safe Disposal for
Persons with Diabetes
While a wide range of treatments require self-injection of phar-
maceuticals, diabetes affects the largest number of people. As of
1999, in New York State an estimated 832,000 adults age 18 years
and older had diabetes and diabetes was the seventh leading cause
of death.4 According to the Centers for Disease Control and
Prevention (CDC), 5% to 10% of all diagnosed cases of diabetes
are type 1, the management of which requires several injections of
insulin per day.5 These data suggest that between 41,600 and
83,200 individuals in New York State have type 1 diabetes. In
addition, 40% of persons with type 2 diabetes, approximately
300,000 individuals in the state, inject insulin.5 We estimated that
people with diabetes use approximately 250 million syringes each
year in the state of New York.
Most individuals with diabetes have access to sterile syringes
through prescriptions provided by their medical care providers. A
prescription often enables individuals to purchase a large quantity
of syringes, with insurance covering most of the cost. The avail-
ability of syringes without a prescription through ESAP provides
a safety net for individuals who may need to purchase syringes
when traveling or who may need a short-term supply of syringes.
ESAP’s emphasis on safe syringe disposal also benefits persons
with diabetes. Studies at Grady Memorial Hospital in Atlanta
found that most individuals with diabetes failed to use puncture-
resistant containers at home or away from home and disposed of
their used syringes in household trash; accidental needle-stick
injuries among housemates were reported.6,7 A 1989 study of 100
HIV-infected individuals with diabetes in New York City revealed
that 83% disposed of their needles directly into the trash. Only
14% stated they used a puncture-resistant container.8
Finally, while diabetes educators “provide necessary skills and
education for individuals with diabetes…, safe disposal prac-
tice...has not been consistently included in the agenda of diabetes
educators.”9(p321) We identified a need to reach out to diabetes edu-
cators to inform people with diabetes about syringe access and safe
disposal options through ESAP.
NYSDOH Response
Within NYSDOH, the AIDS Institute (which has lead responsi-
bility for ESAP) and the Diabetes Control and Prevention Program
(DCPP) have collaborated on strategies to assure that persons with
diabetes also benefit from ESAP. First, we established routine
meetings of AIDS Institute and DCPP staff regarding ESAP. Day-
to-day communications around specific work projects and prod-
ucts ensued. We collaborated on materials development, letters,
and presentations to the diabetes community. Support of
NYSDOH senior management, the CDC, and an Advocacy
Director of the National American Diabetes Association facilitat-
ed the interdisciplinary collaboration.
Second, we corresponded with the New York State chapters of
the American Diabetes Association and Juvenile Diabetes
Research Foundation, providing updates on ESAP. The DCPP
sent an e-mail letter about ESAP to over 400 participants in a
statewide diabetes listserv and we presented an ESAP overview at
the American Diabetes Association Task Force meeting.
Third, we promoted involvement of diabetes programs and edu-
cators in several community-based syringe access and safe dispos-
al demonstration projects. Staff from the DCPP participated in
statewide demonstration project meetings. These projects provide
unique opportunities to design and develop locally tailored syringe
access and safe disposal programs. One example is a project in
Amsterdam, a town in upstate New York, in which Centro Civico,
an HIV/acquired immunodeficiency syndrome (AIDS) communi-
ty-based organization, developed Project Needle Smart with an
independent pharmacy (Tag’s) and a hospital (St. Mary’s). Project
staff distributed sharps containers at no cost, developed a multi-
media informational campaign, and helped assure that all county
pharmacies were registered with ESAP. Tag’s Pharmacy installed
a sharps collection kiosk, which St. Mary’s Hospital maintains. At
the kick-off event, several persons with diabetes expressed their
appreciation for this new program.
Fourth, we developed a brochure specifically for diabetes edu-
cators and persons with diabetes and their families. We created a
poster for a general audience addressing safe disposal for use in
diabetes clinics, pharmacies, and other provider settings and
updated a consumer brochure entitled Household Sharps–Dispose
of Them Safely. The DCPP provided a sample article about ESAP
to local diabetes coalitions statewide for use in their newsletters. A
hotline for persons with diabetes with information about obtaining
and disposing of syringes is being developed and staff from both
programs are developing training, messages, and resource infor-
mation for hotline operators.
Finally, we convened diabetes educators from all regions of
New York State to: (1) provide them with basic information on
ESAP, (2) identify optimal approaches to inform the diabetes com-
munity about ESAP, and (3) examine ways to evaluate the impact
of ESAP on the diabetes community. In the opening remarks, a
person with diabetes described her personal experience of being
stranded in New York City without necessary supplies, including
syringes, when a prescription was still required, a powerful affir-
mation of the relevance of ESAP to persons with diabetes. The dia-
betes educators who attended provided feedback on materials
being developed. We are creating a 15- to 20-minute videotape
and trainers’ manual to be used to train diabetes educators and
providers about expanded syringe access and safe disposal
options.
Linking ESAP and Diabetes
Linking AIDS Institute and DCPP staff allowed us to accom-
plish a great deal in a short period of time. We found that messages
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and methods designed for IDUs needed to be adapted to the needs
of individuals with diabetes, their families, diabetes educators, and
other diabetes providers. Diabetes educators and others in the dia-
betes community had strong negative reactions to ESAP materials
tailored to the needs of IDUs. Persons with diabetes do not want to
be confused with or identified as IDUs. Public perceptions about
HIV/AIDS also meant that use of already-existing statewide
HIV/AIDS hotlines that routinely provide ESAP-related informa-
tion was not an appealing option for the diabetes community, nor
was access to ESAP information on the NYSDOH Web site
through the “HIV/AIDS” portion of the site. Alternatives had to be
found for the program to be effective.
Diabetes educators were interested in learning about ESAP and
provided feedback on a consumer brochure and training needs and
strategies. They believed their patients could benefit from easier
access to syringes and improved disposal options and indicated
that they would utilize materials that effectively addressed these
needs.
We also engaged endocrinologists and clinical care centers.
When we discussed ESAP via telephone conference call with the
NYSDOH-designated “Diabetes Centers of Excellence,” endocri-
nologists identified safe disposal as a major challenge that they and
their patients face. We offered to develop the safe disposal poster,
noted above, and agreed to collaborate on a survey regarding dis-
posal practices, to be implemented at the Centers of Excellence.
AIDS Institute staff has identified other clinical facilities interest-
ed in implementing the survey.
Conclusion
We have found that ESAP, a program that was intended for
IDUs, has wider benefits potentially involving hundreds of thou-
sands of New York State residents who use syringes to inject
insulin. They can now purchase up to 10 syringes at a time, 
without a prescription, and they benefit from new, improved
options for safe syringe disposal. Through collaboration between
NYSDOH program areas and with the larger diabetes community,
we were able, in a short period of time, to generate new educa-
tional programs and materials tailored to the interests of people
with diabetes. The diabetes community has enthusiastically
embraced ESAP-related efforts to enhance the availability and safe
disposal of syringes.
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Encouraging Pharmacy Sale
of Syringes to Injection Drug
Users in New Mexico
Tim Wolfe, Vivian Amelunxen, Donald
Torres, Steven Jenison, and Jack Churchill
Injection drug use is a prominent public health problem in both
urban and rural New Mexico.1 The New Mexico legislature enact-
ed laws in 1997 and 2001 to help increase sterile syringe avail-
ability to injection drug users (IDUs) to prevent transmission of
human immunodeficiency virus (HIV) and other blood-borne
pathogens. The 1997 laws authorized syringe exchange programs
(SEPs) in New Mexico, and the New Mexico Department of
Health (DOH) supported the development of a statewide SEP net-
work. Based on enrollment surveys as of June 19, 2002, 20 SEPs
were operational and served a total of 4,628 clients.
Some IDUs have purchased syringes at community pharmacies,
including those in areas served by SEPs. In the parts of New
Mexico without access to SEPs, pharmacies have been a particu-
larly important source of sterile syringes. In 2001, to alleviate the
concerns of some pharmacists that selling syringes to IDUs might
not be fully legal, the state legislature amended the Controlled
Substances Act to specifically exempt pharmacists from criminal
liability for selling syringes to persons who did not have docu-
mented medical need.
Pharmacy Project
In 2001 DOH’s Infectious Disease Bureau initiated a
“Pharmacy Project” to encourage pharmacy owners, managers,
and staff to sell sterile syringes to persons who might be IDUs. The
project goals were to (1) assess the attitudes of pharmacists about
selling syringes to persons they believe to be IDUs, (2) encourage
pharmacists to sell syringes to persons who might be IDUs, and (3)
encourage pharmacists to refer customers who might be IDUs to
SEPs. DOH also published a brochure describing how pharmacists
could become involved in improving access to sterile syringes in
their communities and mailed the brochure to all state-licensed
pharmacies. The Infectious Disease Bureau mailed all licensed
pharmacies a copy of the new pharmacy law and a letter encour-
aging them to view selling syringes to IDUs as one way to reduce
transmission of HIV and viral hepatitis.
In 2001 there were 486 pharmacies in the state. As the principal
activity of the Pharmacy Project, we selected 100 pharmacies in
areas that lacked convenient access to SEPs and that, based on
consultation with HIV prevention and drug treatment specialists,
had high levels of drug use. In May and June 2001, a DOH repre-
sentative visited these pharmacies and met with pharmacy owners
and managers to determine their level of understanding about
efforts to improve syringe availability and to encourage their par-
ticipation in selling syringes to IDUs in their community.
The DOH representative spoke to the owner or manager at 70
pharmacies and to an on-duty staff pharmacist at 30. The respons-
es of owners/managers and staff pharmacists were similar.
Many Pharmacists Unaware of New
Pharmacy Law
Before DOH’s visit or mailing, 52 pharmacists did not know
about the changes in pharmacy law. Many pharmacists believed
that it had always been legal to sell syringes to customers who did
not have documented medical need. After the DOH representative
explained the new law, most pharmacists applauded the change.
Although most pharmacists were reluctant to report on commu-
nity drug use based solely on their observations of pharmacy cus-
tomers, 67 pharmacists believed that their community had at least
some injection drug use problem and 3 reported no problem.
Eighty-seven pharmacists reported past requests for syringes by
customers lacking documented medical need. Many pharmacists
offered unsolicited reports of having sold syringes to customers
without documented medical need. Many pharmacists expressed
the belief that providing a sterile syringe for an illegal activity was
justified because it could reduce disease transmission. Of the six
pharmacists who stated they had not had requests for syringes, two
did not sell syringes at all, two reported that they did not know of
IDUs in their communities, and two refused to do business with
persons they believed injected illegal drugs.
Sixty-five pharmacists stated that as a result of the new law,
they were more willing to sell syringes without a prescription; 27
that they might be more willing; and 8 that they still were not will-
ing. These “unwilling” pharmacists were in communities that had
at least one other pharmacy that was willing to sell syringes.
Among those pharmacists who might be more willing, all stated
they would sell syringes on a case-by-case basis.
Pharmacists Unaware of SEPs
Pharmacists were asked about their knowledge of SEPs in the
state. Twenty-two pharmacists said they had at least some knowl-
edge of SEPs and 78 reported little or no knowledge. During all
pharmacy visits, the DOH representative provided an overview of
syringe access initiatives. Ninety-one pharmacists were interested
in more information about the Pharmacy Project and other harm-
reduction activities and seven referred the DOH representative to
their owner/manager. The two pharmacists who did not want addi-
tional information worked at pharmacies that turn away suspected
drug users at the door. Most pharmacists were very interested in
brochures about harm-reduction sites in their community that they
could give to persons they believed could benefit from the pro-
gram.
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Safe Syringe Disposal
The DOH representative also discussed options for safe syringe
disposal. At the start of the project, a sharps container was offered
to any pharmacy that indicated they were willing to have cus-
tomers bring in loose used syringes; the local health department
office would collect and dispose of the containers when full.
Twenty-six sites were offered a sharps container and nine accept-
ed. However, DOH suspended this part of the program to investi-
gate a more comprehensive syringe disposal program. At the time
of publication, DOH was considering disposal using repainted
“drop boxes” at fire stations and public health offices. One local
public health office was willing to have a disposal drop box put at
their office and another was interested in placing a sharps contain-
er in the office that could be used by customers.
Conclusion
Before DOH intervention, pharmacists were not well informed
about SEPs or the pharmacy law change. DOH outreach to phar-
macists was well received. Similar public health department out-
reach to pharmacists may be helpful in other states to increase
pharmacist knowledge and acceptance of programs to increase
IDU access to sterile syringes as part of public health interventions
to prevent blood-born disease transmission.
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Provisional Recommendations to Drug Users Who Continue To Inject
Health care workers involved in programs that serve drug users should communicate the following recommendations to drug
users who continue to inject. Adhering to these drug preparation and injection procedures will reduce the public health and
individual health risks associated with drug injection for both drug users and other persons in their communities.
Persons who inject drugs should be regularly counseled to:
I. Stop using and injecting drugs.
II. Enter and complete substance abuse treatment, including relapse prevention.
III. Take the following steps to reduce personal and public health risks, if they continue to inject drugs:
■ Never reuse or “share” syringes, water, or drug preparation equipment.
■ Use only syringes obtained from a reliable source (e.g., pharmacies).
■ Use a new, sterile syringe to prepare and inject drugs.
■ If possible, use sterile water to prepare drugs; otherwise use clean water from a reliable source (such as fresh tap 
water).
■ Use a new or disinfected container (“cooker”) and a new filter (“cotton”) to prepare drugs.
■ Clean the injection site prior to injection with a new alcohol swab.
■ Safely dispose of syringes after one use.
United States Public Health Service. HIV prevention bulletin: medical advice for persons who inject illicit drugs. May 8, 1997. Available at:
www.cdc.gov/idu/pubs/hiv_prev.htm. Accessed October 30, 2002.
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Pharmacy Student Knowledge,
Attitudes, and Beliefs About
Selling Syringes to Injection
Drug Users
Wendy J. Blumenthal, Kristen W. Springer, T. Stephen Jones, and 
Claire E. Sterk
Injection drug use is a major risk factor for human immunode-
ficiency virus (HIV) transmission in the United States.1 As of June
2001, 29% of adult acquired immunodeficiency syndrome (AIDS)
cases in the United States were associated directly or indirectly
with injection drug use.2 A comprehensive approach to HIV pre-
vention among injection drug users (IDUs) includes advising those
who continue to inject drugs to use sterile syringes obtained from
a reliable source such as a pharmacy.  However, many IDUs obtain
syringes from street sources (e.g., needle dealers, other IDUs,
shooting galleries) rather than from pharmacies or syringe
exchange programs.3–4 Laws, pharmacy regulations, and pharma-
cists’ attitudes and beliefs influence whether IDUs can purchase
sterile syringes at pharmacies.5–7
In the state where this study was conducted, a prescription is not
required for pharmacy syringe sales. The state pharmacy board
prohibits pharmacists from selling syringes if the pharmacist
believes the syringes will be used for an unlawful purpose. The
state drug paraphernalia law prohibits the sale, distribution, or pos-
session of paraphernalia used to consume drugs, including
syringes. To be in violation of the drug paraphernalia law, the per-
son selling a syringe has to know that it would be used to inject
illegal drugs.8 There are no known reports of pharmacists prose-
cuted under such a provision in any jurisdiction in the United
States (S. Burris, personal communication, April 2002).
Objectives
The objectives of this study were to explore pharmacy school
education and pharmacy students’ knowledge, attitudes, and beliefs
about HIV/AIDS, drug use, and syringe sales to IDUs. To our
knowledge, this is the first such study of U.S. pharmacy students.
Objective: To explore pharmacy school education and pharmacy students’ knowledge, attitudes, and beliefs about human immunod-
eficiency virus (HIV) and acquired immunodeficiency syndrome (AIDS), drug use, and syringe sales to injection drug users (IDUs).
Design: Qualitative study of a convenience sample of pharmacy school students. Setting: A pharmacy school in the southeastern
United States. Intervention: Two focus groups and nine in-depth interviews were conducted about HIV/AIDS education and counsel-
ing, syringe sales to possible IDUs, and related pharmacy school education. Participants: 19 Doctor of Pharmacy students, including
88 students in their third professional year and 11 in their fourth professional year. Results: Most participants believed that they would
benefit from more class time on HIV/AIDS topics, including AIDS treatment medications and HIV prevention. Most participants believed
that the laws and regulations governing syringe sales in their state were vague, leaving syringe sale decisions to pharmacists’ discre-
tion. Nine study participants supported selling syringes to possible IDUs, five opposed it, and five were undecided or ambivalent.
Classroom education focused on addiction to prescription drugs, with limited attention to illicit drug use. Conclusion: Pharmacy stu-
dents have divided opinions about selling syringes to IDUs. To prepare students for helping their patients with drug-use problems, phar-
macy schools should increase training about HIV/AIDS and addiction. Policy makers should consider changing laws and regulations of
syringe sales to recognize prevention of blood-borne infections as a legitimate medical purpose for selling syringes to IDUs.
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RESEARCH
Methods
We used e-mail, flyers, and in-class announcements to recruit
participants from students in their third and fourth professional
years in a Doctor of Pharmacy program at a pharmacy school in
the southeastern United States. Between November 1997 and
March 1998, after obtaining informed consent, we conducted nine
in-depth interviews and two focus groups of five participants. The
45- to 90-minute interviews and focus groups were conducted in
private rooms at the pharmacy school. We provided participants
with a meal or cash compensation ($5 to $15) for their time. We
included questions about HIV/AIDS education and counseling,
selling syringes to possible IDUs, and pharmacy school education
related to HIV/AIDS, drug use and addiction, and selling syringes.
For example, one interview question asked, “How do you person-
ally feel about the idea of selling syringes to persons who might be
injection drug users?” Readers can obtain copies of the interview
and focus group guide questions by contacting the corresponding
author.
Sessions were recorded by audiotape and transcribed. The
guides for these focus groups and interviews were adapted from
findings of studies of pharmacists9–16 and further refined as themes
emerged. Using transcripts from the first three interviews and the
first focus group, one researcher developed a coding scheme guid-
ed by the research questions and based on important themes in the
data. Two other researchers used this coding scheme to code one
interview, and some alterations were made in the scheme. The
three researchers then coded three more interviews using this
revised scheme, and found strong similarities, suggesting interrater
reliability. Qualitative data management software (The
Ethnograph, Qualis Research Associates, Salt Lake City, Utah)
was used to organize the data for coding and analysis. The names
used in this report are not the participants’ real names.
The Emory University Human Investigations Committee approved
the study proposal and consent forms on October 30, 1997.
Results
The convenience sample of 19 students included 8 students in
their third professional year and 11 students in their fourth profes-
sional year. The participants ranged in age from 22 to 38 years, and
89% were women. All participants had worked in pharmacies as
interns or employees. Four (21%) reported working in a pharmacy
they believed to be in an area with a high or very high level of
injection drug use; however, 12  (63%) had worked in pharmacies
in areas with low, little, or no drug use.
Pharmacy School HIV/AIDS Education
Most participants recalled lectures on the epidemiology, physi-
ology, pathology, and treatment of HIV/AIDS. Several recalled
classroom discussions about HIV transmission but limited infor-
mation on HIV prevention. One participant described a discussion
about reducing syringe sharing among IDUs to prevent HIV trans-
mission.
Most participants suggested that more class time be spent on
HIV/AIDS topics, such as opportunistic infections, organ systems
affected by HIV, HIV prevention, and more in-depth coverage of
AIDS treatment medications. One participant expressed a need for
more exposure to the “personal side” of HIV/AIDS, for example,
hearing from people living with HIV. Another recommended
incorporating HIV prevention (e.g., talking about condoms or
syringes) into a laboratory class discussion.
Knowledge, Attitudes, and Beliefs About
Drug Use, IDUs, and Addiction
According to the participants, issues of injection drug use and
addiction received limited class time. Discussion related to addic-
tion focused on detecting forged prescriptions for controlled sub-
stances and the risk for addiction among pharmacists and other
health professionals. Discussions of substance abuse treatment
were limited to treatment programs for pharmacists.
A few participants reported class discussions about how phar-
macists can respond to and counsel addicted patients. One partici-
pant recalled a lecture about the role of pharmacists in intervening
with addicted persons. Others recalled being taught they cannot
help people who do not want to help themselves.
Some participants expressed varying degrees of intolerance of
drug use, ranging from beliefs that drug use is wrong, a poor
choice, or stupid, to the following more extreme view:
I may be really insensitive, but I think—and this is my per-
sonal opinion; I’m sure no one else thinks this—but if they
are dumb enough to get themselves in that situation, I don’t
have any pity for them…If they’re low enough to use an illic-
it drug, that’s their problem. 
—Alicia, third year
Some expressed beliefs that drug users were a homogeneous
group, referring to IDUs as “they” and “drug abusers.”  Many par-
ticipants expressed negative views of drug users by describing
their appearance as “matted hair and goopy make-up,” and “tat-
tered and…rail thin.” One participant labeled drug users as
“scuzzballs” and “weirdoes.” Some voiced concerns about the
dangers that drug users might pose to pharmacists, staff, other cus-
tomers, and the general community, fearing robberies, attacks,
“raising a scene,” and car crashes.
A contrasting opinion was that pharmacists should not make
moral judgments. One participant spoke at length about society’s
lack of sympathy for, and intolerance of, IDUs compared with
users of legal substances such as alcohol, as follows:
I guess using drugs, unlike using alcohol, is not really con-
sidered a disease…. There’s been more sympathy in the eyes
of the public and health care workers for the alcoholic. I don’t
think there’s that same sympathy for the IV drug user…I don’t
think it’s a desired lifestyle. I don’t think it’s something that
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somebody gets up every day and wants to do it…If it’s a phys-
ical addiction…is that a choice? I don’t think so. 
—Mary, fourth year
Pharmacists’ Role in Counseling and
HIV/AIDS Education
Of the participants who discussed counseling, most believed
that part of the pharmacist’s responsibility is to promote health,
educate, and counsel patients. One participant described counsel-
ing about medications and their adverse effects. Some spoke
specifically about the desire to see an expanded pharmacist role in
health education.
I’d like to see the pharmacist get away from dispensing and
play a very large role in health education. I think doctors
are overwhelmed right now, and I think we’re a valuable
source of information, not to replace, but to work with doc-
tors and nurses… I’d love to see them get away from the tra-
ditional dispensing.
—Mary, fourth year
Participants brought up a number of barriers to providing
HIV/AIDS education and counseling. Concerns raised most fre-
quently were lack of privacy for conversations and possible patient
embarrassment. Greater privacy would make it easier to provide
HIV/AIDS counseling. There was also the concern that offering
HIV/AIDS prevention messages could offend some patients.
Participants believed that pharmacists should be prepared to pro-
vide HIV/AIDS information and counseling if requested, but that
they should not do so unsolicited.
Knowledge, Education, and Interpretation of
Syringe Sale Laws and Regulations
Most of the fourth-year participants, who had completed rele-
vant classes such as Law and Ethics, recalled limited class discus-
sion regarding selling syringes; they recalled an ethics debate and
a discussion of requirements to sell syringes for “legitimate medi-
cal purposes.” However, most of the participants were either unfa-
miliar with or unclear about the state laws and regulations govern-
ing selling syringes.
After the interviewer read the laws and regulations, participants
were asked for their reactions and interpretations. Most viewed the
law as vague, leaving syringe sale decisions up to the pharmacist’s
discretion. Some participants were particularly frustrated by the
position in which they would be placed because of the law’s lack
of clarity.
That’s…leave it up to you open-ended interpretation.
Unlawful purpose, you know, that’s still, still asking phar-
macists to make a moral judgment…The laws are just not
realistic.
—Kelly, fourth year
Several study participants preferred that decisions about selling
syringes be taken out of their hands. Some felt that the current sit-
uation places an “unfair burden” on the pharmacist by leaving the
decision to pharmacist discretion. Several participants in favor of
selling syringes to IDUs would prefer clearer guidance from the
laws and regulations.
The fact that our society is plagued with drug use is a bad
sign of our society, but it’s not fair for the pharmacist to
have to decide…“It’s okay to sell to this person, but it’s not
okay to sell to that person.” People who use drugs, if they
want to use needles to do their drugs then they should be
able to go some place and get needles.
—Angela, fourth year
Many participants would have liked clearer guidance from the
state government and board of pharmacy. Some wanted support
for refusing to sell syringes, and others would feel more comfort-
able selling syringes to IDUs if they knew that state law and/or the
pharmacy board would back them up.
I think that if the law were more supportive of doing it, that
probably more pharmacists would do it; but I think because
we’re put in a position of having to determine the legitimate
medical need that a lot of pharmacists don’t want to be both-
ered with having to figure it out.
—Jill, fourth year
Attitudes and Beliefs About Selling Syringes
When asked for their personal opinions about selling syringes to
possible IDUs as an HIV-prevention strategy, nine participants
supported this strategy, five opposed it, and five were undecided
or ambivalent.
So by all means, sell them. Sell them by the truckload. They
ought to be free, you know?  AIDS is such an amazing epi-
demic; it’s just growing every day. And if we can do this,
pharmacists can do this small part, then take this role and
help prevent the spread of this disease. I’d give them out on
the street corner, free.
—Kelly, fourth year
Others did not believe pharmacy syringe sales would prevent
syringe sharing or HIV transmission. They believed that providing
a sterile syringe to an IDU would not prevent that person from
reusing the syringe and passing it on to other IDUs. Most of those
who opposed selling syringes to IDUs believed that it condones or
promotes drug use.
If [drug use] was never a problem in the first place, we
wouldn’t have to deal with it. I know it always will be, but I
just can’t see promoting it by giving out syringes.
—Alicia, third year
Another strong belief for those who opposed selling syringes to
IDUs was that selling syringes conflicted with their view of the
pharmacist as a health care professional. One participant, who
believed that selling sterile syringes to IDUs would probably help
prevent HIV transmission, felt that doing so violated the pharma-
cist’s oath.
Unless someone had a documented medical reason to use
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them, I’m not going to give it out because I think I’m allow-
ing somebody potentially to…open the door for potential
abuse of a drug; and as a pharmacist, that’s against my
oath. That’s against my whole practice.
—Jonathan, third year
Concerns about selling syringes reflected the negative percep-
tions of drug users. A few participants made general statements
about not wanting “that type of person” to come into the pharma-
cy. Both supportive and opposed participants were concerned
about gaining a reputation as the “neighborhood needle supplier.”
I wouldn’t want those scuzzballs coming into my store and
hanging around because then, I mean, they tell all their
other little druggie friends, “Oh yeah, that person sells me
needles,” and then, you know, they all come in.
—Julie, fourth year
Not all participants expressed these concerns. One had few
reservations and believed strongly that refusing to sell syringes to
certain individuals would reflect an inappropriate moral judgment
about drug use.
I’m not concerned about…you know, drug abusers keep com-
ing into my pharmacy. If they want to keep coming, fine. You
know, if they need syringes, fine; they may have them; I will
sell them to them. I don’t have any concerns about that at all.
—Kelly, fourth year
Some participants viewed selling syringes as not only an oppor-
tunity for HIV/AIDS prevention, but also for drug-use counseling.
The chance and even obligation to intervene by offering help or
providing referrals to substance abuse treatment or other services
were discussed a number of times. Some thought that selling
syringes to IDUs must be accompanied by counseling.
Discussion
Our findings suggest that pharmacy students’ attitudes and
beliefs about selling syringes to IDUs are similar to those of prac-
ticing pharmacists. Individuals from both groups support, oppose,
or are uncertain about selling to IDUs. Like pharmacists, these stu-
dents had strong beliefs and opinions for or against selling syringes
to IDUs, and some were concerned about a potential negative
effect on other business.6,7,17,18
Many participants requested clearer guidance from state law
and the board of pharmacy. Practicing pharmacists have made
similar requests for clearer legal and regulatory policies about sell-
ing syringes to IDUs.6,7,17 The Washington State Board of
Pharmacy has amended its regulations to specify that selling
syringes to prevent blood-borne disease transmission is a legiti-
mate purpose for such sales,19 and the board in Maine clarified
state law by stating that pharmacists are expected to sell nonpre-
scription syringes to all customers.20
A few participants believed that selling syringes would violate
their professional ethics as pharmacists. In fact, leading pharmacy
and medical organizations—including the American
Pharmaceutical Association, National Association of Boards of
Pharmacy, and American Medical Association—issued a joint
statement in 1999, HIV Prevention and Access to Sterile
Syringes.21 The statement clearly supports increasing access to
sterile syringes for IDUs with the closing point that the sponsoring
organizations “believe that coordinated efforts of state leaders in
pharmacy, public health, and medicine are needed to address
access to sterile syringes as a means of preventing further trans-
mission of blood-borne diseases.”21 Each association has estab-
lished policies supporting increasing access to sterile syringes21;
since 1987, 11 states have deregulated the sale or possession of a
least some number of syringes.5 
Findings also highlight topics that could be included in a com-
prehensive pharmacy curriculum designed to address the issues
related to addiction and the prevention of blood-borne infections.
First, students could benefit from more information about drug use
and addiction, particularly to dispel stereotypes of drug users.
Participants who expressed negative views about the character,
appearance, and behavior of IDUs were more often opposed to
selling syringes to IDUs. Those who favored selling syringes to
IDUs had the most tolerant views of drug users. Many studies of
pharmacists’ attitudes have found similar relationships between
attitudes toward IDUs and support or opposition to selling syringes
to them.6,10,11,22 Pharmacy school emphasis on vigilance to detect
bogus prescriptions for controlled substances may contribute to the
negative views of drug users.
A second component of the curriculum could be enhanced
instruction and discussion on HIV/AIDS prevention.  Some par-
ticipants believed that selling syringes promoted drug use or that
increased syringe access would not reduce the risk of HIV/AIDS
transmission.  However, a number of studies have shown that
improved access to sterile syringes does reduce the risk for
HIV/AIDS transmission and does not increase drug use.23–25 Some
studies showed that IDUs engage in less frequent syringe sharing
when they obtain their syringes in pharmacies.26–28 Professional or
continuing education programs for pharmacists about HIV/AIDS
prevention, including the sale of sterile syringes, should address
the concerns raised by participants.
Concerns about pharmacy staff safety and the effect on other
customers agree with findings from surveys of pharmacists.11,12
Pharmacy education could provide students with data about posi-
tive experiences of pharmacists who sell syringes, as well as data
from studies that discuss negative incidents and other effects of
selling syringes on pharmacies.13–16
In recent years pharmacists have been developing new initia-
tives to provide more direct patient care, including health promo-
tion and disease prevention (e.g., influenza immunizations).29
HIV/AIDS counseling and prevention could be a major compo-
nent of this expansion.9,30 Most participants in our study believed
that pharmacists should play a key role in counseling. Thus, phar-
macy schools could also discuss HIV prevention and syringe sales
in the context of the pharmacist’s role in counseling patients,
including those with drug addictions. At the same time, however,
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pharmacy school education should address the perceived barriers
to providing HIV/AIDS risk-reduction messages in the pharmacy;
whether the perception about customers’ discomfort regarding
HIV/AIDS counseling is accurate or not, private counseling areas
in pharmacies may help to overcome this barrier.
Limitations
First, this study used a convenience sample of a small number
of students from one school; its findings may not be generalizable
to all students at this or other pharmacy schools. Second, including
students in their third professional years of study may have led to
an incomplete picture of the coverage of these topics in the school
of pharmacy classes. Third, participant recall of class content may
not have been accurate. Nonetheless, the qualitative research
methods used in this study provided in-depth information on a
topic not previously studied among pharmacy students.
Conclusion
Our study of pharmacy students supports the findings of studies
of practicing pharmacists. It reinforces the need for a collaborative
effort between public health and pharmacy agencies to increase
pharmacy syringe sales to IDUs as part of a comprehensive HIV-
prevention strategy. As pharmacists move away from simply dis-
pensing medications and toward increasing involvement with
patients and development of settings more conducive to discussion
of sensitive topics (including addiction, injection drug use, and
HIV/AIDS prevention), pharmacy students should be more aware
that selling syringes to IDUs for disease prevention has a legiti-
mate medical purpose. It is equally important to focus on changes
and clarifications to the laws and regulations governing syringe
sales. Clear guidance that selling syringes to prevent blood-borne
infections among IDUs is accepted and recommended by pharma-
cy boards and legal authorities should help pharmacists choose to
make such sales.
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HIV Prevention & Access to Sterile Syringes
Dear Colleague:
Approximately one third of all AIDS cases and one half of hepatitis C cases are directly or indirectly linked to injection drug
use. Limited access to sterile syringes contributes to the transmission of these blood-borne infections among injection drug
users (IDUs), their sex partners, and their children.
The United States Public Health Service recommends that drug users who continue to inject use a new, sterile syringe for each
injection to prevent the transmission of blood-borne pathogens and that they obtain syringes from reliable sources such as pharmacies.
In many states, there are legal and regulatory barriers to the pharmacy sale of sterile syringes to IDUs, including prescription
and drug paraphernalia laws and pharmacy regulations on syringe sales. The American Medical Association (AMA), the
American Pharmaceutical Association (APhA), the Association of State and Territorial Health Officials (ASTHO), and the
National Alliance of State and Territorial AIDS Directors (NASTAD) have suggested that the removal or modification of legal
barriers is an important step in increasing the availability of sterile syringes through pharmacies. Connecticut, Minnesota, and
Maine have made such changes.
.   .   .   .   .   
AMA, APhA, ASHTO, NASTAD, and the National Association of Boards of Pharmacy (NABP) believe that coordinated
efforts of state leaders in pharmacy, public health, and medicine are needed to address access to sterile syringes as a means of
preventing further transmission of blood-borne diseases.
We encourage you and other state leaders in these fields to meet, assess the situation in your state, and decide on appropriate
approaches to these important public health issues. Other issues that may be important to consider are the availability of sub-
stance abuse treatment and options for safe disposal of syringes
National Alliance of State and Territorial AIDS Directors. HIV prevention and access to sterile syringes. [Joint letter issued by the American Medical Association, American
Pharmaceutical Association, Association of State and Territorial Health Officials, National Association of Boards of Pharmacy, National Alliance of State and Territorial AIDS
Directors.] October 1999. Available at: www.nastad.org/PUBLICPOLICYRESOURCES/HIVPREVSTERILESYRINES.PDF.  Accessed October 18, 2002.
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Individual and Structural
Influences Shaping Pharmacists’
Decisions to Sell Syringes to
Injection Drug Users in Atlanta,
Georgia
Jennifer Taussig, Benjamin Junge, Scott Burris, T. Stephen Jones, and
Claire E. Sterk 
In the United States, approximately one-third of all reported
cases of acquired immunodeficiency syndrome (AIDS)1,2 and
about one-half of new cases of hepatitis C virus3 are directly or
indirectly associated with injection drug use. These associations
are largely attributed to the sharing and reuse of syringes and other
injection equipment.4–6 Multiperson use of syringes among injec-
tion drug users (IDUs) is primarily caused by an artificial scarcity
of sterile syringes in the community.7 Multiple barriers restrict
IDU access to sterile syringes from reliable sources such as com-
munity pharmacies. These barriers include laws and regulations
governing syringe sales and restrictive syringe sale practices of
some pharmacists.8–17
Community pharmacies are a means for providing IDUs with
access to sterile syringes. Pharmacies are conveniently located
throughout communities, are customer oriented, typically operate
6 or 7 days a week, and provide easy access to a health care pro-
fessional.
In the United States, the main structural barriers limiting IDUs’
access to sterile syringes from pharmacies are state laws and regu-
lations governing the sale and possession of syringes.7,8 Laws in 10
U.S. states and 1 U.S. territory require a prescription for the pur-
chase of syringes; however, in 4 of these states, 10 or fewer
syringes can be purchased without a prescription. Drug parapher-
nalia laws in the District of Columbia and every state (except
Alaska) prohibit the sale, distribution, and possession of a variety
of injection equipment, including syringes, although a number of
Objective: To better understand the individual (e.g., attitudes and beliefs) and structural (e.g., laws and regulations) factors that influ-
ence and shape pharmacists’ decisions about selling syringes to injection drug users (IDUs). Design: Qualitative research. Setting:
Metropolitan Atlanta. Participants: 20 practicing pharmacists who work in or near areas of high drug use in Atlanta, and nine phar-
macists who are considered leaders in their profession in Georgia. Interventions: Semistructured, in-depth interviews. Main
Outcome Measures: Individual and structural factors that influence pharmacists’ decisions about selling syringes to IDUs. Results:
Pharmacists reported that they use their professional discretion in making syringe sale decisions and that these decisions are influenced
by individuals factors such as their personal attitudes and beliefs about the nature and causes of drug use, and by structural factors
such as the Georgia Board of Pharmacy regulation stating that syringes cannot be sold if they will be used for an “unlawful purpose.”
Conclusions: IDUs’ access to sterile syringes from pharmacies in Atlanta, would likely be increased by (1) providing practicing phar-
macists with professional education programs that describe the broad professional support for IDU access to sterile syringes and why
blood-borne infection prevention is a legitimate medical purpose for selling syringes and (2) removing or modifying the restrictive
Board of Pharmacy regulation governing syringe sales.
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RESEARCH
states’ laws contain exemptions that allow at least some syringe
sales to IDUs at the discretion of the pharmacist. Pharmacy boards
or state health agencies may also regulate syringe sales by requir-
ing syringe purchasers to show identification or demonstrate that
the syringes will be used for a lawful or legitimate medical purpose.
Regardless of the legal status of selling syringes to IDUs, indi-
vidual pharmacists make the final decision about selling syringes
to a possible IDU. Individual barriers include negative attitudes
and moral beliefs about drug users, human immunodeficiency
virus (HIV) prevention, and selling syringes.9–17
We present findings from a qualitative study conducted in 1998
on the determinants of pharmacists’ syringe sale practices with IDUs
in Atlanta. Georgia has no law requiring a prescription for syringe
purchases; however, a Georgia State Board of Pharmacy regulation
requires pharmacists to determine with “reasonable cause” that
syringes they sell will not be used for an “unlawful purpose.”18 The
Georgia drug paraphernalia law prohibits the sale, distribution, and
possession of paraphernalia, including syringes, that may be used for
injecting illegal drugs.19 Whether the drug paraphernalia law applies
to selling syringes to IDUs in pharmacies is unclear, although no
pharmacist in Georgia has been prosecuted for violating the drug
paraphernalia law by selling syringes to IDUs.20
Objectives
The goal of this study was to gain a better understanding of how
(1) individual pharmacist’s attitudes and (2) syringe laws and reg-
ulations influence pharmacists’ decisions whether to sell syringes
to persons who may be IDUs.
Methods
The findings of a 1995 survey of pharmacists’ attitudes and
practices toward the sale of syringes to IDUs in metropolitan
Atlanta were used to plan this study.13
We conducted semistructured, in-depth interviews with 
(1) pharmacists who work in or near areas of high drug use in
Atlanta, and (2) pharmacists considered leaders in their profes-
sion in Georgia.
The 29 participants were recruited using a modified conve-
nience sample. We used theoretical sampling to ensure that we
reached a point of saturation.21,22 Saturation means that no new
patterns or themes are identified; qualitative researchers typically
stop data collection once the point of saturation has been
reached.23,24 We used drug treatment admissions, emergency room
episodes, and informal conversations with researchers and service
providers working with drug users to identify pharmacies in or
near areas of high drug use.25,26 The leaders, selected because of
their potential influence on state laws, regulations, and opinion,
were pharmacists involved in the state pharmacy professional
association, members of the Georgia State Board of Pharmacy,
faculty members at a school of pharmacy, or members of the
Georgia Legislature.
Trained interviewers asked written core questions and probed to
clarify responses. The main interview topics were pharmacists’ 
(1) attitudes and beliefs about the sale of syringes to IDUs and 
(2) syringe sale practices and the individual and structural factors that
influence these practices. Interviewers were a graduate student in
public health and the research coordinator, both of whom were
trained for this study by a PhD qualitative researcher. All interviews
were audiotaped and transcribed verbatim. QSR NU*DIST software
(Scolari, Sage Publications, London, England, 1997) was used to
manage and analyze the qualitative data.27 Data were coded using a
coding scheme based upon the research questions and emerging vari-
ables. Intercoder reliability was established by having three qualita-
tive researchers code all of the interviews. The Emory University
Institutional Review Board approved this study in April 1998.
To protect study participant confidentiality, no names or identi-
fying information are used in this report. We use verbatim quotes
in the results section and provide demographic information about
the respondent being quoted. These quotes are representative of
salient themes rather than representative of the overall sample. The
latter would be important in quantitative research.24
Results
Of the 29 respondents, 20 were practicing pharmacists and 9 were
pharmacist–leaders. All 9 leaders held pharmacy degrees, and 7
were practicing pharmacists in addition to their leadership roles. The
total sample (29) was approximately two-thirds male, 46% African
American, 54% white, with a mean age of 44.8 years. Among the 27
respondents currently practicing as pharmacists, the mean number
of years of practice was 17.5, with a mean of 9.5 years at the current
pharmacy. Almost one-half (48%) of the pharmacies were indepen-
dent; the rest were part of pharmacy chains. Slightly more than one-
half (16; 57%) of all respondents held bachelor in pharmacy
degrees; the others had doctor of pharmacy degrees.
Practicing Pharmacists
We found that decisions about selling syringes to potential
IDUs are largely left to the discretion of the pharmacist.
It’s left for the pharmacist who is on duty to decide. So my
personal opinion is different from my partner…They use
their own discretional measures. I leave those things to
them. These are professionals. I cannot tell them how to
operate, but they can use their own simple rational way of
deciding when or when not to sell the syringes.
—44-year-old African American
male chain pharmacy manager
Three clusters of influences that shape these decisions emerged,
two individual and one structural: (1) personal attitudes and beliefs
about drug users and HIV/AIDS, (2) concerns about deception,
and (3) concerns about legality.
Vol. 42, No. 6, Suppl. 2    November/December 2002 Supplement to the Journal of the American Pharmaceutical Association S41
Atlanta     PHARMACISTS’ ATTITUDES
Attitudes and Beliefs
Pharmacists’ attitudes and beliefs about drug use, drug users, and
HIV/AIDS were strongly linked to their decisions whether to sell
syringes to suspected IDUs. Not surprisingly, respondents who con-
sider drug addiction a personal choice and a matter of personal
responsibility were less disposed to sell syringes to a suspected IDU.
Well, I think they’re irresponsible. I think they’re a source of
a vast majority of crime in this country…I think they’re mis-
guided…They’re still going to use dirty needles. 
—45-year-old African American 
female pharmacist in a chain pharmacy
From my understanding…it’s that they want to share, it’s
not because of a lack of syringes that they are
sharing…They want to share it.
—30-year-old African American 
female pharmacist in a chain pharmacy
To me it’s just too risky, just putting it in somebody’s
hands who’s not responsible. You know that from the
beginning they’re drug users. To me, it’s just not a
responsible thing to do. To me, you’re infecting even more
people.
—28-year-old African American 
female chain pharmacy manager
Another pharmacist was reluctant to sell syringes to IDUs
because of her belief that the syringes would be unsafely discard-
ed in the community, endangering neighborhood children.
Some pharmacists believed that having IDUs in their pharma-
cies caused personal discomfort or had a negative effect on busi-
ness. These opinions can result either in refusing to sell or selling
syringes to shorten the IDU’s time in the pharmacy.
I’m reluctant to sell drug users syringes because I don’t
want that type of clientele frequenting the store. Usually, in
my experience, that gets into robbery or some other kind of
unfortunate condition that these people bring in. They come
in without money. They want you to lend them money, they
ask for money or something like that. We prefer not to have
that type of clientele.
—75-year-old African American
male pharmacy owner
In contrast, other pharmacists viewed drug users and their
addiction problems as health concerns.
I don’t hate them or despise them…They have a disease like
any other disease; it just needs to be treated.
—44-year-old African American 
male pharmacist at a chain pharmacy
Pharmacists who viewed drug use as a health issue were more
likely to discuss working with drug users to achieve public health
benefits (e.g., cessation of drug use, reduction in syringe sharing).
I’ve had [customers] that are abusers…They’ve tried every
type of con game in the world, and usually I’m just straight-
forward with them…Usually when you approach them that
way, you gain their confidence, and they’re not going to pull
tricks with you, and you can be their ally and their friend
and assist as part of a team with medical care and with their
support. That’s the experience that I’ve had. Again, don’t
look down on them, but see it as a point of compassion.
—51-year-old white male 
independent pharmacy owner
Pharmacists who accepted syringe access as an HIV-prevention
strategy were more willing to sell syringes to IDUs. This acceptance
was generally associated with knowing HIV-infected drug users,
usually because of working at pharmacies frequented by drug users.
These pharmacists view their authority to sell syringes as potential-
ly life-saving and, therefore, feel ethically required to do so.
They’re going to get them somewhere, and I’d rather they
use clean needles than share them or whatever they do. So I
sell it to them. It bothered me at first when I was right out of
school; I thought it was a little unethical. But the older I have
gotten, I would think it would be kind of unethical not to.
—52-year-old white female
independent pharmacy manager
We see a fairly large population of HIV patients and…I see
an awful lot of IV [drug use] …the policy of this pharmacy
is to go ahead and dispense and sell to syringes pretty much
anybody who asks for [them].
—40ish white male
independent pharmacy owner
Concerns About Deception
Pharmacists’ fear of being duped by a customer is a salient con-
cern that is addressed by screening customers.
If somebody just comes in, I would say, “Okay, what do you
want these syringes for?” And they say “I’m diabetic”…and
I say, “What type of insulin do you use?” They say, “I use
this.” I say, “How many units in the morning, afternoon,
and evening?” Based on that, I know if they’re telling me the
truth or not. If I determine they’re lying to me, then I know
these are not going to be used in the legal way so I would
have to decline them.
—44-year-old African American 
male chain pharmacy manager
Another pharmacist, a 45-year-old African American female
pharmacy manager, indicated that when an IDU was “honest” and
“willing to confide” about his or her intentions to use syringes to
inject drugs, then she was more likely to sell syringes to that person.
Pharmacists’ concerns are substantially reduced, and the likeli-
hood of a syringe sale increased, if the customer (1) answers ques-
tions about diabetes and insulin dosages correctly and without hes-
itation, (2) is willing to show identification, or (3) is comfortable
with the pharmacist creating a patient profile.
If I have a patient that comes in and asks for a 3-cc, 21-
gauge syringe, I’m going to say…“I need a doctor’s order
for that”…We can sell, of course, the insulin syringes upon
request, but I like to have a patient profile.
—34-year-old white male owner
of an independent pharmacy
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Concerns About Legality
Pharmacists were concerned whether selling syringes to an IDU
would be legal. However, most of the pharmacists in this study had
limited knowledge of the laws and regulations affecting syringe
sales. Practicing pharmacists had little or no understanding of the
state drug paraphernalia law and its stipulations regarding syringe
sales. Most practicing pharmacists indicated that the Georgia drug
paraphernalia law had very little, if any, influence on their syringe
sale decisions.
While pharmacists were generally aware that the state pharma-
cy board has a formal regulation on syringe sales, knowledge, and
interpretations of it varied widely. Very few pharmacists knew
about the reasonable cause and unlawful purpose clauses in the
regulation.18 These two concepts appeared to be merged by sever-
al of these pharmacists into a looser construction of legitimacy of
syringe sales that was used as a general guide in deciding about
selling syringes.
Well, certainly I feel I can fall back on that regulation, but
at the same time…I can refuse to fill a prescription if I don’t
feel it’s legitimate. The decision to fill or not fill a prescrip-
tion, sell or not sell syringes, is mine. You can follow the law
and even the law says “lawful use.” If I were of a mind, I
could justify selling syringes, but I’m not of that mind.
—54-year-old white female
independent pharmacy owner
Many pharmacists perceived the pharmacy board regulation as
vesting them with the authority to assess each request and make a
decision about the sale. On the other hand, a pharmacist may
choose not to judge the case.
If I don’t ask, ignorance is bliss. Therefore, I will assume
they’re all diabetics and [that] all their grandparents are
diabetics. 
—44-year-old white male
independent pharmacy owner
However, most pharmacists did not appear to have rigorously
examined their criteria for reasonable cause. Interpretations of
unlawful purpose were similarly vague. Some pharmacists
focused on the likelihood that illegal drug use will be facilitated
through a syringe sale.
Well, it does affect me greatly because if I know this is a drug
user, I will not sell it. If there were a different rule, then I
would have to abide by those rules; but telling me I should
only sell it for legal use, I would have to go by those criteria.
—44-year-old African American
male chain pharmacy manager
In the formulation that drug use is illegal, selling syringes to a
drug user would facilitate drug use and would be interpreted as an
unlawful purpose. However, pharmacists may also focus on the
broader outcomes associated with selling syringes to drug users.
Among pharmacists who have some HIV-infected patients, HIV
prevention is interpreted as a valid justification for a syringe sale.
In this second formulation, lawful purpose is established through a
combination of compassion and public health good associated
with preventing human suffering and disease.
Anything that doesn’t break the law, period. So drug use
would be not a lawful purpose, but the spread of HIV would
be a lawful purpose, so that’s a matter of interpretation.
—45-year-old African American 
female pharmacist in a chain pharmacy
When asked whether they would be more likely to sell syringes
to IDUs if the wording of the state pharmacy board regulation on
syringe sales indicated that the sale of sterile syringes to prevent
the transmission of blood-borne infections was a lawful purpose,
some pharmacists indicated that they would be more at ease know-
ing that they were not violating pharmacy practice regulations.
That will remove me from any legal problems with the
Board. I will be very willing to sell it to those people based
on…criteria that include people using illegal drugs… So it’s
the wording, that wording that includes you can sell
syringes to illegal drug users, then I will sell it. It’s the
wording and the rule that has everything to do with it.
—44-year-old African American 
male pharmacist
Another believed that increasing IDUs’ access to sterile
syringes in pharmacies might constitute reasonable justification.
Absolutely, certainly. If the state and federal regulators
would allow such, I think it’s very justifiable as a health pro-
fessional.
—34-year-old white male owner
of an independent pharmacy
Not all pharmacists, however, agreed that preventing blood-
borne infection was a justification for selling syringes to IDUs.
Pharmacy Leaders
When the nine leaders were asked about changing the state
pharmacy board regulation on syringe sales so that the sale of ster-
ile syringes to prevent the transmission of blood-borne infections
would be considered a lawful purpose, responses included, “I like
that idea,” “I have no problem with that,” “I would react somewhat
positively to that,” and “That would be a positive move.” Only one
responded negatively. However, despite indicating that they would
support a change in the wording of the regulation, some differen-
tiated between their professional support for such a change and
their nonsupportive personal beliefs.
Discussion
Our study found that in metropolitan Atlanta, pharmacists’
syringe sale decisions are largely left to the individual pharma-
cist’s discretion and that these decisions are shaped by individual
and structural factors. These findings are consistent with recent
studies of pharmacists’ practices and attitudes about selling
syringe to IDUs.9–17
That syringe sale decisions are largely left to the individual
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pharmacist’s discretion has significant implications for HIV pre-
vention. Pharmacists have differing personal beliefs about drug
users, HIV, and prevention strategies for preventing transmission
of HIV and other blood-borne infections. When pharmacists
decide about selling syringes to IDUs, these beliefs strongly shape
if and how they screen customers. Further, pharmacists had differ-
ing views about how selling syringes to IDUs as a public health
prevention strategy fits with their role as health care professionals.
Pharmacists’ varying levels of concern about the legality of sell-
ing syringes to persons who may use them to inject illicit drugs
stem partially from the ambiguous language of the Board of
Pharmacy regulation and the Georgia drug paraphernalia law.
Interpretation among pharmacists of these issues varies consider-
ably. Some interpret the prevention of HIV and other blood-borne
diseases as a lawful and medically legitimate reason for selling
syringes to IDUs. Others, however, perceive the use of syringes for
injecting drugs as illegal and not legitimate pharmacy practice.
This study does not rank the individual and structural factors
influencing pharmacists’ decisions about selling syringes to IDUs.
However, for some, the foremost concern appears to be determin-
ing whether the syringes will be used for a legal purpose; for oth-
ers, it appears to be preventing HIV transmission. For some phar-
macists, beliefs that drug users are immoral, irresponsible, and a
threat to store staff and clientele appear strongly related to their
syringe sale decisions.
Addressing both the individual and structural factors would
likely increase availability of sterile syringes for IDUs in Atlanta.
A combination of continuing professional education and support-
ive public positions by Georgia pharmacy leaders would help
address the individual factors. Changes in the regulations and laws
governing syringe sales and clarification of their interpretations
would address the structural factors.
Although current educational programs for pharmacists focus
on the pharmaceutical treatment of HIV/AIDS, public health and
pharmacy agencies could collaborate to offer new courses, semi-
nars, and workshops focused on HIV and viral hepatitis prevention
(e.g., condom use, substance abuse treatment, access to sterile
syringes, hepatitis A and B immunizations). These programs could
present scientific research demonstrating that access to sterile
syringes from pharmacies and other sources can lead to substantial
decreases in injection-related risk behaviors among IDUs and in
HIV and hepatitis transmission.28–30 Addiction is another impor-
tant topic. Presentation of the current scientific understanding of
drug addiction as a chronic, relapsing, and treatable medical con-
dition with a biological basis may help pharmacists see drug users
as persons with medical problems rather than as immoral individ-
uals who are responsible for their addiction. In addition, pharma-
cy schools could increase the class time devoted to HIV preven-
tion and addiction and thereby better prepare pharmacy students to
make syringe-sale decisions.31
The fundamental structural-level intervention to improve IDUs’
syringe access from pharmacies in metropolitan Atlanta would be
changing the Georgia Board of Pharmacy regulation that makes it
illegal to sell syringes for an unlawful purpose. This regulation
appeared to be the primary legal concern for pharmacists in this
study. In its present form, the regulation makes it illegal for a
Georgia pharmacist to dispense syringes to an IDU even if the IDU
has a physician’s prescription.32 Options for change include delet-
ing the phrase “unlawful purpose” and a formal Board statement
that preventing transmission of HIV and other blood-borne
pathogens is a lawful purpose for selling syringes.  Pharmacy lead-
ers, who have the authority to help enact such changes, largely
supported this approach. In addition, syringes could be excluded
from the Georgia drug paraphernalia law. Removing the possibil-
ity of legal or professional sanctions for selling syringes to IDUs
would likely increase the number of pharmacists willing to sell to
IDUs, according to more than one-half of the pharmacists inter-
viewed.
Recent actions by the boards of pharmacy in Washington and
Maine could be used as models for Georgia. In Washington State
guidelines “allow the sale without a prescription to reduce trans-
mission of HIV, hepatitis, and other blood-borne viruses.”33 In
Maine, the Board of Pharmacy clearly supported the interpretation
that selling syringes to IDUs was a legitimate medical and phar-
maceutical practice.34 In Seattle, Minnesota, and New York State,
collaborative efforts of public health departments and profession-
al pharmacy organizations were instrumental in changing syringe
laws to allow and then promote increased syringe sales in phar-
macies as a public health prevention strategy.35–38
Limitations
This study interviewed a small convenience sample, so general-
izability is limited. Nonetheless, it allowed for in-depth explo-
ration of themes and provides important insight into some of the
determining factors shaping pharmacists’ decisions about selling
syringes to IDUs.
Conclusion
This study highlights the importance of understanding and
addressing both individual and structural factors influencing phar-
macists’ decisions about selling syringes to IDUs. It also helps
identify steps that could increase such sales. Pharmacists can serve
an important role in the prevention of HIV and other blood-borne
infections by facilitating syringe sales to IDUs and promoting the
safe disposal of used syringes.
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Pharmacists’ Attitudes and
Concerns Regarding Syringe
Sales to Injection Drug Users 
in Denver, Colorado
Beth A. Lewis, Stephen K. Koester, and Trevor W. Bush
Injection drug use is related to more than one-third of acquired
immunodeficiency syndrome (AIDS)1 and more than one-half of
hepatitis C cases in the United States and continues to be a domi-
nant risk factor in new cases of human immunodeficiency virus
(HIV) and hepatitis C virus.2 Encouraging injection drug users
(IDUs) to use sterile syringes every time they prepare and inject
drugs is one proven way to reduce the spread of these diseases. In
many areas, however, this public health goal is impossible for IDUs
to follow because of structural factors that create an artificial scarci-
ty of syringes. Structural impediments include laws, state pharma-
cy board regulations, and the sales policies of some pharmacies.
In Maine, which repealed the prescription and paraphernalia
laws limiting syringe access in 1993, and Baltimore, which never
had such laws, studies have found that some pharmacists contin-
ued to require prescriptions for sterile syringes.3,4 The Baltimore
study found that pharmacists ranked their familiarity with the cus-
tomer as “very important” in influencing whether they would sell
syringes without a prescription.3 Concerns about improperly dis-
carded syringes, staff and customer safety, and business concerns
such as fears of increased theft and harassment of customers have
been shown to influence a pharmacist’s decision to sell syringes to
suspected IDUs.4–8 Farley and colleagues found that almost one-
half of the pharmacists interviewed in Louisiana who did not sell
nonprescription syringes believed that such sales would increase
drug use.8
Denver has no prescription law or state pharmacy board regula-
tion governing syringe sales. In a 1999 syringe-buying survey, we
found that pharmacy staff at 13 of 22 Denver pharmacies refused
to sell syringes to some (10 pharmacies) or all (3 pharmacies) of
our IDU research assistants. Overall, only 54% of 206 purchase
attempts were successful.9 This is particularly troubling in Denver,
a geographically dispersed city in which IDUs have no other legal
means of obtaining sterile syringes. We assumed that the reticence
of some pharmacists to sell syringes was the result of a state statute
and complementary Denver ordinance regulating drug parapher-
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Objective: To identify factors influencing pharmacists’ decisions about selling syringes to injection drug users (IDUs). Design:
Audiotaped interviews. Setting: Denver, Colorado. Participants: Thirty-two pharmacists at 24 pharmacies. Intervention: One-hour
semistructured interviews. Main Outcome Measures: Practices regarding syringe sales to IDUs and factors influencing the practices.
Results: Of the 32 pharmacists interviewed, 16 indicated that they sold syringes to all customers (“pro-sell”), 11 refused to sell unless
shown proof of diabetic status (“no-sell”), and 5 were “undecided.” Several factors influenced the decision to sell. A perceived conflict
between prevention of disease and prevention of drug abuse most clearly distinguished the three categories, with pro-sell pharmacists
more likely than others to prioritize disease prevention and believe that syringe sales would not increase drug abuse. Business con-
cerns, such as the effect of the presence of IDUs on other customers and the possibility of discarded syringes around the store, were
especially prevalent among no-sell and undecided pharmacists. Seventeen pharmacists did not know about Colorado laws governing
syringe sales. Four no-sell pharmacists used the laws to justify their decision not to sell, and two undecided pharmacists said they used
the law when they did not want to sell syringes to IDU. All pharmacists supported syringe exchange programs. Conclusion: One-half
of the pharmacists sold syringes to IDUs, and several more indicated that they would do so if certain concerns were addressed. These
data suggest that improved syringe disposal options, continuing education programs, and clarification of existing laws and regulations
would encourage more pharmacists in Denver to sell syringes to IDUs.
J Am Pharm Assoc. 2002;42(suppl 2):S46–51.
S46 Supplement to the Journal of the American Pharmaceutical Association November/December 2002    Vol. 42, No. 6, Suppl. 2
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nalia. Currently, more than 40 states have paraphernalia laws
modeled after the Drug Enforcement Agency’s Model
Paraphernalia Act of 1979. Syringes are included as paraphernalia
in most of these laws, and IDUs are frequently cited for violating
the provision making it illegal to possess syringes.10 Although no
pharmacist in Colorado or any state with a similar statute has ever
been cited for violating a paraphernalia statute by selling syringes
to IDUs (Scott Burris, written communication, October 2000), we
assumed that Colorado’s paraphernalia statute11 might deter com-
munity pharmacists from selling syringes without a prescription to
individuals they suspected to be IDUs.
Objective
Our objective was to identify what factors, including the
Colorado drug paraphernalia statute and a similar provision in a
Denver city ordinance, influence pharmacists’ decisions regarding
selling syringes without a prescription.
Design
A total of 51 pharmacies were identified on the basis of their
location within or adjacent to areas in the metropolitan area of
Denver known to have high levels of drug use. Arrest and drug
overdose admission data were used to identify high drug use areas.
Selected neighborhoods included those targeted for our National
Institute on Drug Abuse grant (DA 09232), an HIV intervention
study aimed at reducing injection-risk behaviors among networks
of IDUs.
Seven pharmacies were ineligible (six had gone out of business
and one did not stock syringes). We invited licensed, practicing
pharmacists at the remaining pharmacies to participate. At 24 of
the 44 eligible pharmacies, 32 pharmacists agreed to participate
and were interviewed. Of those who refused to participate, the
majority cited time constraints, two stated that the pharmacy man-
ager would not allow them to take part, and one said that he was
not comfortable talking about this issue.
A semistructured question guide was developed and modified to
complement a similar study among Atlanta pharmacists.12 The
guide included open-ended questions on attitudes and policies
toward IDUs and selling syringes to suspected IDUs, the impact of
HIV and hepatitis C on the pharmacists and their pharmacies, and
thoughts about increasing the availability of syringes for IDUs.
The guide was piloted with pharmacy students at the University of
Colorado Health Sciences Center. Trained qualitative researchers
conducted all interviews.
Before the interview, pharmacists were fully informed about the
study and asked to sign a consent form. Interviews were audio-
taped, conducted in a location that was convenient to the pharma-
cist (e.g., coffee shop, the pharmacy), and lasted approximately 1
hour. Pharmacists were compensated $50 for their time.
Audiotapes were transcribed, individually coded, and analyzed for
significant, recurring themes. The study was approved by the
University of Colorado at Denver Human Research Committee.
Results
Of the 32 pharmacists, 16 willingly sold syringes to all cus-
tomers (“pro-sell”), 11 pharmacists refused to sell unless shown
proof of diabetes (“no-sell”), and five pharmacists described them-
selves as being “undecided.” Four themes emerged:
■ Concerns about disease transmission and increased drug use.
■ Business concerns.
■ Uncertainty about legality of syringe sales.
■ Views on syringe exchange programs.
Concerns About Disease Transmission and
Increased Drug Use
Pharmacists who reported selling syringes to all individuals and
those who only sold to customers they believed to be insulin users
had divergent views on their roles in helping to prevent disease
transmission among drug users. Pro-sell pharmacists stated that
their primary motivation was preventing blood-borne disease
transmission; these pharmacists did not believe that providing ster-
ile syringes encouraged drug use, and they did not think that drug
users would quit injecting if syringes were more difficult to obtain.
Pro-sell pharmacists commented that IDUs would most likely find
other ways to obtain syringes if unable to purchase them in phar-
macies, including borrowing one or picking a syringe up off the
street. Pro-sell pharmacists emphasized that they would rather
provide sterile syringes than have IDUs use contaminated
syringes:
Usually the popular thing to do is just say, “No, don’t give
them [syringes], you are encouraging intravenous drug
usage if you provide syringes.” I disagree with that. People
are going to share syringes if they don’t have access to ster-
ile syringes. You are not going to stop that behavior by stop-
ping the providing of syringes.
—41-year-old white man, 5 years’ experience,
independent pharmacy
Whether syringes are available or not does not stop users
from becoming an addict. If they are going to become an
addict, they are going to become an addict anyway. Having
sterile syringes available just decreases the possibility of
spreading the disease, whether it being AIDS or hepatitis, or
whatever....I know people who are users, whether it is a
good clean syringe is not going to help them to decide
whether they want to be or don’t want to become an addict.
—32-year-old African American man, 3 years’ experience,
independent store
No-sell pharmacists were concerned about the implications of
selling syringes to individuals they suspected were IDUs, although
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for different reasons. Several expressed the view that, as health care
providers, they had an important role to play in preventing drug
abuse. Almost one-half of the no-sell pharmacists stated that they
had no interest in supporting a behavior that was detrimental to a
person’s health. They believed that they were discouraging drug
use by restricting sales. Some suggested that by denying an IDU a
syringe, they might encourage that person to seek substance abuse
treatment. Other no-sell pharmacists contended that by denying
syringe sales they might be decreasing drug injection and thus,
decreasing the potential for blood-borne disease transmission.
I don’t think that two wrongs make a right as far as dis-
pensing the syringes because they’ll have clean syringes
when they use their heroin so they won’t share needles and
nobody will get HIV. Ideally that may be the case, but I think
there will still be sharing of needles...I don’t think you
should be handing out sterile syringes and saying, “Okay,
see ya.” That’s not helping anybody, not them, not society,
it’s not helping the prevention of anything, in my opinion. I
just think that’s like a quick fix.
—29-year-old white woman, 6 years’ experience,
chain pharmacy
Undecided pharmacists were concerned about both drug addic-
tion and blood-borne disease transmission and, as a result, were
uncertain about whether to sell syringes. They were uncomfortable
supporting a destructive behavior, but they were equally uncom-
fortable knowing that denying syringe sales might increase disease
transmission.
I don’t want to spread AIDS and for part of me, turning peo-
ple down bothers me. But then I can justify it by telling
myself that if I sell this guy a 10-pack of syringes, he’s prob-
ably going to share those 10 anyways. So I shouldn’t feel
bad about that. But the pharmacist in me says I shouldn’t be
helping them. The human being in me says I shouldn’t be let-
ting AIDS get spread, so where do you go? It’s a tough one.
—33-year-old white woman, more than 10 years’
experience, supermarket chain
I still maintain that by selling them the clean syringe, they’re
probably going to avoid hepatitis because they’ve already
got the stuff they’re going to shoot, but I also feel like there
has been enough information spread about through the Drug
Enforcement Agency, through the various agencies against
drug use, their programs and etc., that people are pretty
much aware of the danger that they’re involved in if they
start using drugs…they’ve made a bad decision and I don’t
feel like I want to support a bad decision.
—60-year-old white man, 35 years’ experience,
independent pharmacy
Two factors separated these undecided pharmacists from no-sell
pharmacists: their acknowledgment of the public health benefits of
sterile syringe sales and their skepticism that selling syringes
would increase injection drug use. Nevertheless, they rarely, if
ever, sold sterile syringes to IDUs. A few undecided pharmacists
admitted selling syringes under certain circumstances or to indi-
viduals they knew. One of these pharmacists said that he sold
syringes a “couple of times” to visibly ill addicts, and another said
that he sold syringes to an IDU who was honest about his purpose
for requesting syringes.
Business Concerns
The second most commonly stated reason for not selling
syringes to IDUs was the feared effect on business and other cus-
tomers. Nevertheless, 11 of 16 pro-sell pharmacists stated that the
presence of IDUs in their store had little or no detrimental effect
on business. One pro-sell pharmacist observed that his store’s
recent policy of selling syringes to IDUs, a change made at the cor-
porate level, actually seemed to alleviate some problems they had
when they previously denied sales to IDUs.
It seems now that we’ve changed our policy and we sell
them more freely to people, we don’t seem to be at odds with
the addicts. I haven’t noticed any problems.
—35-year-old white man, 10 years’experience,
chain pharmacy
Several pro-sell pharmacists noted that IDUs were focused on
their purchase when they came to buy syringes and always left
without incident. These pharmacists believed that most IDUs did
not want to attract attention and would therefore cause few, if any,
disturbances. The five pro-sell pharmacists who did report prob-
lems with IDUs in their store stated that the health benefits of sell-
ing sterile syringes outweighed their business concerns. Problems
mentioned by these pharmacists included theft, finding used
syringes on store premises, and concerns for staff and customer
safety.
Four of 11 no-sell pharmacists cited business concerns as the
primary reason not to sell but were worried about the potential for
disease transmission through injection drug use. Four others men-
tioned business concerns as an important secondary motivation for
not selling syringes to IDUs. Several no-sell pharmacists feared
that if they sold syringes to suspected IDUs their stores would
develop reputations as being IDU-friendly, leading to an increase
in IDU customers; they were apprehensive about the possible loss
of other customers.
I think they’d [regular customers] feel uncomfortable being
in the store. I think they would be uncomfortable having
their children come in to the store.
—60-year-old white man, 35 years’ experience,
independent pharmacy
No-sell pharmacists were concerned about how their willing-
ness to sell syringes to drug users would be interpreted by other
customers:
It just sends the wrong message to other customers in the
store, depending on appearance and attitude and things like
that. If a customer sees them in there buying syringes and
they give the appearance or have the attitude that they’re an
abuser, it doesn’t give the store a very good reputation and
people develop a fear to go into places like that where they
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see that kind of activity going on.
—39-year-old white woman, 15 years’ experience,
independent pharmacy
Several no-sell pharmacists were worried about the potential for
theft if IDUs routinely came to their store to purchase syringes. A
few went further, describing IDUs as “riffraff” and “bad clientele”
who were untrustworthy, and more apt to shoplift than other clien-
tele. They were apprehensive that IDUs might vandalize their
stores or leave used syringes in the bathrooms and parking lots, a
potential threat to other customers and employees.
They are demanding. They are usually untrustworthy. And
usually, there is certainly more potential to be a shoplifter
than the average person, because they are out of money usu-
ally all the time. So, I don’t have a problem with it morally.
I just think that the pharmacy isn’t the place for that.”
—52-year-old white man, 25 years’ experience,
chain pharmacy
Four of the five undecided pharmacists identified business con-
cerns as a reason they did not feel comfortable selling syringes to
IDUs. Only one reported it as his primary concern.
Uncertain Legality of Syringe Sales
Only one-third (11 of 32) of the pharmacists interviewed were
aware of a state statute (Colorado’s paraphernalia law) with a pos-
sible effect on syringe sales; 17 pharmacists were unaware of any
law or regulation; four did not comment. Five of the sixteen pro-
sell pharmacists knew of the statute. These pharmacists stated that
the law was not a deterrent to syringe sales.
No big deal. What are they going to do? Are they going to
fine me? I don’t think so.
—29-year-old Latino man, 12 years’ experience,
independent pharmacy
If I sell someone a package of syringes and they don’t look
like a diabetic or if I think they’re not a diabetic, they’re say-
ing we can be prosecuted for that. I don’t see how you could
be.... I can’t imagine someone coming up to you later and
trying to prosecute you because you knew that person was a
drug addict. There’s no way to know that.
—39-year-old white man, 15 years’ experience,
chain pharmacy
Four of 11 no-sell pharmacists knew of the law and used it to
support their decision not to sell syringes.
They are coming in asking for insulin syringes, but they
aren’t using them for insulin. So they are disguising their
needs, and so technically what we are doing is illegal by
selling them to somebody who is not a diabetic. So it takes
the risk off our back by not doing it.
—52-year-old white man, 25 years’ experience,
chain pharmacy
This pharmacist’s interpretation of the law appears inaccurate
given that no legal action or judicial interpretation supports the
claim. Only two no-sell pharmacists cited the law as their primary
reason for not selling syringes to individuals they suspected were
IDUs.
Two of the five undecided pharmacists knew of the statute and
were unsure how to reconcile it with their desire to prevent blood-
borne disease transmission. They stated that they used the law
when they did not want to sell syringes.
And I tell them, “No, I only sell them [syringes] if, suppos-
edly by law, you are using them for insulin.”
However, this same pharmacist stated that sometimes she sold
syringes because the Colorado Pharmacy Board did not have a pre-
scription requirement. In fact, the Colorado Pharmacy Board does
not have a regulation concerning syringe sales.
That’s why I’m more and more lenient in selling it [10-packs
of syringes] to them because since the [pharmacy] board is
not so clear about it, they didn’t require a prescription for
it, so I go, “Well, it’s up to me.”
—27-year-old Asian woman, 2 years’ experience,
chain pharmacy
Data from the 11 pharmacists representing all three sales cate-
gories who reported knowledge of the Colorado paraphernalia law
suggest that the actual implications of the law on pharmacy sales
are not clear. Pharmacists who were unclear or unaware of the law
needed more guidance before deciding to sell. Four pharmacists,
three undecided and one no-sell, stated that they would sell sterile
syringes without personal conflict if the paraphernalia law’s pro-
vision on syringe sales clearly exempted pharmacies.
Views on Syringe Exchange Programs
Regardless of their personal stance on syringe sales, all the phar-
macists we interviewed supported community syringe exchange
programs (SEPs). Several indicated that their acceptance of SEPs
was due in part to information provided by the media and in part to
conversations with other pharmacists. One pro-sell pharmacist said:
That’s an alternative. … If I should run out, God forbid, you
just tell them, “Okay, go to this clinic and you can get some
clean syringes or exchange them.” To me, that’s great.
That’s something that should actually happen around the
United States.
—29-year-old Latino man, more than 5 years’ of experience,
independent pharmacy
Some pharmacists believed that SEPs would be more accept-
able to IDUs and better equipped than pharmacies to provide harm
reduction and supplementary health information on topics such as
HIV and hepatitis. Some believed that SEPs would reduce their
burden of being the only reliable and legal source for sterile
syringes, particularly important for pharmacists concerned about
the effects of syringe sales on business.
Two no-sell pharmacists stated that a primary reason they did
not sell syringes was because there was no option for their safe dis-
posal; others expressed this concern as well. Pharmacists believed
that a SEP would offer a safe and comfortable option for users
interested in both receiving and returning syringes. Some pharma-
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cists also said they would be more comfortable selling syringes
knowing that SEPs offered a means of safe disposal. Pharmacists
in all three categories suggested that access to health information
and reduced IDU traffic in pharmacies were potential benefits of
SEPs. Two no-sell pharmacists who were opposed to selling
syringes to IDUs for moral reasons believed that SEPs should be
coupled with substance abuse treatment.
Discussion
Contrary to our assumption, the Colorado drug paraphernalia
statute was not a principal reason pharmacists gave for denying
sales to IDUs. Only one-third of the pharmacists interviewed were
aware of the possible legal restriction on syringe sales. Five of
those who were aware sold syringes to IDUs. Only 2 of the 32
pharmacists identified the statute as their primary reason for not
selling syringes to IDUs. However, some interviewed indicated
that if pharmacists and pharmacies were plainly exempted from
the statute’s authority, they would be willing to sell syringes to
IDUs.
The concerns expressed by no-sell and undecided pharmacists
in our study are subjects of intervention and research. Numerous
efforts have been made to change statutes and ordinances that
restricted syringe access through prescription requirements or
paraphernalia laws and programs aimed at ensuring the safe dis-
posal of used syringes have been implemented in several munici-
palities and states.13 Increased access to syringes through these
legal and programmatic changes has been associated with decreas-
es in high risk injection practices14,15 and actual negative encoun-
ters between IDU and pharmacists appear to be infrequent.16 As
our findings suggest, affirming the legality of syringe sales in
states with existing paraphernalia laws can also help.
Our finding that all the pharmacists interviewed support the idea
of syringe exchange programs is very promising. However, phar-
macists should not perceive SEPs as replacing pharmacies as the
source of sterile syringes. Recent research demonstrates that dif-
ferent sterile syringe sources (pharmacies, SEPs, and vending
machines) serve the needs of distinct groups of IDUs.17 In addi-
tion, a SEP’s effectiveness may be limited by location and hours
of operation. Even in places with SEPs, pharmacies constitute a
decentralized, neighborhood site for obtaining sterile syringes.
Studies with pharmacists in Maine, Connecticut, and Georgia
identified similar concerns to those voiced by pharmacists in
Denver and concluded by recommending educational programs
focusing on these issues.4,12,18 An initial program in Connecticut
was based on peer education.18 In Colorado, we have presented
our findings and developed a continuing education course that we
presented to University of Colorado School of Pharmacy students
and at annual meetings of two pharmacist associations. Feedback
suggests that these presentations were well received. As indicated
by our study and others, such efforts should address pharmacist-
identified issues including information about IDUs, substance
abuse treatment, the role of sterile syringes in decreasing blood-
borne disease transmission, clarification of existing laws and reg-
ulations, the role of SEPs, and syringe disposal options.
Limitations
The purpose of this study was to elicit pharmacists’ thoughts
about selling syringes to IDU. The data presented are based on
semistructured interviews with consenting pharmacists working at
community pharmacies in the Denver metropolitan area. The sam-
ple was small and purposive. As such, the study is not representa-
tive and the findings cannot be generalized.
Conclusion
Syringe sales by pharmacists are a critical element of compre-
hensive, community-level disease prevention. One-half of the
pharmacists we interviewed were selling sterile syringes to IDUs,
and several more indicated they would if some of their legal and
practical concerns were addressed. All of the pharmacists in this
study supported SEPs, a clear indication that they understood the
role of sterile syringe access in preventing blood-borne disease
transmission. Our results suggest that addressing the perceived
conflict between blood-borne disease prevention and drug abuse
prevention through continuing education programs, improving
syringe disposal options and clarifying existing laws and policies
governing syringe sales could encourage more pharmacists in
Denver to sell syringes to IDUs.
This research was conducted as part of the ongoing research program of
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Baron at Urban Links. Most importantly, we would like to thank the pharma-
cists who took the time to discuss this issue with us.
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Dearth of Sterile Syringes
HIV, hepatitis and other infections spread through the use of unsterile injection equipment pose a major health threat in the
United States, causing thousands of deaths and millions of dollars in preventable health care expenditures every year. The vic-
tims include not only drug users themselves, but also indirectly their sex partners and their children, whose infections at birth
can be attributed to drug use.
Scarcity of clean needles for injection drug users (IDUs) is one of the main causes of the problem. Scarcity of needles is, in
turn, almost entirely the result of public policy. Drug paraphernalia, needle prescription and pharmacy practice laws and regula-
tions were intended to make it difficult for IDUs to purchase syringes, and have done so. These rules, and the steps police take
to enforce them, often make IDUs who have needles reluctant to carry them for fear of arrest. Public health dictates reducing or
eliminating legal barriers to syringe access.
Burris S, ed. Deregulation of Hypodermic Needles and Syringes as a Public Health Measure: A Report on Emerging Policy and Law in the
United States. Washington, DC: American Bar Association, AIDS Coordinating Committee; 2001. Available at: www.abanet.org/irr/
aidsproject/aba.pdf. Accessed September 30, 2002.
F R O M  T H E  L I T E R A T U R E
Pharmacist Ambivalence About
Sale of Syringes to Injection
Drug Users
Wendy Reich, Wilson M. Compton, Joe C. Horton, Linda B. Cottler, Renee
M. Cunningham-Williams, Robert Booth, Merrill Singer, Carl Leukefeld,
Joseph Fink, Tom Stopka, Karen Fortuin Corsi, and Michelle Staton Tindall
Injection drug users (IDUs) are at risk for human immunodefi-
ciency virus (HIV), hepatitis B, and hepatitis C through the shar-
ing of contaminated injection equipment including syringes, rinse
water, cookers, and cotton. According to the Centers for Disease
Control and Prevention,1 injection drug use accounted for more
than one-third (36%) of the cumulative acquired immunodeficien-
cy syndrome (AIDS) cases in the United States in 1998. A higher
rate, 50%, was reported for 96 U.S. metropolitan areas,2 and one
study reported that 51% of people infected with HIV in the north-
eastern United States were IDUs.3
While syringe exchange programs (SEPs) play an important
role in reducing blood-borne disease transmission through sterile
syringe distribution, several barriers limit their efficacy in the
United States: SEPs exist only in selected locations, some IDUs
hesitate to participate in SEPs because state paraphernalia laws
make them vulnerable to arrest if found in possession of a syringe,4
and some IDUs are reluctant to dispose of used syringes in SEP
sharps biohazard containers because they do not want to identify
themselves as IDUs.4
Access to syringes through pharmacy sale is limited by laws and
regulations. Even where syringes may be purchased legally with-
out a prescription, many pharmacists refuse to sell syringes to sus-
pected drug users.5 Studies have shown that pharmacists may be
unwilling to sell to IDUs because they lack knowledge about the
efficacy of sterile syringes in preventing HIV and hepatitis trans-
mission, because of stigma associated with injection drug use, or
because of concerns about improperly disposed syringes.6
Objective: To examine pharmacists’ attitudes and practices surrounding human immunodeficiency virus (HIV) prevention among
injection drug users. Design: Focus groups. Setting: Urban and rural sites in Colorado, Connecticut, Kentucky, and Missouri. Patients
or Other Participants: Eight focus groups, with 4 to 11 pharmacists participating in each group. Interventions: Transcripts of focus
group discussions were evaluated for common themes by the authors and through the use of NUD*IST. Main Outcome Measures:
Willingness to sell syringes to all customers, views on syringe exchange programs (SEPs), knowledge of laws governing syringe sales
and racial, ethnic, or gender biases in syringe selling practices. Results: Two pharmacists established their own policies of selling
syringes to everyone, and three expressed a willingness to have their pharmacies serve as SEPs. A total of 20% of the pharmacists
expressed an interest in learning more about the efficacy of SEPs and distribution of syringes by pharmacists, and were willing to
change their views based on this information. Many also indicated a general willingness to work with SEPs or to participate in the effort
to curb the spread of HIV. However, a majority of pharmacists opposed having SEPs in their pharmacies and reported selling syringes
only within specific limits: to known diabetics, to individuals who looked reasonable, or to individuals who presented a logical expla-
nation. No racial, ethnic, or gender bias was observed. Conclusion: Opinions among pharmacists varied across and within sites. While
a majority of pharmacists would not establish SEPs in their own pharmacies, nearly all would participate in other HIV-prevention pro-
grams. Educational programs for pharmacists may be valuable in HIV-prevention efforts.
J Am Pharm Assoc. 2002;42(suppl 2):S52–7.
Received June 24, 2002, and in revised form August 26, 2002. Accepted
for publication August 26, 2002.
Wendy Reich, PhD, is research associate professor of anthropology in
psychiatry, Washington University, St. Louis. Wilson M. Compton, MD,
MPE, is director, Division of Epidemiology, Services and Prevention
Research, National Institute on Drug Abuse, Bethesda, Md.; at the time
this research was done, Dr. Compton was associate professor,
Washington University, St. Louis. Joe C. Horton, MSW, is research
associate; Linda B. Cottler, PhD, is professor of epidemiology; Renee M.
Cunningham-Williams, PhD, MPE, research assistant professor,
Washington University, St. Louis. Robert Booth, PhD, is professor;
Karen Fortuin Corsi, MPH, is project director, University of Colorado,
Denver. Merrill Singer, PhD, is associate director and chief of research;
Tom Stopka, MHS, is project director, Hispanic Health Council, Hartford,
Conn. Carl Leukefeld, DSW, is professor of psychiatry and behavioral
science; Joseph Fink, BSPharm, JD, is vice president of research;
Michelle Staton Tindall, MSW, is project director, University of
Kentucky, Lexington.
Correspondence: Wendy Reich, PhD, Washington University School of
Medicine, Department of Psychiatry, 660 South Euclid, Campus Box
8134, St. Louis, MO 63110. Fax: 314-747-6777. E-mail: wendyr@
twins.wustl.edu.
S52 Supplement to the Journal of the American Pharmaceutical Association November/December 2002    Vol. 42, No. 6, Suppl. 2
RESEARCH
States that relaxed syringe laws have documented increases in
IDU purchases of sterile syringes from pharmacies with no appar-
ent increase in the rate of injection drug use.7–12 In cities where
SEPs provide a ready supply of sterile syringes, HIV prevalence
has remained at 5%, and HIV incidence has remained at 1 per 100
person years at risk or less.13 These findings are supported by sim-
ilar results in other countries with syringe-access programs such as
the United Kingdom14 and Australia.15
Given the serious public health risk in reusing potentially con-
taminated injection equipment, comprehensive programs aimed at
reducing infections typically include multiple methods to increase
access to sterile syringes,16,17 including SEPs and pharmacy sales.
In October 1999 the American Medical Association, the
American Pharmaceutical Association (APhA), the Association of
State and Territorial Health Officials, the National Association of
Boards of Pharmacy, and the National Alliance of State and
Territorial AIDS Directors issued a joint statement recommending
that pharmacists help to disseminate sterile syringes to IDUs.18
Such a policy position is consistent with pharmacists’ roles as
health educators, advocates, and sources of health equipment.
Objectives
We conducted focus groups with pharmacists to determine their
opinions about the role of pharmacists in preventing the spread of
HIV and to determine issues to be overcome to increase participa-
tion in such efforts.
Methods
Detailed scripts and procedure manuals were prepared by an
anthropologist (W.R.) to ensure standardized methods. Each site
conducted two pharmacist focus groups, one urban and one rural, for
a total of four urban (census-defined metropolitan areas) and four
rural (less populated areas that were generally more than 75 miles
from urban areas) groups in each of the four study states (Colorado,
Connecticut, Kentucky, and Missouri). Because of the small size
and generally dense population of the state, Connecticut areas were
selected from the nonurban areas surrounding Hartford. Pharmacies
that had participated in phase 1 of the study, in which research assis-
tants who were former drug addicts attempted to buy syringes from
urban and rural pharmacists5 were divided into two groups: those
who sold the syringes to the assistant, and those who refused.
Pharmacists were called randomly from each group and invited to
participate in a focus group about attitudes and behavior towards
persons attempting to purchase syringes. The size of individual
focus groups varied from 4 to 11 persons. A total of 34 urban phar-
macists (ranging from 6 to 11 per group) and 24 rural pharmacists
(4 to 9 per group) participated. Informed consent, approved by each
local human subjects committee, was obtained from all participants.
Focus groups were held over a 3-month period. Each 1-hour
focus group was led by two facilitators. Trained research assistants
took notes. Sessions were recorded using two audiotape recorders
to ensure accurate transcription, and each participant was assigned
a number to enhance participant confidentiality.
The discussions focused on four main topics:
■ Legal aspects of syringe sales in the study states.
■ How pharmacists distinguish IDUs from customers who have
diabetes.
■ Pharmacists’ attitudes toward selling syringes to nondiabetic
customers.
■ Pharmacists’ views about and participation in SEPs.
Transcripts were analyzed for “themes” by the authors by hand
and with the qualitative analysis software program NUD*IST.19
NUD*IST was used primarily to perform word searches that put
repeated terms and phrases in context and to select coding schemes
for topics discussed. These coding schemes were also arranged
into “themes.” The opinion of one pharmacist was considered a
“theme” if it constituted a significant departure from the opinions
of other members of the focus group. There were no differences in
the number and content of the themes whether the data were ana-
lyzed with NUD*IST or by hand.
Results
Table 1 lists demographic characteristics of participating phar-
macists and the urban versus rural distribution in Colorado,
Connecticut, Kentucky, and Missouri. Results are presented based
on major themes and urban versus rural groups. The categories
under which the themes were grouped included: “Will Sell,”
“Conditional Sales,” and “Won’t Sell.”
Views of Selling Syringes
Ambivalent and divergent views of pharmacists both among
and within sites are shown in Table 2. Twelve pharmacists said
that they would sell to anyone. One pharmacist from the urban
Connecticut group had participated in a video that encouraged oth-
ers to sell to all customers in the context of preventing HIV and
hepatitis transmission. A few pharmacists described customers
who purchased syringes for nonmedical uses, including people
who used syringes to squirt glue into corners, finish floors, baste
turkeys, clean carburetors and hearing aids, and make beer. All but
one of the themes in the category of “Will Sell” were from urban
and rural focus groups of Colorado and Connecticut; the urban
Missouri group had one theme represented in this category, and the
Kentucky groups had none.
Opinions of some pharmacists in all sites fell into the category
“Conditional Sales.” These pharmacists did not want to sell to
known IDUs but generally did not investigate the drug status of
their customers. They would sell syringes to anyone who looked
and acted “reasonably” and had “plausible” reasons for purchasing
syringes. Under these circumstances a drug user with a good
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knowledge of diabetes needs and the capacity to look and act “rea-
sonably” could get syringes.
Opinions of some pharmacists from all sites except rural
Connecticut fell into the category “Won’t Sell.” This group was
larger than the “Conditional Sales” group and included pharma-
cists who were adamant that syringes should not be sold to drug
users. Some reported that it was morally wrong to sell to drug
users or that such sales would promote drug use. Others were more
concerned that their pharmacy would develop a reputation for sell-
ing syringes and would attract an “undesirable” clientele. Some
pharmacists also worried that IDUs would discard syringes on
pharmacy property, possibly resulting in needle stick injuries.
Several pharmacists described ways they discouraged IDUs
from purchasing syringes in their stores, such as “grilling” cus-
tomers with questions about how much and what kind of insulin
they used and the size of the syringe they needed. Pharmacists from
the “Conditional Sales” group did not endorse the “grilling”
method because it could result in the harassment of “real diabetics.”
Among the “Won’t Sell” pharmacists were some with mistaken
presumptions, including beliefs that sale of syringes by pharma-
cists would promote drug use and that AIDS is acquired chiefly
through unsafe sex. A small number of pharmacists, chiefly from
Missouri and Kentucky, indicated that neither ready access to ster-
ile syringes from pharmacies nor SEPs would have any effect on
HIV-risk behavior among IDUs. One pharmacist characterized the
sharing of syringes as a “bonding thing,” part of the injection ritu-
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Table 1. Demographic Characteristics of Focus Group Participants (n = 101)
Characteristic No. Respondents (%)
Gender
Men 59 (59)
Race
White 91 (91)
Black 2 (2)
Asian/Pacific Islander 1 (1)
Middle Eastern 4 (4)
Other 2 (2)
Age, mean ± SD, years 44.0 ± 13.7
Years worked in current pharmacy, mean ± SD 9.1 ± 11.2
Position
Owner and managing pharmacist 19 (19)
Non-owner and managing pharmacist 18 (18)
Staff pharmacist 49 (49)
Supervising pharmacist 8 (8)
Other 6 (6)
Pharmacy type
Independent 38 (38)
Chain 61 (61)
Other 1 (1)
Pharmacy setting
Freestanding, direct street access 65 (65)
Part of larger retail store 17 (17)
Storefront in mall or shopping plaza 14 (14)
Part of medical, hospital, convalescent facility 2 (2)
Other 2 (2)
Perceived level of drug activity in neighborhood of pharmacy
Moderate or high 52 (52)
Low or none 48 (48)
Aware of law change before survey 95 (95)
Participation in syringe sale to IDU in 4 weeks before survey 23 (23)
Pharmacy availability of the following items
Syringes in packs of 10 or 100 99 (99)
Personal sharps disposal containers 79 (79)
Spoken with customers about the following topics in the past year
Safer injection practices 38 (38)
Safe syringe disposal 78 (78)
Drug treatment services 38 (38)
Pharmacy acceptance of the following items for biohazard disposal
Syringes in personal sharps containers 22 (22)
Loose syringes 6 (6)
IDU = injection drug user; SD = standard deviation.
al. Others believed the distribution of sterile syringes would pro-
mote drug use or cited information they had heard that made them
believe SEPs would not work.
Views of Syringe Exchange
Only a few pharmacists’ from the Connecticut urban and rural
sites were willing to consider using their pharmacies as syringe
exchange sites. However, the majority of participants was willing
to consider either participating in an SEP not connected with their
pharmacies or being involved in HIV prevention in some other
way (Table 3). Their unwillingness to use their own pharmacies as
syringe exchange sites arose from concerns about customer safety
and the reputation of their pharmacies or doubting that IDUs
would identify themselves as drug users by purchasing syringes in
a pharmacy.
Some pharmacists expressed interest in volunteering in off-site
SEPs. Several pharmacists acknowledged that they knew little
about the efficacy of SEPs or access to sterile syringes from phar-
macies. These participants appeared eager for education.
Pharmacists expressed a willingness to distribute pamphlets and to
play a role in educating others. In rural Missouri, pharmacists who
had taken part in prevention education programs for elementary
and high school students saw themselves as “pillars of the com-
munity,” and felt an obligation to lend their expertise in the face of
an epidemic balanced by concerns about offending regular clien-
tele. A minority was against SEPs of any kind.
Knowledge of Syringe Laws
Nearly all pharmacists reported familiarity with state laws gov-
erning the sale of syringes. None of the four states had prescrip-
tion-only laws (except Connecticut where a prescription was
required for purchasing more than 10 syringes at one time), and
every group agreed that the decision to sell syringes was at the dis-
cretion of the individual pharmacist. All but one pharmacist
believed that drug paraphernalia laws, which generally prohibit the
possession (or sale) of syringes to be used for injecting illicit sub-
stances, had no effect on their decision to sell or not sell. The par-
ticipant who discussed the possibility of legal consequences from
paraphernalia laws admitted no knowledge of any pharmacist
being prosecuted under these laws. This particular pharmacist was
a proponent of the theory that distributing syringes promoted drug
use. Other participants described being told by their state pharma-
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Table 2. Themes Related to Syringe Sales
Will Sell Conditional Sales Won’t Sell
Will sell if person looks/acts
reasonable (Connecticut,a,b
Kentucky,a Missouria)
Won’t sell 10-pack to customer
twice in one day (Connecticuta)
Will sell if story sounded reasonable
(Connecticut,a Kentucky,a Missouria)
Pressure on chains to make a profit
(Missouria,b)
Ask to sign a log (Kentucky,a,b
Missourib)
Don’t want to give “real diabetics” a
hard time (Colorado,a Missourib)
Won’t sell to strangers (Kentucky,b
Missourib)
Will sell if plausible nonmedical
reasons are provided (Connecticut,a
Kentuckya)
Easier to sell than argue when you
have people waiting in line
(Connecticutb)
If you don’t sell, “they” could be
waiting for you in the parking lot
(Kentuckya)
Don’t want kids picking up syringes
(Missouria)
Don’t sell syringes at all (Missouria)
Won’t sell without insulin (Kentucky,a
Missouria,b)
Won’t sell but will direct to pharmacy that
will sell (Connecticuta)
Won’t sell without prescription (Kentuckyb)
Promotes drug use (Kentuckyb)
Morally wrong (Colorado,b Connecticut,a
Kentucky,b Missouria,b)
Don’t want syringes lying about
(Connecticut,a Kentucky,b Missouria,b)
Diabetics don’t run out of syringes
(Missouria)
Boxes of 100s to known people only
(Missouria)
All the addicts will start coming (Colorado,a
Kentucky,a,b Missouria,b)
Ask for a “diabetic card” (Coloradoa)
Upset regular customers (Colorado,a,b
Missouria,b)
Won’t sell without “grilling them”
(Colorado,a,b Kentucky,a,b Missouria,b
Will sell to anyone (Colorado,b Connecticuta,b)
It is our job as pharmacists to sell (Colorado,b
Connecticuta,b)
Selling syringes helps to stop the spread of
AIDS (Colorado,a,b Missouria)
Tell customers not to use on premises
(Coloradoa)
AIDS = acquired immunodeficiency syndrome.
aUrban.
bRural. 
cy organizations that pharmacists could sell syringes at their own
discretion, emphasizing that they were not required to sell
syringes. Two pharmacists in Connecticut and Missouri described
syringe sales as being motivated by profits.
Urban Versus Rural Pharmacists
The rural pharmacists were considerably less supportive of sell-
ing syringes and participating in syringe exchange than the urban
pharmacists. One pharmacist from rural Colorado reported that he
had refused to sell syringes to IDUs in the past, but had been edu-
cated about the AIDS epidemic and believed that pharmacists had
a duty to “protect people and prevent AIDS.” A rural Connecticut
pharmacist felt that it was “unprofessional” to refuse to sell
syringes to anyone. Yet other rural Colorado and Connecticut
pharmacists were adamant that syringes should be sold for medi-
cal purposes only.
Rural Kentucky and Missouri pharmacists were the least sup-
portive groups. Several rural Kentucky pharmacists reported that
they would sell syringes only by prescription, while others said
they would sell only to customers they knew well. Rural Missouri
pharmacists were less concerned with the spread of HIV or hep-
atitis than with preventing methamphetamine use, probably as a
result of extensive methamphetamine production and consumption
throughout the area.
Discrimination in Selling Practices
There was little evidence of racial, ethnic, gender, or socioeco-
nomic biases. Participants generally agreed that, barring observ-
able signs such as track marks, it was difficult to identify someone
as an IDU. A number of anecdotes described professional-looking
persons turning out to be IDUs, and casually dressed persons with
diabetes who could have been mistaken for IDUs. The two groups
that indicated a possible bias, urban and rural Missouri, reported
perceiving IDUs as predominantly white. Rural Missouri pharma-
cists agreed that young men sometimes sent their girlfriends to buy
syringes, believing that women would be less suspect of illicit
behaviors.
Discussion
Pharmacy sale of syringes to help prevent blood-borne disease
transmission relies on pharmacist cooperation. Our study results
suggest that the attitudes and behaviors of many pharmacists
impede easy access to sterile syringes. The Colorado and
Connecticut sites appeared more likely to allow syringe sales to
IDUs than the Missouri or Kentucky sites. Urban Connecticut
pharmacists were the most willing to sell syringes to all customers.
The rural Connecticut group was more polarized. Rural and urban
Colorado were similar to the Connecticut sites, with a number of
pharmacists wanting IDUs to have easy access to sterile syringes
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Table 3. Themes Related to Participation in Syringe Exchange Programs
Support Syringe Exchange Conditionally Support Syringe Exchange Not Support Syringe Exchange
Not in the pharmacy (Colorado,a,b Connecticut,a,b
Kentucky,a,b Missouria,b)
Don’t want those people in my pharmacy
(Colorado,a Missourib).
Inhibit regular clientele (Colorado,a Kentucky,a,b
Missouria)
Should be run by County Health or some federal
or state agency (Colorado,a Connecticut,a
Missouria,b)
Churches should do it (Missouria)
Need studies/statistics to see if syringe exchange
works (Colorado,a Connecticut,a Missouria)
Who would discard the sharps containers?
(Colorado,a,b Connecticut,a,b Missouria)
Willing to participate in education programs
(Connecticut,a,b Missouria,b)
We’re “professionals in the community” and
should be involved in some way (Colorado,a
Connecticut,a,b Missouria,b)
Would pass out pamphlets (Connecticut,a,b
Kentucky,a Missouria)
Wouldn’t work, they don’t bother with
clean syringes (Kentucky,a Missourib)
In Sweden syringe exchange didn’t
work (Missouria)
Don’t think it worked in England
(Kentuckyb)
AIDS isn’t a big problem down here
(Missouria)
Tested syringes from exchange and
found 4 or 5 different kinds of blood
(Connecticuta)
Would promote drug use (Kentucky,a,b
Missouria)
A syringe could be used as a weapon
(Missouria)
Accidental sticks are a concern
(Connecticuta)
Willing to have sharps containers in
store (Colorado,a Connecticuta)
AIDS = acquired immunodeficiency syndrome.
aUrban.
bRural. 
Ambivalence    PHARMACISTS’ ATTITUDES
Vol. 42, No. 6, Suppl. 2    November/December 2002 Supplement to the Journal of the American Pharmaceutical Association S57
and some considering that selling syringes promoted drug use.
The rural Missouri site presented a special case, as rural
Missouri is, according to pharmacists and print and television
media, in the midst of a methamphetamine epidemic. These phar-
macists felt that fighting methamphetamine production and con-
sumption was a higher priority than disease prevention. Urban
Missouri pharmacists, although unlikely to sell syringes to IDUs,
viewed themselves as community professionals and voiced will-
ingness to participate in programs to reduce HIV transmission.
The two Kentucky sites followed the pattern of the Missouri
groups, with rural pharmacists less likely to sell syringes to IDUs.
In every site, pharmacists agreed that the decision to sell
syringes should be at their discretion, consistent with the stated
policies of APhA and other professional organizations.18 Some
pharmacists were not only willing to sell syringes to all customers
but appeared proactive in doing so. However, the majority
appeared to be against providing syringes without documented
medical necessity because they either did not connect syringe sale
with disease prevention or were concerned about the impact on
their business.
Limitations
Data gathered by means of focus groups are considered qualita-
tive, in contrast with the quantitative data produced by means of
more formal methods, such as structured interviews. Specific
questions may not be asked in focus groups, resulting in a loss of
certain kinds of information. Additionally, there may be some bias
with respect to the type of people who agree to participate in focus
groups. Due to the sampling methods used in this study, the find-
ings are not generalizable to all pharmacists in the states studied.
On the other hand, qualitative information from the comfortable
and informal setting of focus groups results in data that may not be
gathered by other means, and is also important for crafting specif-
ic questions for a more formal interview.
Conclusion
Differences in pharmacists’ attitudes and opinions among the
four states and between rural and urban areas indicate that any
intervention to increase availability of syringes must be tailored to
local circumstances. Evidence of misinformation among the phar-
macists and the general willingness of the pharmacists to involve
themselves in prevention efforts indicate that education programs
to increase awareness of pharmacists’ role in preventing blood-
borne disease transmission through voluntary sale of syringes to
all customers could be valuable.
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RESEARCH
Laws and regulations controlling access to needles and syringes
(referred to as “syringes” in this article), intended to discourage
injection drug use, have resulted in an artificial scarcity of sterile
injection equipment for injection drug users (IDUs)1 and further
stigmatization of this group.2 The difficulty faced by IDUs in the
procurement of sterile syringes and the fear of arrest has encour-
aged the multiperson use and reuse of syringes.3,4 Such sharing and
reuse of injection equipment is of public health concern because it
is a principal route by which IDUs can acquire blood-borne infec-
tions such as human immunodeficiency virus (HIV), hepatitis B
virus (HBV), and hepatitis C virus (HCV).4–6 Further, once HIV
becomes well established in a large, at-risk population, such as
IDUs, the epidemic has a strong tendency to self-perpetuate.2
Before July 1998, Rhode Island’s syringe prescription and para-
phernalia laws were among the strictest and most vigorously
enforced in the nation. Those in possession of a syringe without a
prescription, regardless of intent, could receive a prison sentence
of up to 5 years and a $5,000 fine.3 Between 1994 and 1996,
syringe arrests accounted for 10% of all drug possession arrests
and 7% of all drug possession-related convictions in the state, cost-
ing the state more than $4 million in incarceration costs alone. The
mean time served by individuals incarcerated for illegal possession
of syringes was 13 months.7
Such strict syringe possession laws may have been responsible
for increased HIV and hepatitis transmission among IDUs in the
state.3 In the general United States population, 25% of the acquired
immunodeficiency syndrome (AIDS) cases from 1982 to 1999
have injection drug use reported as their only risk factor; in Rhode
Island, this percentage is 38%. Further, according to the Rhode
Island Department of Health (T. Latta, oral communication, April
2001), since 1993, more than one-half of all the new AIDS cases
in Rhode Island have been associated with IDUs (personal injec-
tion, sex with an IDU, and perinatal transmission from mothers
who injected or who had sex with an IDU).8
As a response to the widespread transmission of blood-borne
pathogens among IDUs, Rhode Island legalized syringe exchange
programs (SEPs), which began operations in April 1995. A fol-
low-up study documented a significant decrease in the proportion
of users sharing syringes and other paraphernalia (e.g., cotton fil-
ters, cookers, and rinse water); however, enrollment statistics show
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that the majority of IDUs in the state are not regularly using the
program (T. Latta, oral communication, April 2001). Factors lim-
iting SEP participation in Rhode Island include lack of awareness
of the program, inconvenient location and hours of operation, and
fear of identification and police harassment.8 To facilitate access to
sterile syringes, Rhode Island passed legislation legalizing non-
prescription syringe sales by pharmacists effective September
2000.
Syringe deregulation has already demonstrated efficacy in facil-
itating access to sterile injection equipment in several other states
and countries. In 1987 France was one of the first countries to
repeal its syringe prescription law to legalize nonprescription
syringe sales. Follow-up studies documented decreased sharing of
syringes, greater use of sterile injection equipment, and increased
purchase of syringes in pharmacies.9 The 1992 legalization of non-
prescription syringe sales in Connecticut resulted in similar find-
ings.10–12 In addition to its obvious role in reducing IDU-associat-
ed HIV and hepatitis transmission, nonprescription pharmacy
syringe sales have been proposed to be cost-effective.13 Further,
the large number and widespread geographic distribution of phar-
macies with their convenient hours of operation may facilitate
access to sterile syringes more than SEPs, which operate at a lim-
ited number of sites and hours.14
Based on the success of the deregulation of syringes in other
countries and states, a decrease in IDU-related transmission of
HIV and hepatitis is anticipated in Rhode Island. However, suc-
cessful intervention of pharmacy-based HIV and hepatitis preven-
tion largely relies on local pharmacists’ willingness to sell syringes
to IDUs.15 In previous studies, factors precluding pharmacists sell-
ing syringes to IDUs without prescriptions include lack of knowl-
edge about paraphernalia laws and concern about discarded
syringes, the health of IDUs, the safety of customers and pharma-
cy workers, and customer sobriety.16–20 Additionally, a 1992
observational study in St. Louis found racial discrimination in the
nonprescription purchase of syringes from local pharmacies.21
Such barriers to pharmacist syringe sales should be addressed to
increase IDU access to sterile injection equipment.
Objectives
The purpose of this study was to examine pharmacists’ attitudes
and obstacles to selling syringes to IDUs without a prescription in
Rhode Island around the time that such sales became legal in the
state. Such information should be useful in devising future inter-
ventions to encourage pharmacy syringe sales.
Methods
A self-administered written survey was mailed to 400 random-
ly selected members (of approximately 500 members) of the
Rhode Island Pharmacists Association (RIPhA) in August 2000 
(1 month before the law change) to assess current attitudes, knowl-
edge, and practices of nonprescription syringe sales to IDUs. The
survey instrument included questions about (1) willingness to pro-
vide health education, referral services, syringe disposal units, and
accept used syringes; (2) factors influencing the sale of syringes
without a prescription, including concerns about the possible
impact of nonprescription syringe sales on businesses, the com-
munity, and the amount of injection drug use; and (3) demograph-
ic characteristics, including the clientele of the pharmacy in which
the respondent worked.
Data analysis was descriptive and correlational based on Pearson
χ2 tests with SAS 8.2 (SAS Institute, Inc., Cary, N.C.; 2001).
Statistical tests that were performed did not include “don’t know”
and “refused” responses. The level of significance was set at P < .05.
Results
Of the 400 pharmacists contacted, 131 (33%) completed and
returned the survey. All calculations below were based on the
responses of the 101 (77%) pharmacists who worked in stores that
provided direct nonprescription syringe sales to the public.
Most pharmacists surveyed were white and middle-aged and
had been working in their stores for almost 10 years. Twenty-three
percent reported having sold a syringe to an IDU in the 4 weeks
before the survey. Although the majority of pharmacists had
addressed safe disposal practices with clients in the past year, less
than one-half had discussed safer injection practices or drug treat-
ment services. Only a minority of respondents reported that their
pharmacies accepted used syringes for disposal. One-half of the
pharmacists reported moderate or high levels of illicit drug activi-
ty in the neighborhood of the pharmacy. (See Table 1.)
When asked whether they would be willing to sell syringes to
IDUs without a prescription (after the law change), 32% of the 101
pharmacists were “very willing,” 33% were “somewhat willing,”
26% were “not at all willing,” and 10% were “unsure.”
Pharmacists were significantly more willing to sell syringes non-
prescription to IDUs who had a referral card from a clinic or agen-
cy: in this situation, 45% were “very willing,” 40% were “some-
what willing,” 11% were “not at all willing,” and 4% were
“unsure” (χ2 = 47.2, P < .0001).
Pharmacists were also asked whether they supported having the
pharmacies in which they worked provide various services. The
majority of the 101 pharmacists supported the provision of free
biohazard containers (77%), pamphlets on safer injection drug use
(94%), counseling to customers on safer injection practices (80%),
and referrals to drug treatment (92%). Less than one-half (38%)
supported having the pharmacy provide sharps containers in which
customers could discard their used syringes.
To elucidate the factors affecting willingness to sell syringes to
IDUs, participants were asked about their agreement with various
statements regarding the consequences of such sales. Agreement
with the items, “If I sell syringes to IDUs, the community will be
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littered with dirty syringes,” “Selling sterile syringes to IDUs will
increase drug use,” and “My business will suffer if I sell syringes
to IDUs because the community will not want to support a phar-
macy that they feel encourages drug use” was negatively correlat-
ed with willingness to sell syringes to IDUs. Similarly, agreement
with the statements, “Selling syringes to IDUs is an important part
of a comprehensive approach to HIV/AIDS prevention” and
“Selling sterile syringes will decrease HIV transmission among
persons who inject drugs and their sex partners and children” was
positively associated with willingness to sell. All correlations were
statistically significant at the P = .01 level (see Table 2). There was
no significant correlation between perceived level of illegal drug
use in the area and willingness to sell (r = 0.134, P = .265).
Discussion
This study provides important information on Rhode Island
pharmacists’ attitudes toward nonprescription syringe sales to IDUs
at a critical time in the change of the legal status of these sales.
Encouragingly, approximately two-thirds of pharmacists were very
or somewhat willing to sell nonprescription syringes to a suspected
IDU: this level of support is comparable with that of pharmacists in
Connecticut and higher than was found in Maine and New York
City.22 These findings are also similar to those of an unpublished
1997–1998 prederegulation study performed by the authors, in
which 59% of Rhode Island pharmacists expressed willingness to
sell syringes nonprescription to suspected IDUs if laws were
changed, 12% were unsure, and 29% would not. Pharmacists were
more willing to sell nonprescription syringes to an IDU if the client
had a referral card from an agency or clinic, implying perhaps that
some would be more comfortable if another professional supported
the decision to sell syringes to an individual IDU. Additionally, a
majority of pharmacists supported having their pharmacies provide
pamphlets on safer injection practices. These data also reflect find-
ings from our 1997–1998 survey, in which 78% of pharmacists
replied that they thought it was appropriate to ask pharmacists to
take an active role in educating clients about HIV prevention. This
high degree of support might not be found in other states, since
RIPhA’s policy has supported syringe access to IDUs since 1998,
2 years before syringe deregulation.
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Table 1. Demographic Characteristics of Survey
Respondents (n = 101) 
Respondents 
Characteristic No. (%)
Gender
Men 59 (59)
Race
White 91 (91)
Black 2 (2)
Asian/Pacific Islander 1 (1)
Middle Eastern 4 (4)
Other 2 (2)
Age, mean ± SD, years 44.0 ± 13.7
Years worked in current pharmacy, mean ± SD 9.1 ± 11.2
Position
Owner and managing pharmacist 19 (19)
Non-owner and managing pharmacist 18 (18)
Staff pharmacist 49 (49)
Supervising pharmacist 8 (8)
Other 6 (6)
Pharmacy type
Independent 38 (38)
Chain 61 (61)
Other 1 (1)
Pharmacy setting
Freestanding, direct street access 65 (65)
Part of larger retail store 17 (17)
Storefront in mall or shopping plaza 14 (14)
Part of medical, hospital, convalescent facility 2 (2)
Other 2 (2)
Perceived level of drug activity in neighborhood of pharmacy
Moderate or high 52 (52)
Low or none 48 (48)
Aware of law change before survey 95 (95)
Participation in syringe sale to IDU 23 (23)
in 4 weeks before survey
Pharmacy availability of the following items
Individual syringes 64 (64)
Syringes in packs of 10 or 100 99 (99)
Personal sharps disposal containers 79 (79)
Spoken with customers about the 
following topics in the past year
Safer injection drug practices 38 (38)
Safe syringe disposal 78 (78)
Drug treatment services 38 (38)
Pharmacy acceptance of the following 
items for biohazard disposal
Syringes in personal sharps containers 22 (22)
Loose syringes 6 (6)
IDU = injection drug user; SD = standard deviation.
Table 2. Correlation Between Willingness to Sell
Syringes to IDUsa and Pharmacists’ Beliefs
Regarding Nonprescription Syringe Sales
Pharmacists’ Belief r P
If I sell syringes to IDUs, the community –0.537 < .0001
will be littered with dirty syringes.
Selling syringes to IDUs is an important 0.520 < .0001
part of a comprehensive approach to 
HIV/AIDS prevention.
Selling sterile syringes to IDUs –0.515 < .0001
will increase drug use.
Selling sterile syringes will decrease 0.508 < .0001
HIV transmission among persons who 
inject drugs, their sex partners, and 
their children.
My business will suffer if I sell –0.462 .0002
syringes to IDUs because the community 
will not want to support a pharmacy 
that they feel encourages drug use.
aMeasured as “very willing,” “somewhat willing,” and “not at all
willing.” “Unsure” and nonresponders were excluded.
When pharmacists who identified as being very or somewhat
willing to sell syringes to IDUs were compared with those who
were unsure or unwilling to do so, several differences were found
in their attitudes toward such sales. In particular, those willing to
sell syringes were more likely to agree that selling syringes to IDUs
is an important part of a comprehensive approach to HIV/AIDS
prevention and that such sales would decrease IDU-related HIV
transmission. Further, they were less likely to believe that nonpre-
scription syringe sales to IDUs would result in an increase in the
amount of discarded syringes in the community, an increase in drug
use, and have a negative impact on their business. That such views
are significantly associated with willingness to sell syringes to
IDUs suggests that an intervention addressing such beliefs might
encourage these pharmacists to sell syringes to IDUs.
Limitations
The findings of this study should be interpreted with caution
given the relatively low response rate (33%), which may have
resulted in a nonrepresentative sample. Despite this and the limit-
ed sample size, this study provides insight into the high degree of
support for nonprescription pharmacy syringe sales to IDUs in
Rhode Island and highlights factors associated with reluctance to
sell syringes to this population.
Conclusion
For nonprescription syringe sales to be successful in decreasing
HIV and hepatitis transmission, pharmacists must sell syringes to
IDUs. We found that factors associated with reluctance to sell
syringes included perceptions that such sales will increase the num-
ber of discarded syringes in the community, increase drug use, and
cause a pharmacist’s business to suffer. Additionally, pharmacists
unwilling or unsure about their willingness to sell nonprescription
syringes to IDUs were not as likely to believe that selling syringes
to IDUs would decrease HIV transmission in this population. The
significant association between these beliefs and willingness to sell
syringes suggests that educational interventions could be useful in
encouraging pharmacists to sell syringes to IDUs. Future research
could address ways to most effectively encourage pharmacists to
participate in such IDU-targeted interventions.
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As of June 2000 more than 35% of cumulative acquired immun-
odeficiency syndrome (AIDS) cases reported to the U.S. Centers
for Disease Control and Prevention were among injection drug
users (IDUs), their sexual partners, and their children.1 That figure
approached 50% in New York City (NYC)2 and, at the end of
2000, more than 17,000 adults in NYC were living with AIDS
acquired through injection drug use.3
Multiperson use of needles and syringes (hereafter “syringes”)
has been the major route of human immunodeficiency virus (HIV)
transmission among IDUs in NYC4 and has been driven by lack of
access to sterile syringes.5 Syringe exchange programs (SEPs)
have proved effective in reducing injection-related HIV risks. In
1996 an analysis of three studies in NYC (total n = 1,442) found
that HIV incidence was more than threefold lower in participants
at SEPs versus nonparticipants.4 Partly attributable to SEPs, which
opened in the early 1990s, HIV incidence among IDUs in NYC
dropped from 4.4 per 100 person years in 19926 to approximately
0.7 per 100 person years by 1997.7 However, SEP coverage is lim-
ited to the populations of IDUs with access to one of the nine legal
programs in NYC.
An analysis of different modalities for improving syringe access
estimated that subsidizing SEPs for 50% of all syringes used by
IDUs would cost $0.97 per syringe and would be cost-neutral for
a community if HIV seroincidence in IDUs exceeded 2.1%.8
Subsidizing pharmacy sale would be cost-neutral if HIV seroinci-
dence was 0.3% or higher.8 With declining HIV incidence in
NYC, a law change to permit pharmacy access would be consis-
tent with cost-effectiveness modeling. Nonetheless, an IDU survey
in Marseille, France, where IDUs could obtain syringes through
SEPs, pharmacies, and vending machines, found that each site
attracted different types of IDUs, suggesting that having multiple
syringe sources increased the number of IDUs who obtained ster-
ile syringes.9
U.S. government-funded studies conducted by the National
Commission on AIDS,10 the University of California,11 the
National Academy of Sciences,5 and the Office for Technology
Objective: To document changes in pharmacists’ opinions and practices from the time of passage to implementation of a law per-
mitting selling syringes without a prescription (the Expanded Syringe Access Demonstration Program [ESAP]). Design: Two cross-sec-
tional randomized telephone surveys. Setting: High-risk neighborhoods of New York City. Subjects: Pharmacists. Main Outcome
Measure: Support for selling syringes without a prescription to injection drug users (IDUs). Results: We completed 130 surveys at
baseline (BL) in August 2000, from neighborhoods with high numbers of injection-related acquired immunodeficiency syndrome (AIDS)
cases and 231 surveys at law change (LC) in January 2001. To correct for differences in sampling, we limited the analysis to pharma-
cies in ZIP Codes represented in both samples and weighted results to adjust for the median income level of those postal codes. From
BL (n = 83) to LC (n = 84), law awareness increased (43% to 90%, P < .001), as did personal support for selling syringes without a pre-
scription to IDUs (36% to 63%, P < .001). From BL to LC, a larger proportion of supporters believed that selling syringes was an impor-
tant part of human immunodeficiency virus (HIV) prevention and would help decrease HIV transmission, and a smaller proportion was
concerned about customer discomfort and increased drug use. A total of 40% of respondents were ESAP registered at LC but registra-
tion was not associated with support for selling syringes to IDUs. Conclusions: Support for ESAP among pharmacists increased in
high-risk neighborhoods as the program was implemented. The finding that some pharmacists were ESAP registered but did not sup-
port selling syringes to IDUs and others were supportive, but not ESAP registered, may have program implications.
J Am Pharm Assoc. 2002;42(suppl 2):S62–7.
Received June 16, 2002, and in revised form July 25, 2002. Accepted for
publication August 20, 2002.
Phillip O. Coffin, MIA, is project director; Jennifer Ahern, MPH, is data
analyst; Stacy Dorris, is research assistant; Lori Stevenson, PhD, is
investigator; Crystal Fuller, PhD, is investigator; David Vlahov, PhD, is
director; The Center for Urban Epidemiologic Studies, New York
Academy of Medicine.
Correspondence: Phillip Coffin, MIA, New York Academy of Medicine,
1216 Fifth Avenue, New York, NY 10029. Fax: 212-876-6220. E-mail: 
pcoffin@nyam.org.
More Pharmacists in High-Risk
Neighborhoods of New York City
Support Selling Syringes to
Injection Drug Users
Phillip O. Coffin, Jennifer Ahern, Stacy Dorris, Lori Stevenson, 
Crystal Fuller, and David Vlahov
Assessment12 have concluded that syringe clauses in parapherna-
lia laws and prescription requirements should be repealed or
amended to increase access to sterile syringes among IDUs to help
prevent blood-borne pathogen transmission.13 In New York State,
a law passed May 2000, and effective January 1, 2001, established
the Expanded Syringe Access Demonstration Program (ESAP).
ESAP permits the sale of up to 10 syringes without a prescription
to individuals 18 years of age and older by providers who register
with ESAP through the State Department of Health (DOH).
Similar to laws passed in Connecticut in 1992, Minnesota and
Maine in 1997, and Rhode Island and New Hampshire in 2000,
ESAP is intended to reduce blood-borne pathogen transmission
among IDUs, their sexual partners, and children.
We conducted a telephone survey of pharmacists in NYC just after
the law was passed to determine baseline attitudes.14 When the law
went into effect and after DOH mailings and meetings with pharma-
cists to promote ESAP, we conducted a follow-up survey.
Objective
Our objective was to document any changes in pharmacists’
opinions and practices from the time of ESAP passage to the time
of implementation.
Methods
Two anonymous cross-sectional telephone surveys of pharma-
cists in NYC were conducted to assess pharmacists’ attitudes and
practices related to selling syringes to IDUs without a prescription
and changes from the time of law passage—baseline (BL)—to the
time of law implementation—law change (LC).
At BL, we obtained a list of all pharmacies from www.
yellowpages.com, a no-charge online directory of phone books and
new business listings. We identified pharmacies in the three ZIP
Code groupings in each of the five NYC boroughs with the highest
number of AIDS cases among IDUs,2 and randomly selected 40
pharmacies from each borough, for a total of 200 pharmacies.
At LC, we obtained an updated listing of all licensed pharma-
cies from DOH. We excluded the 166 pharmacies that completed
or refused to complete the BL survey to limit the number of phar-
macists likely to refuse because they had recently completed the
previous survey. We then stratified the list by the median house-
hold income of the ZIP Code in which the pharmacy was located15
and randomly selected 525 pharmacies, 50% from the lowest quar-
tile of median incomes, 20% from each of the two middle quar-
tiles, and 10% from the highest quartile.
We piloted the survey in June 2000 and adapted language to
ensure clarity (e.g., “drug injection” was changed to “illegal drug
injection” or “intravenous drug injection”). For both surveys, if
any selected pharmacy did not provide over-the-counter service,
telephone was disconnected, or the managing pharmacist was on
vacation through the time of the study, the next pharmacy on the
list was selected. If a respondent refused to participate or five
attempts to administer the survey were unsuccessful (e.g., respon-
dent was busy), the next pharmacy on the list was selected.
Pharmacies were called during regular business hours, at times
when, based on the pilot, customer volume was expected to be low
(i.e., Tuesday through Thursday, 10:00 to 11:00 am and 2:00 to
3:00 pm).
Following procedures used in a Connecticut survey,16 the inter-
viewer asked to speak to the managing pharmacist, briefly explained
the new law, the purpose and the confidentiality of the study, and
requested consent. If the pharmacist was busy or unavailable, the
interviewer arranged to call at another time. If no other pharmacist
was available after three or more calls, the interviewer attempted to
speak with the staff pharmacist. Unless the pharmacist refused to
participate, contact was attempted a minimum of five times. After
five unsuccessful attempts, the pharmacist was coded “unavailable,”
unless the interviewer was asked to call again. The interview lasted
10 minutes; call length varied as interviewers complied with
requests to hold while pharmacists attended to customers.
The interview gathered respondent and pharmacy characteris-
tics, briefly described ESAP, and asked if respondent was aware of
the new law, willing to sell syringes without a prescription in dif-
ferent situations, influenced by several factors in syringe transac-
tions, supportive of several public health services in the pharmacy,
and in agreement with a series of statements about the effects of
selling syringes to IDUs. The interviewer also asked if respon-
dent’s pharmacy was registered with ESAP; these responses were
compared to the DOH list of ESAP-registered pharmacies.
Both surveys were exempted from review by the New York
Academy of Medicine Institutional Review Board in July 2000.
Data analysis was descriptive and correlational. Frequency distri-
butions, Pearson χ2, and Fisher exact tests, confidence intervals,
and Cronbach’s reliability coefficient were used with SAS 6.12
(SAS Institute, Cary, N.C.).
Results
At BL, out of 166 valid pharmacies, the pharmacist was
unavailable at 13 (7.8%), 23 (13.9%) refused to participate, and
130 completed the survey, for an overall response rate of 78.3%.
At LC, out of 398 valid pharmacies, the pharmacist was unavail-
able in 102 (25.6%), 65 (16.3%) refused to participate, and 231
completed the survey, for an overall response rate of 58.0%. The
majority who refused to participate in each survey were “too
busy”; 4 refused to participate because they disapproved of ESAP.
There were no differences in socioeconomic quartile or borough
among those who refused, were unavailable, and completed at BL
and LC. At LC there were no significant variations in demograph-
ics or attitudinal measurements based on the number of times each
pharmacy was called before completing the survey or between
those pharmacists who completed the survey within 2 weeks of
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first contact and those who completed the survey later.
To control for differences in sampling methodology for this
analysis, we selected only pharmacies in ZIP codes that were
included in both samples. The combined effect of the two sam-
pling methodologies was that these pharmacies were in areas with
the highest numbers of drug injection-related AIDS cases for the
borough and were also more likely to be in low-income areas
(“high-risk neighborhoods”). We were able to include 83 pharma-
cies from BL and 84 pharmacies from LC. Because the LC sam-
ple included more pharmacies from low-income areas, we weight-
ed the LC analysis so that the distribution of pharmacies by
income quartile would represent the distribution of income quar-
tiles in the group of ZIP Codes that we included in the analysis.
Respondent demographics were consistent from BL to LC (see
Table 1). Among respondents at BL and LC, respectively, 76.8%
and 76.5% were male, 24.1% and 27.4% were white, 44.6% and
33.8% were Asian or Pacific Islander (including individuals of
south Asian descent, such as Indian and Pakistani), and 78.3% and
83.7% were owners, managers, or supervisors. The median year in
which pharmacists had received their license was 1985 and 1986,
respectively (median 15 years in practice for both surveys). The
proportion of pharmacies that were independently owned was
79.5% and 75.1%, respectively.
From BL to LC, awareness of ESAP increased significantly
(43.4% to 89.5%, P < .001). In both surveys, 94.0% were “some-
what” or “very” willing to provide nonprescription sale of syringes
to a “known diabetic.” Respondents answered two separate ques-
tions about selling syringes to IDUs. The proportion of pharmacists
who “personally supported” selling syringes to IDUs from their
pharmacy increased from 35.5% to 63.2% (P < .001). The propor-
tion of pharmacists “very” or “somewhat” willing to sell syringes
to an IDU increased from 39.8% to 60.2% (P = .04). Support for
selling syringes to IDUs and willingness to sell syringes to IDUs
were internally consistent (Cronbach α = .66 and .47, respectively).
Consistent with our previous study,14 support for selling syringes to
IDUs was the outcome variable for this analysis.
Factors influencing the decision to sell syringes without a pre-
scription were grouped as concerns about “safety,” “context of
sale,” and “customer-related” issues and compared with support
for selling syringes to IDUs (see Table 2). At BL and LC, most
pharmacists considered HIV prevention among IDUs and the risk
of discarded syringes in or around their pharmacy as “very impor-
tant” in deciding whether or not to sell syringes nonprescription.
From BL to LC, a declining proportion of pharmacists rated safe-
ty of self and staff as “very important” (P = .049), while increas-
ing proportions rated as “very important” customer appearance
(P = .007) and customer knowledge about diabetes, insulin, and
syringes (P = .012). Willingness to sell single syringes without a
prescription increased from BL to LC (P = .002). Support for sell-
ing syringes to IDUs was associated with willingness to sell
syringes without a prescription as 10 packs (P < .001, P < .001)
and as singles (P = .04, P = .013), at BL and LC, respectively.
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Table 1. Characteristics of New York City
Pharmacists and Pharmacies at Baseline (August
2000) and Law Change (January 2001)
Law 
Baseline % Change %
Characteristic (n = 83) (n = 84) P Value
Men 76.8 76.5 .965
Race/ethnicity .570
White 24.1 27.4
Asian or Pacific Islander 44.6 33.8
African American 6.0 8.7
Latino 9.6 11.9
Other 8.5 9.4
Position .384
Owner/manager/supervisor 78.3 83.7
Staff/other 21.7 16.3
Type of pharmacy .662
Independently owned 79.5 75.1
Chain 20.5 23.9
Setting of pharmacy .786
Free-standing 79.5 74.1
Larger retail store/16.9 21.2
shopping plaza
Aware of law allowing 43.4 89.5 < .001a
nonprescription syringe 
sales
Support for selling 35.5 63.2 < .001a
syringes to IDUs
IDU = injection drug users.
aSignificant.
Table 2. “Very Important” Influences on Decision
to Sell Syringes Without a Prescription at Baseline
and Law Change 
Law 
Baseline % Change %
Influences on Sell Decision (n = 83) (n = 84) P Value
Safety
Safety of self/staff 72.3 53.6 .049a
Risk of theft/robbery 57.8 48.6 .450
Risk of discarded needles 75.9 57.5 .088
Risk of use on premises 58.8 41.8 .089
Potential liability 57.3 50.4 .498
Context of sale
Customer appearance 14.6 35.8 .007a
Customer sobriety 61.0 53.9 .543
Customer knowledge 60.2 82.3 .012a
about syringes, 
insulin, diabetes
Customer familiarity 49.4 49.9 .271
Presence of other customers 12.1 16.8 .816
Potential income 8.5 12.5 .253
As 10 packs of syringesb 27.7 41.3 .269
As individual syringesb 13.6 31.0 .002a
Customer-related factors
Concern for HIV prevention 74.4 66.9 .336
Patient a diabeticb 77.1 80.4 .504
Patients an IDUb 14.5 22.0 .041a
HIV = human immunodeficiency virus; IDU = injection drug user.
aSignificant.
b“Very willing” to sell syringes in given situation.
Pharmacists were asked if they supported having their pharma-
cy offer a variety of public health services. At BL and LC, respec-
tively, the majority supported providing free sharps disposal con-
tainers (68.4% and 74.9%), pamphlets on safer sex practices
(98.8% and 92.1%), pamphlets (87.8% and 83.2%) and counseling
(80.3% and 80.0%) on safer intravenous drug injection, and refer-
rals to substance abuse treatment (93.9% and 92.1%). The propor-
tions supporting providing sharps containers in the store for cus-
tomers to discard used syringes increased from 25.0% at BL and
43.4% at LC (P = .016).
At BL support for these services was not associated with sup-
port for selling syringes to IDUs, but at LC support for pamphlets
on safer sex (P < .01) and pamphlets (P < .001) and counseling
(P < .001) on safer intravenous drug use were associated with sup-
port for selling syringes to IDUs. Table 3 illustrates that, among
supporters of selling syringes to IDUs, support for a SEP in the
pharmacy increased from BL to LC (P = .025). Among nonsup-
porters of selling syringes to IDUs, support for pamphlets on safer
sex (P = .002) and on safer injection drug use (P = .016) declined.
Pharmacists were asked if they agreed or disagreed with two
statements about the benefits and four statements about the harms
of selling syringes to IDUs (Table 4). Among supporters of selling
syringes to IDUs, the proportion of respondents that believed sell-
ing syringes to IDUs was an important part of HIV prevention
(P = .004) and would decrease HIV transmission (P = .042)
increased significantly from BL to LC and the proportion con-
cerned about customer discomfort (P = .034) and increased drug
use (P = .031) declined significantly. Among nonsupporters, a
larger proportion was concerned about discarded syringes (P =
.049).
At LC, 40% of the pharmacies were ESAP registered; all
respondents knew whether or not their pharmacy was ESAP reg-
istered. Among respondents at ESAP-registered pharmacies,
41.4% did not support selling syringes to IDUs. There were no
associations between ESAP registration status and support for sell-
ing syringes to IDUs (P = .667) or willingness to sell syringes to
IDUs (P = .854). In an attempt to characterize those pharmacists
that worked at ESAP-registered pharmacies but did not support
selling syringes to IDUs, several variables were examined but no
association was found between ESAP registration status and any
pharmacist or pharmacy characteristics.
Discussion
NYC pharmacists’ support for nonprescription syringe sales to
IDUs rose from a modest level at BL to a level at LC comparable
with the levels found in states that already allowed nonprescription
syringe sales (64% in Connecticut cities16; 67% in Baltimore17).
Moreover, a greater proportion of supporters than nonsupporters
believed selling syringes would have a positive impact on HIV
prevention and fewer believed that selling syringes would harm
their business or community; this subgroup was also more likely
to support the provision of a variety of public health services from
their pharmacy at LC. These results suggest that the increased
level of support for syringe sales encompassed broader disease
prevention efforts with IDUs. These findings are promising, as
studies conducted in Louisiana,18 England,19 and Canada20 found
that pharmacists have regular contact with IDUs and are in a posi-
tion to contribute significantly to HIV prevention goals.
Between BL and LC, a number of efforts were made to inform
pharmacists about ESAP, including a mailing by DOH to all phar-
macies and several multimedia events hosted by DOH and com-
munity-based organizations, to increase awareness of and partici-
pation in ESAP.21 Although we could not attribute the changes
from BL to LC to any single intervention, ongoing dissemination
of information about ESAP may have contributed to increased and
more comprehensive support for selling nonprescription syringes
to IDUs among pharmacists in high-risk neighborhoods of NYC.
The proportion of pharmacists who did not support selling
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Table 3. Support for Public Health Services Among Those Who Support and Those Who Do Not Support
Selling Syringes to Injection Drug Users at Baseline and Law Change 
Support Not Support
Law Law 
Baseline % Change % Baseline % Change %
Respondents Respondents Respondents Respondents 
Public Health Concept (n = 27) (n = 50) P Value (n = 49) (n = 29) P Value
Provide free sharps containers 74.1 80.7 .560 66.7 63.5 .785
Allow disposal of sharps in store 24.0 44.7 .083 24.4 39.7 .167
Provide pamphlets on safer sex 96.3 98.3 .576 100.0 80.7 .002a
Provide pamphlets on IV injection 85.2 93.3 .245 87.5 64.3 .016a
Offer counseling on IV injection 77.8 91.9 .080 79.2 60.3 .076
Provide referrals to drug treatment 92.6 89.0 .612 93.8 97.1 .524
Offer syringe exchange in pharmacy 19.2 45.4 .025a 8.3 11.8 .619
IV = intravenous.
aSignificant differences.
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syringes to IDUs declined from BL to LC, and those who were
nonsupporters were more likely to not support other public health
services for IDUs and to agree with statements about the harm of
syringe sales to IDUs. These findings suggest that many of the
nonsupporters at BL may have been unsure about their opinion,
while nonsupporters at LC consisted mostly of those firmly
opposed to selling syringes to IDUs.
It was encouraging that all respondents knew if their pharmacy
was ESAP registered, but we were unable to explain the lack of an
association between ESAP registration and support for selling
syringes to IDUs. We will address this question in future surveys.
Limitations
We attempted to account for the use of two different sampling
methods by restricting our analysis to pharmacies in regions of
NYC represented in both surveys. This limits the applicability of
our findings to pharmacies in high-risk neighborhoods.
Because of a high rate of “unavailable” pharmacists at LC, the
response rate was higher at BL than at LC. It is possible that phar-
macists who were willing to complete the survey were more like-
ly to support selling syringes to IDUs, and thus that we captured a
more supportive sample at LC than at BL. To examine that possi-
bility, we compared demographics of respondent pharmacists and
the pharmacies where they worked and found no difference
between BL and LC. To determine if pharmacists who required
multiple call-backs to complete the survey were more likely to
oppose ESAP, we compared the attitudes of respondent pharma-
cists at LC who completed the survey immediately with those who
required multiple call-backs over several weeks and found no dif-
ferences, supporting the comparability of these two samples.
Conclusion
Although our survey conducted soon after the ESAP law passed
showed only a modest level of enthusiasm for selling syringes
without a prescription to IDUs, implementation of the law was
associated with increased support, similar to reports from states
that already permitted nonprescription syringe sales. Further
surveillance will be needed to monitor changes in attitudes and
practices of pharmacists as they gain experience with ESAP.
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Access to Syringes and Preventing HIV Transmission Among Injection
Drug Users
The main factor associated with HIV infection among injection drug users is the practice of sharing injection equipment.(p2)
This multiperson use of syringes is particularly dangerous because residual blood retained in the syringe from one person
can be unintentionally and, even with rinsing, inconspicuously passed along to the next person using the syringe.(p2)
This sharing behavior is in part a consequence of the restricted availability of sterile needles and syringes.(p2)
For injection drug users who cannot or will not stop injecting drugs, the once-only use of sterile needles and syringes
remains the safest, most effective approach for limiting HIV transmission. (p2) (Emphasis added.)
Laws that make it a criminal offense to possess injection equipment (paraphernalia laws) were designed to decrease the
prevalence of injection drug abuse, but they also inhibit users from carrying their own supply of needles and thus unwittingly
contribute to the sharing of contaminated ones.(p158)
Laws requiring a prescription for the purchase of new needles and syringes (prescription laws) constrain the availability of
sterile injection equipment and thus promote the sharing of contaminated equipment.(p158)
■ Legislative bodies remove legal sanctions for the possession of injection paraphernalia.(p158)
■ Appropriate legislative bodies should repeal laws in the nine states that require a prescription in order to purchase injection
equipment.(p158)
Normand J, Vlahov D, Moses LE, eds. Preventing HIV Transmission: The Role of Sterile Needles and Bleach. Washington, DC: National
Academy Press; 1995. Available at: www.nap.edu/catalog/4975.html. Accessed October 30, 2002.
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RESEARCH
Injection Drug Users Report
Good Access to Pharmacy Sale
of Syringes
Wendy Reich, Wilson M. Compton, Joseph C. Horton, Linda B. Cottler,
Renee M. Cunningham-Williams, Robert Booth, Merrill Singer, 
Carl Leukefeld, Joseph Fink, Tom J. Stopka, Karen Fortuin Corsi, 
and Michelle Staton Tindall
Injection drug users (IDUs) are at risk for acquiring human
immunodeficiency virus (HIV), hepatitis B virus, and hepatitis C
virus through the sharing of contaminated syringes, water, cookers,
cotton, and other injection equipment.1–3 Pharmacies are an obvious
source of sterile syringes for IDUs.4–7 However, a number of barri-
ers, including drug paraphernalia and syringe prescription laws,
make access to syringes from pharmacies difficult for IDUs.8,9 In
addition, some pharmacists may have negative feelings about IDUs
and be unwilling to have them as customers. They may also be
unwilling to sell sterile syringes to IDUs because they worry about
used syringes being unsafely disposed of in public areas.1,10
Objectives
To learn more about these issues, we conducted a series of phar-
macist focus groups in urban and rural areas of four states, and the
results of this study are reported elsewhere in this supplement.1 We
also addressed these issues from the perspective of the IDUs in a
parallel series of focus groups conducted as part of the same study,
funded by the National Institute on Drug Abuse, of the availabili-
ty of syringes. This article presents results of the IDU focus groups
Objective: To examine injection drug users (IDUs) opinions and behavior regarding purchase of sterile syringes from pharmacies.
Design: Focus groups. Setting: Urban and rural sites in Colorado, Connecticut, Kentucky, and Missouri. Patients or Other
Participants: Eight focus groups, with 4 to 15 IDU participants per group. Interventions: Transcripts of focus group discussions were
evaluated for common themes by the authors and through the use of the software program NUD*IST. Main Outcome Measures:
Knowledge of human immunodeficiency virus (HIV), pharmacy use, barriers to access from pharmacies, high-risk and risk-reducing
behavior, and rural/urban difference. Results: Almost all participants knew the importance of using sterile syringes for disease preven-
tion and reported buying syringes from pharmacies more than from any other source. Two IDUs believed pharmacists knew the syringes
were being used for injecting drugs and perceived pharmacists’ sales of syringes to be an attempt to contribute to HIV prevention. Most
IDUs reported that sterile syringes were relativity easy to buy from pharmacies, but most also reported barriers to access, such as hav-
ing to buy in packs of 50 or 100, being made to sign a book, having to make up a story about being diabetic, or having the feeling that
the pharmacists were demeaning them. While the majority of IDUs reported properly cleaning or not sharing syringes and safely dis-
posing of them, others reported inadequate cleaning of syringes and instances of sharing syringes or of improper disposal. There were
few differences in IDUs’ reported ability to buy syringes among states or between urban and rural sites, although the data suggest that
IDUs could buy syringes more easily in the urban settings. Conclusion: For the most part, participants understood the need for sterile
syringes in order to protect themselves from HIV, hepatitis B virus, and hepatitis C virus and saw pharmacies as the best source of ster-
ile syringes. Although these data are not generalizable, they suggest that pharmacists can and do serve as HIV-prevention service
providers in their communities.
J Am Pharm Assoc. 2002;42(suppl 2):S68–72.
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completed in four states: Missouri, Connecticut, Colorado, and
Kentucky, with the objective of gathering information about
IDUs’ experiences in purchasing sterile syringes from pharmacies.
In each state, research staff conducted one urban and one rural
focus group. The informal atmosphere of a focus group allowed
IDUs to express their views about the role of syringe access in pre-
venting the spread of HIV and report the sources from which they
bought sterile syringes, how easy it was to buy syringes, and the
barriers to buying sterile syringes from pharmacies.
Methods
Methods were similar to those described in a study of pharma-
cists.1 Focus groups were coordinated by researchers from
Washington University in St. Louis. Detailed scripts and proce-
dure manuals were prepared by an anthropologist (W.R.) with
extensive training in qualitative studies. Scripts and manuals were
sent to all sites and a pre-focus group conference call was held to
ensure that all the focus groups would use standardized methods.
Urban (census-defined metropolitan areas) and rural (defini-
tions varied) focus groups were conducted. In Missouri, Kentucky,
and Colorado, the rural sites were remote areas more than 75 miles
from any defined metropolitan areas. Connecticut “rural” areas
were selected from the nonurban areas surrounding Hartford;
because of the generally dense population in Connecticut, no
remote rural areas were available.
IDUs were recruited from substance abuse treatment centers
and by word of mouth. Once a roster was obtained, IDUs were
called and invited to participate in the focus group. This resulted in
convenience samples at all sites. IDUs were informed that they
would be taking part in a study of attitudes and behaviors of per-
sons attempting to purchase syringes. Focus group participants
were paid $20. Before the focus groups, all participants signed
informed consent statements using procedures approved by each
site’s Institutional Review Board.
Two facilitators led each focus group. One facilitator was the
moderator; the other ensured that all questions were covered and
that all participants had an opportunity to voice their feelings and
opinions. Each participant was assigned a number, which was used
instead of names to protect confidentiality. Each focus group last-
ed about an hour and was audiotaped.
Facilitators focused the discussion on five main topics: (1) gen-
eral syringe practices, (2) where syringes were obtained, (3) ease or
difficulty in obtaining syringes, (4) knowledge of laws and regula-
tions, and (5) prevention of HIV and hepatitis B and C infections.
The transcripts from all eight focus groups were analyzed by the
researchers at Washington University using the qualitative analy-
sis software, NUD*IST.11 NUD*IST was used primarily for word
searches that put topics in context so that themes could be devel-
oped. We also reviewed the transcripts.
Results
Focus groups of 4 to 15 participants were conducted over a 6-
week period in June and July 2000. Seventy-nine IDUs participat-
ed: 39 men and 40 women. The majority of participants were
white, with the second largest group composed of African
Americans (see Table 1). An unexpected finding was the few dif-
ferences among states, and between urban and rural sites, although
syringe purchase appeared easier in urban areas. IDUs in Colorado
showed the most risk-reducing behavior, followed by Missouri
and Connecticut. Kentucky showed the least.
Two major themes were identified: “Access to sterile syringes
from pharmacies,” and “risk behaviors.” In “risk behaviors” we
included syringe-disposal behaviors. The most common facility
from which focus group participants obtained sterile syringes
were pharmacies, and their reports indicated less difficulty pur-
chasing them from this source than we had anticipated.11 Many
participants indicated that pharmacies were the best source of
sterile syringes, and that syringes could be obtained there with
relative ease (Table 2). However, other participants reported dif-
ficulties, such as tough drug paraphernalia laws, only being able
to buy in boxes of 50 to 100, being made to sign a book, and
believing that the pharmacists viewed them negatively.8 A few
participants reported that the only source of obtaining sterile
syringes was stealing syringes from hospitals or doctor’s offices
or getting syringes from diabetics. While some Connecticut
IDUs obtained sterile syringes from a syringe exchange program
(SEP), others, in Colorado, believed that the van-based SEP was
not available frequently enough to provide regular access to ster-
ile syringes.
By far the majority of focus group members appeared aware of
the dangers of contracting HIV or hepatitis B or C viruses through
sharing needles. Aside from buying sterile syringes, chiefly from
pharmacies, many IDUs engaged in other risk-reducing behaviors,
such as cleaning their syringes with bleach or never sharing their
syringes with others (Table 3). A number of participants made sure
that their syringes were safely disposed of by putting the syringes
in biohazard boxes, flushing tips down the toilet and putting the
rest in a dumpster, or by breaking tips and putting syringes in a
milk bottle or other container.
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Table 1. Injection Drug User Focus Groups (n = 79)
Characteristic No.
Men 39
Women 40
Race/Ethnicity
White 41
African American 21
Puerto Rican 9
Dominican 1
Native American 1
Asian 1
Multiracial 2
Other 3
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Table 2. IDU Opinions about Pharmacy Syringe Access
Easy Access Difficult Access
Some pharmacists act like they don’t want you Have to know which pharmacies to go to (Missourib)
to get AIDS; very helpful (Colorado,a Missouria)
Easy to obtain (Connecticut,a Missouria) Have to learn the right things to say about insulin 
(Colorado,b Kentucky,b Missouria)
No problems with pharmacies (Connecticut,a Missouri,b Coloradoa) Have to buy 50 to 100 at a time (Colorado,b Connecticut,b
Kentucky,a Missouri,a,b)
Compared to other states, Colorado is easy (to get syringes) Steal syringes—hospitals, doctors’ offices (Missourib)
(Coloradoa)
People are so helpful. They know what you’re doing (Coloradoa) Some pharmacists make you sign a book (Missouri,b Kentuckyb)
Police don’t do too much (Colorado,a Missourib) Feels ashamed when have to buy packs of 50 or 100 (Colorado,b
Missourib)
Walk into any pharmacy and buy them (Colorado,a Kentuckya) Hard to get a syringe late at night (Kentucky,b Connecticut,b
Missourib)
Don’t need a prescription (Colorado,a,b Missourib) Some pharmacists judge them negatively (Colorado,b
Connecticut,b Kentucky,b Missouri b)
Get them at drive through pharmacies (Missourib) Tough drug paraphernalia laws (Missouri,b Connecticut,b
Kentuckyb)
Get them from diabetics (Missouri,a Connecticutb) If police find a needle when they pat you down you get in real 
trouble (Missouria)
Gone to pharmacies looking like “death warmed over” (Missourib) Syringe van doesn’t come around often enough (Coloradoa)
Easier to get down here than in Denver (Coloradob)
Don’t need ID (Coloradoa)
Syringe exchange program (Connecticutb)
AIDS = acquired immunodeficiency syndrome; IDU = injection drug user.
aUrban.
bRural. 
Table 3. Themes Related to IDU Risk Behaviors
Risk-Reducing Behaviors High-Risk Behaviors
Scared of AIDS (Colorado,b Missouri,a,b Connecticut,b Kentuckyb) Shoots bleach through a couple of times (Colorado,b Missouri,b
Kentuckyb)
If you can afford drugs you can afford to buy in bulk (Missouria) Cleans syringes with vodka (Connecticutb)
Clean with bleach (Coloradoa,b) Cleans syringes with peroxide (Connecticutb)
Always uses sterile syringes (Colorado,a Kentucky,a Connecticutb) Cleans syringes with rubbing alcohol (Colorado,a Kentuckya)
Scratches name (identification) on syringe to make sure—doesn’t Rinses with water (Connecticutb)
get someone else’s (Colorado,a Connecticut,b Missouria)
Doesn’t share syringes (Connecticut,b Kentucky,b Coloradob) When “drug sick” will use dirty needles (Connecticut,b Missourib)
Carries own water (Coloradoa,b) Knows of people who share needles without cleaning them 
(Missouria)
Buys month’s supply of syringes at a time (Colorado,b Missourib) Get hepatitis C from doing drugs and drinking, not from sharing 
needles (Kentuckyb)
Gets sterile syringes from pharmacies (all groups) People are lazy (Colorado,a Missouria)
Flushes tips down toilet—puts rest in dumpster (Colorado,a,b All I think about is getting high (Coloradoa)
Missouria)
Breaks tips—put syringe in safe container, then in dumpster Try not to but when you need drugs you take a risk and share 
(Missouria) syringes (Connecticutb)
Puts tips in biohazard boxes (Connecticutb) Some [other] people leave syringes in the street (Colorado,a
Kentucky,b Missouria)
Leaves syringes in abandoned buildings (Missourib)
Pitch syringes out the window if you see the police coming 
( Missouria)
AIDS = acquired immunodeficiency syndrome; IDU = injection drug user.
aUrban.
bRural.
Although most group members recognized the need for clean
syringes, some still engaged in high-risk behaviors. Some IDUs
still showed a lack of knowledge about the safe ways of cleaning
syringes with bleach. Some cleaned their syringes with vodka, per-
oxide, or rubbing alcohol, while others simply rinsed them with
water. A few said that, at times when they really craved the drugs
(i.e., when they were feeling “drug sick”), they didn’t care whether
or not they shared syringes. A minority did not dispose of needles
safely. Some group members reported that they “knew” of people
who disposed of syringes unsafely; while others admitted that they
had done so.
Many of the group members indicated that drug paraphernalia
laws made buying sterile syringes from pharmacies more difficult.9
A number of participants were concerned that carrying sterile
syringes could result in legal trouble, ranging from harassment by
the police to jail time. One group member from urban Missouri
reported that he and his associates would pitch syringes out the car
window if they saw the police.
Despite the barriers to access, group members on the whole
reported that pharmacies were their main source for sterile
syringes and made efforts to dispose of them safely.
Discussion
The data from the eight focus groups showed few differences.
Syringes appeared easier to obtain from pharmacies in urban areas.
IDUs in Colorado exhibited the most risk-reducing behavior while
Kentucky showed the least. The majority of the IDUs understood
the necessity for sterile syringes and saw pharmacies as the best
source for them. The IDUs from all eight focus groups reported
that syringes could be obtained from pharmacies with relative
ease. This differs from focus group information obtained from
pharmacists from the same eight sites,1 many of whom reported
being on the lookout for IDUs posing as legitimate customers.
These data do not allow us to determine whether pharmacists were
being deceived by the IDUs, were more lax in their practices than
they admitted, or were satisfied that selling syringes in boxes of 50
to 100 prevented IDUs from purchasing them. The IDUs may have
exaggerated the ease of purchase syringes, or may have adjusted to
buying in large quantities, or pretended to be diabetic. Also, the
IDUs in our study may not have used the pharmacies in which the
pharmacist study participants worked. However, it is clear that
group members viewed buying from pharmacies as the best source
for sterile syringes.
Despite the IDUs’ assertions that, except in rare cases, they
could obtain syringes from pharmacists, many reported having to
deceive the pharmacists to obtain the syringes. A number of focus
group members reported having to submit to what they considered
degrading behavior, such as having to buy in large quantities, sign
a book, pretend that they were diabetic, or deal with the perception
that the pharmacists were judging them negatively.
Even when IDUs were able to purchase sterile syringes, drug
paraphernalia laws made carrying a sterile syringe risky. None of
the states in this study requires pharmacists to sell syringes only
upon presentation of a prescription, but clearly drug paraphernalia
laws would impede IDUs’ acquisition of sterile syringes from a
safe source and also reduce the likelihood that they would attempt
to dispose of used syringes safely.
Limitations
The findings of this study were subject to the following limita-
tions. Data gathered from focus group discussions are qualitative.
Specific questions may not be asked, which could result in an
unintended loss of information. There may be bias with respect to
the type of people who would agree to participate in a group. On
the other hand, the informal setting of focus groups can elicit qual-
itative data that might not be obtained through quantitative studies.
Qualitative data can help define issues and questions that can be
further explored.
Conclusion
For the most part, IDUs understood the need for sterile syringes
to protect themselves from HIV, hepatitis B, and hepatitis C infec-
tions. A large majority of IDUs viewed pharmacies as the best
source of sterile syringes. Pharmacists can play an important role
in increasing IDU access to sterile syringes and in counseling drug
users about safe syringe disposal, substance abuse treatment, and
use of condoms.
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June 25, 2002
Safe Community Disposal of Needles and Other Sharps
Dear Colleague:
.   .   .   .   .   
In the community, improperly disposed used sharps pose a public health hazard to both workers and the public.
While this complex problem requires national leadership, successful solutions must be focused at the state, local
and community levels. Collaborative efforts involving national, state, and local governments, the solid waste indus-
try, labor organizations, syringe and pharmaceutical manufacturers, pharmacies and pharmaceutical distributors,
and health associations are needed to identify, develop, and implement strategies to ensure safe disposal of used
sharps in the community. Ideally, these strategies should reduce or eliminate sharps in solid waste, should be low-
cost and convenient for the public, and should be easily implemented.
We encourage organizations and state leaders in these fields to convene state and local governments, the solid waste indus-
try, syringe and pharmaceutical manufacturers, pharmacies and pharmaceutical distributors, health associations, and other inter-
ested parties to review and improve the current options for safe disposal of used sharps generated in the community by patients
and IDUs and to plan public education efforts on safe disposal.
.   .   .   .   .   
Sincerely,
American Association of Diabetes Educators, American Diabetes Association, American Medical Association, American Pharmaceutical Association, 
Association of State and Territorial Health Officials, and National Alliance of State and Territorial AIDS Directors. Safe Community Disposal of Needles and
Other Sharps. Houston, Tex: August 7, 2002. Available at: www. safeneedledisposal. org/Call%20to%20Action. html. Accessed September 2, 2002.
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RESEARCH
Legal Syringe Purchases by
Injection Drug Users, Brooklyn
and Queens, New York City,
2000–2001
Don C. Des Jarlais, Courtney McKnight, and Patricia Friedmann
Providing access to sterile injection equipment is a central com-
ponent of human immunodeficiency virus (HIV) prevention for
IDUs.1 Syringe exchange programs (SEPs) and legal pharmacy
sales of needles and syringes (hereafter “syringes”) to drug users
are the two primary methods of providing access. Each has its own
strengths and limitations. SEPs provide for disposal of used injec-
tion equipment, can be a site for providing multiple health and
social services, and require no outlay of money on the part of the
drug user. In contrast, pharmacies can usually provide easier
access because of better geographic coverage and much longer
hours of operation. Therefore, syringe exchange and pharmacy
sales are complementary rather than competing ways of providing
access to sterile injection equipment.
A relatively large number of studies have evaluated SEPs,
including trials that have used biological outcomes.2–5 The gener-
al conclusion of the syringe exchange literature is that these pro-
grams are usually, but not always, effective in reducing HIV trans-
mission among IDUs.6 Researchers have also studied pharmacy
sales as a method for reducing HIV risk among IDUs; for exam-
ple, pharmacy sales were an important component of limiting HIV
transmission among IDUs in Glasgow,7 a national program in
France led to substantial reductions in risk behavior,8 a statewide
program in Connecticut also led to substantial reductions in risk
behavior,9 and a similar statewide program in Minnesota led to an
increase in the use of pharmacies by IDUs.10
On January 1, 2001, New York State began the Expanded
Syringe Access Demonstration Program (ESAP). This program
allowed drug users and others to legally purchase up to 10 syringes
from pharmacies without prescriptions, which were previously
required for all syringe sales. Possession of up to 10 syringes was
also legalized (these syringes are not subject to narcotics para-
phernalia laws). Participation by pharmacies is voluntary and the
participating pharmacies are required to register with the New
York State Department of Health. Pharmacies are not allowed to
advertise that they sell syringes without a prescription.
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Objective: To assess preliminary results of the Expanded Syringe Access Demonstration Program (ESAP) in New York City. Design:
Temporal trends of pharmacy use among injection drug users (IDUs) in Brooklyn and Queens were analyzed from December 2000
through December 2001. Setting: Brooklyn and Queens, New York City. Participants: IDUs. Main Outcome Measures: Attempts
to purchase syringes from pharmacies and success in doing so. Results: Of the 1,072 IDUs interviewed from December 2000 through
December 2001, the majority were daily heroin injectors, but there was also substantial speedball and cocaine injection.  There was a
clear increase over time in both the percentage of subjects who attempted to purchase syringes in pharmacies and in the percentage
who successfully purchased syringes. Among IDUs interviewed 4 or more months after ESAP began, large majorities of those who
attempted to purchase syringes were successful in doing so. No differences in use of ESAP by IDUs were identified in Brooklyn versus
Queens: 27% of IDUs interviewed in Queens reported that they had attempted to purchase syringes in pharmacies versus 28% in
Brooklyn. Persons who reported injecting on a daily or more frequent basis were more likely to have attempted pharmacy purchases
than persons who reported injecting less frequently, 32% versus 21%.  Conclusions: The ESAP program has led to an increase in the
use of pharmacies as sources of sterile injection equipment among IDUs in New York City. The extent to which pharmacies become an
important source of sterile injection equipment and the effect of legal pharmacy sales on risk behaviors for human immunodeficiency
virus (HIV) infection remain to be determined.
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Objectives
This paper contains preliminary data on a study conducted on
pharmacy syringe sales among IDUs in the boroughs of Queens
and Brooklyn in New York City. These two boroughs were select-
ed because they have relatively few syringe exchange programs
(Brooklyn has three programs, and Queens has none). Thus, ESAP
may fill a particular need for access to sterile syringes for IDUs in
these two boroughs.
Methods
Beginning in December 2000, IDUs were recruited on the
streets of Brooklyn and Queens to participate in a survey about
their knowledge of ESAP, knowledge of pharmacies participating
in ESAP, and the extent to which IDUs were using pharmacies to
obtain syringes. The behavioral questions referred to behaviors in
the 6 months before the interview. The subjects were recruited in
conjunction with the AIDS Outreach Project, a street outreach pro-
gram that has been operating in New York City since the mid-
1980s. The recruitment procedures did not change during the
course of data collection, and there were no difficulties in recruit-
ing subjects throughout data collection.
The interviews lasted approximately 15 minutes and partici-
pants were paid $10 for their time. Subjects were assigned a
unique identifier when recruited, which was entered into a
database and was used to avoid duplication of interviews (subjects
were interviewed only once during this study).
The data reported here are part of larger, ongoing evaluation of
ESAP.
The research protocol was approved by the Institutional Review
Board of Beth Israel Medical Center.
For analysis, subjects were divided into five groups, based on
date of interview:
■ Pre-ESAP: December 1–31, 2000.
■ ESAP I: January 1–April 9, 2001.
■ ESAP II: April 10–June 30, 2001.
■ ESAP III: July 1–September 30, 2001.
■ ESAP IV: October 1–December 31, 2001.
Differences between periods were tested using χ2 analysis, and
the level of significance was set at P < .05.
Although the law prohibits the advertisement of nonprescription
syringe sales, the New York State Department of Health issued a
list of ESAP-participating pharmacies. This list was distributed on
April 10, 2001. The ESAP I time period covers the time that the
law was in effect but that the knowledge of participating pharma-
cies was limited. The time periods thereafter are quarters. 
Results
Table 1 shows the demographic and recent drug use character-
istics of the subjects by borough. The racial/ethnic differences
reflect the population differences between the boroughs. Table 2
shows the frequency of the injection of heroin alone, cocaine
alone, and speedballs (heroin and cocaine mixture) by the subjects
in the 6 months before the interview. The majority of subjects were
daily heroin injectors, but there was also substantial speedball and
cocaine injection.
Table 3 shows the percentage of subjects who attempted to pur-
chase syringes from pharmacies, and the percentage of those
attempting who successfully purchased syringes in each of the five
time periods. Note that the question referred to attempts and suc-
cessful attempts in the 6 months before the interview. There is a
clear increase over time in both the percentage of subjects who
made purchase attempts in pharmacies and in the percentage who
successfully purchased syringes there. During the last three peri-
ods, large majorities of those who attempted to purchase syringes
were successful in doing so. 
There were no differences in use of ESAP by IDUs in Brooklyn
versus Queens. For all of the ESAP time periods combined, 27%
of IDUs interviewed in Queens reported that they had attempted to
purchase syringes in pharmacies versus 28% in Brooklyn.
Persons who reported injecting on a daily or more frequent basis
were more likely to have attempted pharmacy purchases than per-
sons who reported injecting less frequently, 32% versus 21% (P =
.002). There were also significant differences in use of pharmacies
by race/ethnicity. Table 4 shows the percentage attempting phar-
macy purchases by race/ethnicity and by time. There is a clear sep-
aration of the three groups, with white IDUs becoming the most
likely to attempt pharmacy purchases and African American IDUs
becoming the least likely to attempt pharmacy purchases.
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Table 1. Characteristics of Street-Recruited
Injection Drug Users 
Brooklyn Queens 
No. (%) No. (%)
(n = 611) (n = 461)
Mean Age (years) 40.5 42.0
Race/Ethnicity
Latino 305 (51) 125 (28)
African American 203 (34) 198 (44)
White 86 (14) 128 (28)
Sex
Male 403 (66) 301 (65)
Table 2. Drug Injection Frequency During Last 6
Months by Drug Type 
Heroin % Speedball % Cocaine %
None 6 51 60
< daily 28 29 27
1+ times/day 66 20 13
Discussion
The data in this preliminary report reflect experiences during an
extended start-up phase for ESAP among IDUs in Brooklyn and
Queens. This start-up period is consistent with several of the fea-
tures of the ESAP law, including the need for pharmacies to regis-
ter with the Department of Health and the prohibition on advertis-
ing nonprescription syringe sales. That one-half of the subjects
interviewed in our last time period had attempted pharmacy pur-
chases, and that more than 90% of those attempting were success-
ful does clearly show that ESAP was operational on a large scale
by the end of 2001 in Brooklyn and Queens.
The eventual extent of pharmacy purchasing by IDUs and the
effect of pharmacy sales on injection risk behavior remain to be
determined. ESAP does appear to be used more frequently by
those IDUs who inject daily, and thus have a more frequent need
for sterile injection equipment. We suspect that the relationship
between pharmacy purchases and risk behavior is likely to vary
with the degree of ESAP implementation and that substantial
reductions in injection risk behavior will occur when large num-
bers of high-risk IDUs purchase from pharmacies on a frequent
basis. We also note that any trends in risk behavior among IDUs
who purchase from pharmacies would need to be interpreted in
conjunction with trends in risk behavior among IDUs who are not
purchasing from pharmacies.
The emerging racial/ethnic differences in pharmacy sales in our
data are of considerable concern. At present, we do not have an
explanation for these differences. This is an area in which further
research is needed and in which additional ESAP implementation
efforts addressing Latino and African American IDUs are needed.
Limitations
Data reported in this paper should be interpreted cautiously,
given the preliminary nature of the results. The data reported on
pharmacy purchases did not assess the effect of ESAP on the trans-
mission of HIV and other blood-borne pathogens.   Finally, IDUs
were recruited on the streets in both Brooklyn and Queens; there-
fore the results and experiences reported here may not be repre-
sentative of all IDUs in New York City. 
Conclusion
The first year of ESAP in Brooklyn and Queens included a
lengthy implementation period. By the end of 2001, the program
had reached a point where one-half of the street-recruited IDUs in
Brooklyn and Queens had attempted to purchase syringes in phar-
macies, and almost all who attempted such purchases were suc-
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Table 4. Racial and Ethnic Differences in Pharmacy Purchase of Syringes Over ESAP Implementation
Periods 
Pre-ESAPa % ESAP Ib % ESAP IIc % ESAP IIId % ESAP IVe %
(n = 202) (n = 331) (n = 170) (n = 169) (n = 175)
Race/Ethnicity
White 11 17 40 49 79
African American 13 11 22 30 35
Latino 11 27 35 42 49
P Valuef .988 .003 .093 .157 .001
ESAP = Expanded Syringe Access Demonstration Program.
aDecember 1 – 31, 2000.
bJanuary 1 – April 9, 2001.
cApril 10 – June 30, 2001.
dJuly 1 – September 30, 2001.
eOctober 1 – December 31, 2001.
fBy χ2 test for trend. P values < .05 were considered significant.
Table 3. Attempts and Success of Pharmacy Purchase of Syringes Over ESAP Implementation Periods 
Pre-ESAPa % ESAP Ib % ESAP IIc % ESAP IIId % ESAP IVe %
(n = 210) (n = 339) (n = 175) (n = 179) (n = 181)
Tried (P < .0001 by χ2 test for trend) 12 18 31 40 50
Succeeded (P < .0001 by χ2 test for trend) 54 35 74 82 92
ESAP = Expanded Syringe Access Demonstration Program.
aDecember 1 – 31, 2000.
bJanuary 1 – April 9, 2001.
cApril 10 – June 30, 2001.
dJuly 1 – September 30, 2001.
eOctober 1 – December 31, 2001.
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cessful. However, throughout the five time periods analyzed, con-
siderable racial/ethnic differences emerged among IDUs using
pharmacies, with African Americans being the least likely to pur-
chase syringes in a pharmacy.
Continued expansion of pharmacy purchases by IDUs is still
needed, as well as an increase in outreach and education regarding
ESAP. These expanded efforts should focus on Latinos and
African Americans to increase their use of pharmacies for obtain-
ing sterile injection equipment.
The authors declare no conflicts of interest or financial interests in any
product or service mentioned in this article.
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On January 1, 2001, the Expanded Syringe Access Demonstration Program (ESAP) went into effect in New York State.
ESAP offered pharmacies, health care facilities, and health care practitioners the opportunity to register with the New York
State Department of Health to sell or furnish up to 10 syringes without a prescription to persons at least 18 years of age. The
legislation required an extensive independent evaluation.
Seven articles in this supplement report on aspects of ESAP. See pages S28, S29, S62, S77, S83, S92, and S105. Additional
information on ESAP can be found at: www.health.state.ny.us/nysdoh/hivaids/esap/regover.htm.
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RESEARCH
Impact of Increased Syringe
Access: Preliminary Findings 
on Injection Drug User Syringe
Source, Disposal, and Pharmacy
Sales in Harlem, New York
Crystal M. Fuller, Jennifer Ahern, Liza Vadnai, Phillip O. Coffin, 
Sandro Galea, Stephanie H. Factor, and David Vlahov
Injection drug users (IDUs) are at high risk for acquiring human
immunodeficiency virus (HIV), hepatitis B virus, hepatitis C virus,
as well as other blood-borne pathogens.1–4 The primary mode of
transmission for HIV and other blood-borne pathogens among
IDUs is parenteral, specifically through direct syringe sharing or
“multiperson use” of syringes.4,5 Ethnographic and epidemiologic
studies have concluded that multiperson use of syringes is due to
several factors; the two principal factors being lack of access to
sterile syringes and needles (referred to collectively in this paper
as “syringes”), and fear of arrest and detainment for infractions of
paraphernalia possession laws and ordinances.6,7
In 1997 four federal agencies issued an HIV Prevention Bulletin
recommending that to reduce the risk of infectious disease, IDUs
unable to stop injecting drugs should “use a new, sterile syringe to
prepare and inject drugs” and practice safe injection techniques.8
Syringe exchange programs (SEPs; i.e., programs that allow drug
users to exchange used syringes for sterile syringes) have been
implemented worldwide and used as a safe syringe source for
IDUs to combat the spread of HIV. Increased access to sterile
Objective: To evaluate the New York State Expanded Syringe Access Demonstration Program (ESAP) through injection drug user (IDU)
surveys, discarded needles and syringes studies, and pharmacy sales and experiences surveys. Design: Pre–post comparison.
Setting: In Harlem, New York City, risk surveys among street-recruited IDUs, needle/syringe street counts on 27 systematically sam-
pled city blocks, and Harlem pharmacist reports of sales and experiences. Main Outcome Measures: Number and types of IDU
syringe sources, block mean counts of discarded needles and syringes, level of pharmacy nonprescription syringe sales (NPSS), and
pharmacists’ experiences. Results: Comparing 209 pre-ESAP with 396 post-ESAP IDUs, pharmacies as a primary syringe source
increased: 3.4% to 5.3% (P < .001, and ever pharmacy use increased: 4.9% to 12.5% (P < .001), respectively. Compared with pre-ESAP
IDUs, post-ESAP IDUs tended to be younger and more often black. Harlem pharmacy participation in ESAP increased considerably from
March 1, 2001, to March 1, 2002, 49% to 79%, respectively. Among three Harlem pharmacies, there was a modest increase in NPSS;
pharmacists reported no problems, and no discarded needles and syringes were observed in pharmacy areas. In the three pharmacies,
the proportion of syringe sales that were NPSS was 46% (110 to 240 NPSS/month), 3% (25 to 90 NPSS/month), and 0%. The mean ratios
of needles/syringes to background trash have not increased in Harlem since ESAP began. Conclusion: To date, no evidence of harm-
ful effects (discarded needles/syringes, pharmacy altercations) resulting from ESAP were observed. While NPSS have increased in
Harlem, pharmacy use among IDUs remains low. In Harlem, efforts are underway to increase ESAP awareness and reduce socioenvi-
ronmental barriers to ESAP.
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syringes has proved to be an effective response to injection-relat-
ed HIV risks.9 However, in New York City, as well as other cities
across the United States, syringe reuse continues to occur particu-
larly among subgroups of IDUs who do not have access to
SEPs.10,11 Limited days and hours of operation (a result of a fed-
eral ban on funding for SEPs) and long travel distances to an SEP
site may be primary reasons for lack of access to SEPs by some
IDUs.12,13
Numerous researchers have urged the use of pharmacies as safe
syringe sources through sales or exchange programs that would
supplement SEPs.6,14–17 In an effort to increase access to sterile
syringes, New York State enacted legislation, the Expanded
Syringe Access Demonstration Program (ESAP), permitting phar-
macy sale of syringes without a prescription. Since January 1,
2001, New Yorkers 18 years of age or older have been able to pur-
chase up to 10 syringes at a time from pharmacies registered with
the New York State Department of Health (NYSDOH) without a
prescription and to possess those syringes legally. This law is sim-
ilar to the Connecticut law, enacted in 1992, allowing nonpre-
scription syringe purchases from pharmacies. In Connecticut, the
law has been associated with reductions in syringe-sharing among
IDUs as well as increases in nonprescription syringe sales (NPSS)
over time.9,18
The New York State law mandates an independent program
evaluation for submission to state policy makers to determine the
impact of law on: (1) IDU practices (e.g., syringe sharing and
syringe disposal); (2) pharmacy practice (e.g., level of participa-
tion); (3) substance abuse trends (e.g., changes in illicit drug
abuse); (4) criminal activity (e.g., level of drug-related arrests);
and (5) occupational consequences (e.g., needle sticks). As the
independent evaluator of ESAP, the New York Academy of
Medicine (NYAM), in collaboration with Beth Israel Medical
Center and the National Development and Research Institutes,
conducted a focused qualitative and quantitative epidemiologic
assessment of these areas of interest.
Objectives
In this paper, we provide early findings on three ESAP evalua-
tion components underway in the Harlem neighborhood of New
York City: (1) IDU syringe source before and after ESAP legisla-
tion; (2) discarded syringe (i.e., needle and syringe) counts before
and after ESAP legislation; and (3) pharmacy sales and pharma-
cists’ experiences since ESAP began. These analyses provide
information on of the early effects of ESAP on drug users, phar-
macists, and the community of Harlem.
Methods
From September 1997 to December 1998, IDUs were enrolled in
an observational cohort study (CIDUS-2) and followed for 1 year at
6-month intervals in the Harlem neighborhood of New York City.
Study participants were asked about their injection practices as well
as other high-risk practices. In July 2000, enrollment of a new IDU
cohort (Hepatitis C cohort study) began in Harlem, which assessed
high-risk behaviors similar to those of the earlier cohort. A third
observational cross-sectional study (Urban Resource Center [URC]
Cross-Sectional Survey) was implemented in October 2000, which
also captured similar risk practices. Each of these studies used sim-
ilar recruitment and data collection methodologies with one excep-
tion. Two studies (CIDUS-2 and Hepatitis C) targeted IDUs ≤ 35
years of age and one study (URC) had no age requirement.
Participants in all three studies were asked which syringe source
they used most often in the past 6 months, and whether they ever
purchased a syringe from a pharmacy in the last 6 months. These
studies provide data on IDU syringe sources before (pre-ESAP) and
after (post-ESAP) the legislation.
Street counts of discarded syringes were conducted quarterly in
Harlem from October 2000 to December 2001, yielding a total of 8
time points. The methodology has been described in detail else-
where.19 In brief, every fourth city block was systematically sam-
pled yielding a total of 27 blocks. Four survey teams of two 
“counters” and a “recorder” were sent into the field using a standard
protocol. All surveying began in the northeast corner of the block,
and teams walked clockwise until the perimeter of the block was
completed. The teams returned to side streets and alleys within the
block and surveyed these areas systematically and consistently. The
counters surveyed the outer edge of the sidewalk, the middle of the
sidewalk, and 3 feet into a yard or empty lot. As the surveyor
observed each item, the recorder tallied and recorded counts of
syringes, needles, and background trash (drug vials, soft drink bot-
tles, and cans). These counts were conducted on the same day of the
week and by the same survey team to maximize consistency.
In June 2001, 10 ESAP-registered pharmacies were randomly
selected from the ZIP Codes in New York City with the highest
prevalence of acquired immunodeficiency syndrome (AIDS), drug-
related hospitalizations, and juvenile crime to participate in our
Pharmacy Sales and Experiences Study. Each pharmacist (owner or
manager) was required to record monthly prescription and NPSS
data. Participating pharmacists were also asked to participate in a 10-
minute monthly survey that assessed practices and experiences sur-
rounding the sale of nonprescription syringes, conversations that
occurred during sales transactions, cost of syringes as singles and in
packs of 10, and how each of these reported practices and experi-
ences changed over time. Additionally, a 1-block radius around each
participating pharmacy was assessed for discarded needles,
syringes, and background trash. In this paper, we report on a subset
of these 10 pharmacies, including 3 pharmacies located in Harlem.
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Statistical Analysis
Data from the three IDU studies (CIDUS-2, Hepatitis C, URC)
were combined to examine differences between the two time peri-
ods, pre-ESAP versus post-ESAP. We examined demographic
characteristics (i.e., age, sex, race/ethnicity) and syringe source
(i.e., syringe source used most often in the last 6 months, and ever
use of a pharmacy as a syringe source in the past 6 months). After
data cleaning and editing, t tests and χ2 tests were used to deter-
mine bivariate statistical differences for continuous and categori-
cal variables, respectively.
The discarded syringe street counts measured at each time point
included syringes, N, vials, V, and bottles/can, B, per block. The
ratio of needles and syringes to the sum of vials, bottles, and cans,
N/(V + B), was used to account for the background trash or condi-
tion of each block. Additionally, we chose something small (e.g.,
drug vial) and something larger (e.g., beverage bottles and cans) to
help account for a visual “practice” effect over time. Ratios and
counts are commonly skewed to the right. Thus, to reduce the
effect of the skewness on our study findings, the ratio N/(V + B)
for each block count was transformed to log N/(V + B). To ease the
interpretation of the count data, the transformed data were aver-
aged, exponentiated, and presented as needles and syringes per
100 trash items, as follows:
e {mean of log [N / (V + B)]} × 100
This resulted in a geometric mean that reflects the natural scale
of the original (transformed) data.19
The pharmacy sales and experiences data collected from the
three Harlem pharmacies were used to calculate the number of
NPSS by month. Additionally, the proportion of NPSS out of the
total number of syringes sold (e.g., prescription and nonprescrip-
tion) was calculated for the three pharmacies combined.
Qualitative assessments of the practices and experiences of each
Harlem pharmacist were summarized.
Results
As of January 2002, 605 IDUs had been enrolled in the three
IDU studies yielding 209 IDUs enrolled before January 1, 2001
(pre-ESAP period) and 396 after (post-ESAP period). IDUs
enrolled before ESAP implementation were significantly younger
than those enrolled after as shown by the median ages of 26 and
36, respectively (Table 1). There were no significant differences
by gender, however there were significantly more black IDUs
(23.5% versus 9.6%) and fewer white IDUs (4.6% versus 13.4%)
during the post-ESAP period compared with the pre-ESAP period.
A higher proportion of IDUs reported a pharmacy (5.3% versus
3.4%) and an SEP (67.3% versus 48.1%) as the syringe source
most often used during the post-ESAP period compared with the
pre-ESAP period. A lower proportion of IDUs reported a family
member or friend (14.5% versus 17.8%) and other source (12.9%
versus 30.8%) during the post-ESAP period compared with the
pre-ESAP period. Post-ESAP, a significantly higher proportion of
IDUs reported ever purchasing from a pharmacy in the last 6
months (12.5% versus 4.9%) compared with pre-ESAP.
Demographically, significantly higher proportions of syringe 
purchases were observed during the post-ESAP period compared
with the pre-ESAP period among white IDUs (25% versus 3.7%;
P < .04), and Latino IDUs (13.1% versus 5.2%; P < .01), respec-
tively. However, the overall proportion of pharmacy syringe pur-
chases were lower, and these syringe purchases did not signifi-
cantly increase among black IDUs (4.6% versus 0%; P < .36)
when comparing the post- versus pre-ESAP periods, respectively
(data not shown in tables).
Discarded syringe counts over the 27 Harlem selected city
blocks are summarized in Table 2. The syringe counts per block
were low, with many blocks having 0 counts. The actual counts
observed in Harlem ranged from 2 to 5 syringes with the exception
of 1 month in which 32 syringes were counted. However, when
background trash (e.g., bottles/cans and vials) was taken into
account, the block mean of syringes per 100 trash items did not
differ across the five count dates. The block mean ratios of syringe
to background trash have not increased since ESAP was imple-
mented. In fact, there appears to be a decrease in block mean ratios
when comparing pre-ESAP period ratios (1.17 and 1.03) with
post-ESAP period ratios (0.81, 0.53, and 0.73).
Since ESAP began, the proportion of Harlem pharmacies regis-
tered out of the total number of pharmacies has increased consid-
erably from March 2001 to March 2002, 49% to 79%, respective-
ly (81 total pharmacies in Harlem).20 Of the 3 Harlem pharmacies
that participated in the Pharmacy Sales and Experiences Study, 2
are actively selling nonprescription syringes and 1 has sold none
since ESAP began. The pharmacy selling the most nonprescription
syringes sells between 110 and 240 syringes per month, while the
other pharmacy is selling between 25 and 90 nonprescription
syringes. NPSS make up about 46% of the total syringe sales at the
highest selling pharmacy and about 3% of the total syringe sales at
the moderate selling pharmacy. These two pharmacies are located
within five blocks of one another but are reporting very different
syringe sales experiences (one had not sold nonprescription
syringes to date, while the other is the most active among the three
Harlem pharmacies). The active pharmacy is located close to an
active open-air drug market. The pharmacy reporting no syringe
sales is located in a more active SEP area of Harlem compared
with the other two pharmacies. In terms of clientele, this pharma-
cy is tailored to “filling prescriptions only” with a customer base
of pediatric Medicaid patients. This particular pharmacy 
is more of an apothecary shop and does not have a typical 
“drugstore” appearance. It sells only a few nonprescription prod-
ucts, which limits number of customers seeking those products. At
all three pharmacies, single syringes are available for $0.50, and
10-packs range in price from $2.99 to $4.99.
No pharmacists have experienced “unusual events, transactions,
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or incidents” involving syringe sales since ESAP began through
February 2002. Pharmacists reported that customers seeking
syringes are “polite” and “considerate” at best, and “impatient” or
“unwilling to talk” at worst. For the most part, these pharmacists
reported that there was little or no discussion with the customer
during syringe transactions. When there was discussion, it was pri-
marily focused on safe syringe disposal, what the syringes were
used for, and in some cases, substance abuse treatment. The phar-
macist who was selling most actively had indicated concerns
regarding the volume of “daily single syringe sales customers” and
their potential impact on his other business. There have been no
observations of needles or syringes through the systematic counts
conducted in the surrounding area of each selected Harlem phar-
macy. All pharmacists enrolled stated that they were supportive of
ESAP.
Discussion
Entering the second year of ESAP, early information suggests
that the program has been embraced by pharmacies in Harlem, as
demonstrated by the proportion of pharmacies registered in the
program. However, while self-reported nonprescription syringe
purchases have significantly increased among IDUs in Harlem, the
proportion of IDUs reporting pharmacy use is relatively low, com-
pared with Brooklyn and Queens.21 Yet, the results presented here
show no evidence of untoward events as a result of ESAP imple-
mentation. This could be a result of low use of pharmacies as
syringe sources; however, our data provide a detailed account of
actively selling pharmacies and their experiences. Specifically, the
Harlem pharmacies selling nonprescription syringes reported no
disruption, and no discarded syringes were observed in or around
their locations. The low ratios (and lack of increase) in discarded
syringes observed for the 27 systematically sampled Harlem city
blocks further support the lack of adverse effects, namely, the
potential for contaminated syringes to be found on streets.
Several factors may account for the modest uptake of the pro-
gram in its first year in Harlem. First, Harlem, particularly East
Harlem, has the most concentrated number of SEPs in New York.
These programs have been established for several years, have a
legal status that permits carrying syringes, and provides free
syringes (whereas pharmacy sales are legal but involve purchases).
This long-standing availability of SEPs in Harlem provides a basis
for a slower adoption of a new program in this community. In
other cities that offer different venues for syringe access, studies
show that each service meets the needs of different IDU subgroups
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Table 1. Characteristics of Injection Drug Users Enrolled in Three Community Studies Pre- and Post-
ESAPa
Pre-ESAP Post-ESAP
Characteristic (n = 209) (n = 396) P valueb
Age (in years), median (range) 26 (18–34) 36 (18–62) < .001
Gender
Men, No. (%) 148 (70.8) 267 (68.3) < .340
Women, No. (%) 61 (29.2) 118 (30.2)
Other, No. (%) 0 (0.0) 6 (1.5)
Race/Ethnicity
White, No. (%) 28 (13.4) 18 (4.6) < .001
Hispanic/Latino, No. (%) 156 (74.6) 271 (69.1)
Black, No. (%) 20 (9.6) 92 (23.5)
Other, No. (%) 5 (2.4) 11 (2.8)
Primary syringe source in last 6 months
Pharmacy, No. (%) 7 (3.4) 21 (5.3) < .001
Needle exchange program, No. (%) 100 (48.1) 265 (67.3)
Family/friend, No. (%) 37 (17.8) 57 (14.5)
Other, No. (%) 64 (30.8) 51 (12.9)
Ever bought syringes from a pharmacy in last 6 monthsc: 
Yes, No. (%) 10 (4.9) 47 (12.5) < .003
No, No. (%) 194 (95.1) 330 (87.5)
IDU = injection drug user; ESAP = Expanded Syringe Access Demonstration Project.
aCIDUS-2, Hep C, and URC; pre-ESAP period was from September 1997 through December 1998, post-ESAP from January 2001 through
January 2002.
bT tests were used for continuous variables and χ2 square tests for categorical variables.
cThis was originally a dichotomous variable and has not been collapsed.
for HIV prevention.22 Thus, over time, ESAP may complement
existing safe syringe sources, and thereby reach a greater propor-
tion of IDUs in New York City.
Second, those accessing syringes through ESAP (at least early
on in the program) may differ demographically from those who
have not used the program, and this may explain the low level of
pharmacy utilization in the Harlem community. For example, the
overall population studied in Brooklyn and Queens tended to be
older and reflect a relatively lower proportion of black and Latino
IDUs compared with the Harlem IDU study sample. Reports of
ESAP participation among IDUs in Brooklyn and Queens also
demonstrated slower uptake by black and Latino IDUs as com-
pared with white IDUs.21 Similar demographic differences were
also observed among the Harlem population with regard to level of
IDU participation in ESAP over time. Thus, the slow uptake in
Harlem, and potentially elsewhere in the New York City, may be
characterized by a more vulnerable IDU subgroup that may per-
ceive barriers to ESAP, which may warrant attention by public
health practitioners. Based on these data, the Community Action
Board of the Harlem Urban Research Center at NYAM has under-
taken efforts that began in the summer of 2002 to increase the use
of ESAP, thereby potentially reducing levels of multiperson
syringe use and HIV transmission in Harlem. This will provide the
subject of a separate evaluation.
Finally, ESAP has not included advertising (which is banned in
the legislation), and efforts to inform IDUs about the law have
been implemented slowly during the study period. In March 2002,
the AIDS Institute provided a decal for participating pharmacies to
post on their windows or doors, and community-based organiza-
tions have taken a role in publicizing the program; the effects of
this will be the subject of future evaluation.
ESAP-participating pharmacists have the opportunity to be
“frontline” public health educators for drug users who patronize
their pharmacies. While generally little conversation between
pharmacists and IDUs was reported to occur, drug treatment dis-
cussions sometimes took place as well as inquiries on safe syringe
disposal. Pharmacies could develop relationships with other com-
munity and local government agencies that target prevention mes-
sages to high-risk communities to help promote safer injection and
disposal practices as well as provide information on drug treatment
options. The AIDS Institute has involved pharmacies in this fash-
ion as a part of the overall evaluation of ESAP.23
Limitations
A drawback in this study is the potential lack of comparability
between the pre- and post-ESAP populations. This is evidenced by
the older age and increased use of SEPs among the post-ESAP
IDU population compared with the pre-ESAP population (older
IDUs are more likely to participate in SEPs compared with
younger IDUs11). Based on this, and the enrollment criteria stated
earlier, the observed difference between pharmacy use pre- versus
post-ESAP may be somewhat overestimated in this report. For
example, if pre- and post-ESAP populations were more compara-
ble (i.e., both younger or both older), the overall level of pharma-
cy use may have been potentially lower (only if both were
younger) and the difference may have been somewhat diminished.
Previous studies have also shown that older IDU populations tend
to have higher proportions of black participants while younger
IDU populations tend to have larger proportions of white
IDUs.24,25 As the evaluation proceeds over the next year, future
analyses will help explain these early findings, particularly the
importance of individual and contextual sociodemographic effects
on ESAP participation.
Conclusion
Our findings reveal early results of the recently implemented
ESAP legislation through a comprehensive evaluation strategy
that may serve as a basis for future public health policy in the state
of New York, and elsewhere in the United States, using data on
IDU behavior, pharmacy sales and experiences, and discarded
syringes in a relatively high-risk area of New York City. Based on
our findings, no evidence of harmful effects resulted from ESAP
implementation in Harlem. We have provided evidence that sug-
gests relatively low use of pharmacies as a safe syringe source for
Harlem IDUs 1 year after the enactment of this new law. There
may be certain subgroups of IDUs that are not yet comfortable
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Table 2. Total and Block Mean Counts by Date Surveyed
Pre-ESAP Post-ESAPb
Survey Item October 25, 2000 January 30, 2001a April 25, 2001 June 27, 2001 December 5, 2001
No. needles and syringes 4 32 2 3 5
No. vials/other drug containers (V) 80 484 122 187 144
No. bottles/cans (B) 332 781 371 652 490
Block mean = e {mean of log [N / (V + B)]} × 100 1.17 1.03 0.81 0.53 0.73
ESAP = Expanded Syringe Access Demonstration Project.
aAlthough ESAP legislation began in January 1, 2001, components of ESAP continued to be developed (i.e., pharmacy registration for ESAP
were ongoing, ESAP-provider directory was being compiled and made public to public health providers).
bBecause of the events of September 11, 2001, no street count was conducted in September.
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with obtaining syringes through ESAP (i.e., blacks). Investigation
of social and environmental barriers to ESAP is underway in the
Manhattan, Brooklyn, and Bronx boroughs. Additionally, a
Harlem community-based intervention is in progress to increase
awareness and use of ESAP among IDUs, pharmacists, and com-
munity residents, which will be soon evaluated.
The authors declare no conflicts of interest or financial interests in any
product or service mentioned in this article.
Supported by NIDA (R01 DA14219), Robert Woods Johnson Foundation,
and The New York Community Trust Fund.
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RESEARCH
Pharmacy Syringe Sale Practices
During the First Year of
Expanded Syringe Availability in
New York City (2001–2002)
Ruth Finkelstein, Rebecca Tiger, Robert Greenwald, and Rajat Mukherjee
An estimated 200,000 injection drug users (IDUs) reside in
New York City, and 18,000 adults in the city are living with
acquired immunodeficiency syndrome (AIDS) directly acquired
through injection drug use. For years, advocates and practitioners
have highlighted the importance of access to sterile syringes to
reduce the spread of blood-borne diseases among IDUs.
The New York State Legislature’s passage of the Expanded
Syringe Access Demonstration Program (ESAP) constituted an
important step in addressing blood-borne pathogen prevention
among IDUs. ESAP is a 3-year demonstration program that began
on January 1, 2001, allowing anyone 18 years of age or older to
obtain syringes without a prescription from pharmacies and health
care providers that voluntarily register with the New York State
Department of Health (NYSDOH). Registration is a simple proce-
dure, consisting of the submission of one form to NYSDOH and
receipt of free copies of a required safety insert, providing infor-
mation on safe syringe use, methods for preventing disease trans-
mission, proper disposal practices, and substance abuse treatment.1
By increasing IDU access to sterile syringes, effective ESAP imple-
mentation could help reduce IDU exposure to and transmission of
human immunodeficiency virus (HIV) and other blood-borne
infections. As of March 2002, 737 (49%) of pharmacies in New
York City had registered with ESAP. Some evidence, however,
suggests that not all of the ESAP-registered pharmacies do, in fact,
sell syringes without a prescription.2 Other reports suggest that
some pharmacies selling syringes make the purchase onerous, like-
ly deterring customers from returning to the pharmacy. These
observations and reports led to a concern that IDUs might
encounter obstacles to syringe purchase in registered pharmacies
because of a lack of knowledge or support for the program by all
pharmacists and pharmacy staff working within a store since phar-
macies could be registered by a lead pharmacist or the chain’s head-
quarters. Further, we were concerned that there might be variations
in access by gender, race, ethnicity, and location of pharmacies.
Studies of pharmacists in other states have revealed misgivings
among some pharmacists about providing syringes to IDUs. A
Objective: To assess the role that customer characteristics, including race, age, and gender and pharmacy characteristics, including
type and location, play on actual syringe-selling practice by pharmacies registered to sell syringes under the New York State Expanded
Syringe Access Demonstration Program (ESAP). Design: 89 syringe-purchasing visits were made in randomly selected ESAP-regis-
tered pharmacies, stratified by chain and independent status. Setting: Visits were conducted in 14 New York City neighborhoods.
Three neighborhoods (two with high need for human immunodeficiency virus [HIV] prevention services and one with low need) were
selected in each of New York City’s five boroughs (except Staten Island, where only two neighborhoods were visited, as only one exists
with high need for HIV prevention services). Participants: Visits were conducted by syringe-purchasing testers with different demo-
graphic characteristics, including age (≤ 25 and > 25), race/ethnicity (white, black, Latino), and gender (men, women). Results: Testers
were able to purchase syringes in 69% of visits. Tester race, age, and gender did not significantly affect sales of syringe-selling prac-
tices. Location of pharmacy was statistically significant, with only 33% of the registered pharmacies selling syringes in the Bronx, but
67% to 89% selling in other four boroughs. Conclusions: ESAP has been widely implemented among registered pharmacies in four
of New York City’s five boroughs. The program’s effectiveness could be enhanced through pharmacy-based efforts focused broadly on
the ESAP goal of preventing the transmission of HIV and other blood-borne infections among injection drug users.
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1996 survey in Maine, conducted 3 years after its legislature
repealed the law requiring a prescription for syringe sales, found
that while 94% of pharmacists were willing to sell syringes, only
50% (98) were willing if they suspected the customer was an IDU.3
Of that 98, 68% (67) said they would require the customer to pro-
vide information, such as reasonable justification, photo identifica-
tion, and name and address before selling syringes.3 A study of
IDUs and pharmacists in Connecticut found that pharmacies were
an important source of syringes for IDUs.4 However, while more
than 80% of Connecticut pharmacies sold syringes without a pre-
scription in the first 2 years after the law changed5,6 significant geo-
graphic disparities in syringe access persisted after 4 years.7
These studies largely relied on surveys of pharmacists and IDUs.
Little research assesses experiences in actual pharmacy practice. In
one such study, an African American man and a white man, both
in their 40s, made 33 attempts to purchase syringes from St. Louis
pharmacies. The African American man was refused more fre-
quently than the white man; however, the small number of visits
did not permit statistically generalizable conclusions.8
Objective
The objective of the current study was to assess differences in
pharmacy practice of sale of sterile syringes by the gender,
race/ethnicity, or age of the prospective buyer and the location (by
borough and neighborhood) and type of community pharmacy
(chain or independent).
Methods
To assess the impact on pharmacy selling practices of a cus-
tomer’s and pharmacy’s characteristics, we attempted to purchase
syringes at 89 New York City ESAP-registered pharmacies. We
selected two neighborhoods with the highest level of HIV/AIDS
prevention services needs as assessed by the Community Needs
Index (CNI) and one with the lowest from each of New York
City’s five boroughs. CNI is a composite measure developed by
the NYSDOH that ranks ZIP Codes according to statistical health
indicators, including AIDS cases, cocaine and opioid-related hos-
pital discharges, sexually transmitted diseases, and teen pregnan-
cy rates.9 For Staten Island, only one neighborhood had a CNI
ranking outside the low range, resulting in 14 rather than 15 neigh-
borhoods included in the study. The chosen CNI ZIP Codes were
enlarged into neighborhoods based on clusters of ZIP Codes to
capture a sufficient number of registered pharmacies to fulfill the
study design. We then randomly selected pharmacies to visit with-
in the 14 designated neighborhoods by assigning numbers to all of
the registered pharmacies listed in the New York State ESAP reg-
istry, stratifying by chain and independent status, generating a ran-
dom numbers table, and choosing the pharmacies with the
assigned numbers that corresponded to this table.
Each pharmacy received only one visit except in four neighbor-
hoods. Three of these neighborhoods had fewer than three chain
and/or independent registered pharmacies, in which case individ-
ual pharmacies received more than one visit. The fourth neighbor-
hood was in Staten Island where only one neighborhood met the
high need criteria; thus the same pharmacies in this neighborhood
were visited twice to ensure that each borough received an equal
number of pharmacy visits. All together, 10 pharmacies were vis-
ited twice, two of which were visited three times.
Syringe purchasing testers (hereafter referred to as “testers”)
visited the pharmacies and attempted to buy syringes without pre-
scriptions. Testers were chosen from 12 categories based on
race/ethnicity (Latino, black, and white), gender (women and
men), and age (25 years and under and older than 25 years). A total
of 20 testers participated, 10 of whom were women, 10 were men;
5 were Latino, 7 black, 8 white; and 10 older than 25, and 10 who
were 25 and younger. Testers were recruited from and represent-
ed a range of ages, professions, socioeconomic statuses, and
neighborhoods.
The New York Academy of Medicine’s Institutional Review
Board (IRB) extensively reviewed the study protocol and deter-
mined that it was not necessary to obtain informed consent from
pharmacies and that doing so would compromise the study design.
The IRB also required that testers be hired as contractual employ-
ees of the New York Academy of Medicine, and that their training
to conduct the visits include being informed of potential risks to
their participation, not to carry controlled or illegal substances
while participating in the study, to be legal or permanent residents
of the United States, and to have no outstanding arrest warrants.
The study team had a lawyer on call while in the field.
Syringe purchasing visits were conducted throughout the week,
between the hours of 10:00 am and 8:00 pm from August 2001 to
January 2002. Testers were instructed to walk directly to the phar-
macy counter of the store and ask the person staffing the pharma-
cy counter for a syringe. If unable to purchase a single syringe,
testers sought to purchase the smallest number available. The
testers did not differentiate between the pharmacist and pharmacy
assistant, so either may have been asked. No late evening moni-
toring took place, and the study did not measure the impact of time
of day on pharmacy practice. All visits were conducted in English.
For each visit, we documented the tester’s demographic infor-
mation, the pharmacy neighborhood and borough, and the type of
community pharmacy. If a syringe was purchased, we document-
ed whether a safety information insert was included, the minimum
number of syringes available for purchase, the price of the
syringe(s), and the provision of any information about syringe dis-
posal. If a syringe was not purchased, we documented the phar-
macy staff’s stated reason for not selling a syringe and whether
any information was provided about when a syringe would be
available or other locations where a syringe could be purchased.
All questions asked or comments made by pharmacy staff during
the visits were documented. Testers noted if they were provided
any referrals to health care or substance abuse treatment centers.
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Results were tabulated and statistical tests for significant differ-
ences in success of purchase (by participant and pharmacy char-
acteristics) were calculated using χ2 tests with significance
attributed to P ≤ .05.
Results
We conducted 89 pharmacy visits; one pharmacy was never
open and therefore dropped from the analysis. Testers were able to
purchase syringes in 69% (61) of the pharmacy visits (see Table
1). In the 28 unsuccessful visits, pharmacy staff gave several rea-
sons for not selling syringes; the most common explanation was
that it was against the law to sell syringes without a prescription
(offered by 10 staff people). Other reasons given by more than one
pharmacy staff person included: they were not registered to sell
syringes without a prescription (7 mentions); they had run out of
syringes and/or safety inserts (5); or they required proof of dia-
betes or insulin use (2).
In 17% of all visits, testers were asked why they needed to pur-
chase a syringe and for what purpose they intended to use it. In four
of these visits, testers were asked to sign their names and addresses
on a pharmacy log. In these instances, pharmacy staff incorrectly
said that they were required by law, as part of their participation in
ESAP, to collect this information from people purchasing syringes.
In 70% (43) of successful visits, testers did not receive the man-
dated safety information insert; when asked about safety informa-
tion, the majority of pharmacy staff did not know about the safety
insert and could provide no safety information. In 10% (6) of suc-
cessful visits, testers received disposal information without
request; in an additional 39% (24) of successful visits, some dis-
posal advice was provided upon request, yet in many cases the
information was incorrect and, if followed, would have resulted in
unsafe disposal. Improper suggestions were to wrap used syringes
in tissue and discard or to throw used syringes in the garbage.
No statistically significant differences in ability to purchase a
syringe by level of neighborhood need (as measured by CNI),
independent or chain pharmacy status, or the tester’s gender, race,
or age were identified (see Table 2). A statistically significant dif-
ference in syringe access among boroughs was identified: syringe
access through pharmacies in the Bronx was considerably less
than in any other borough. Testers were unable to purchase
syringes at 67% of visits in the Bronx, compared with levels in
other boroughs, ranging from 11% in Staten Island to 33% in
Queens (see Table 3). Close to 50% of the pharmacies visited in
the Bronx said that they could not sell syringes without a pre-
scription, and a smaller proportion required proof of insulin use.
Testers were instructed to purchase the minimum numbers of
syringes possible. In 33% (20) of the successful visits, testers were
able to purchase a single syringe; the price ranged from $0.30 to
$2.00, with a mode of $0.50. In 62% (38) of the transactions,
testers were required to purchase a 10-pack of syringes; the price
ranged from $2.00 to $8.00, with a mode of $3.99.
To draw inferences from the sample of visited pharmacies to the
population of registered pharmacies in New York City, we sepa-
rated our findings into two groups: one for the visits in Brooklyn,
Manhattan, Queens, and Staten Island and one for visits in the
Bronx (see Table 4). Assuming that the randomly selected phar-
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Table 1. Syringe Purchases as a Percentage of
Total Pharmacy Visits
Pharmacy Visits 
No. (%)
Successful syringe purchases 61 (69)
Successful syringe purchases without 
inappropriate questions asked 48 (54)
Single syringes purchased 20 (23) 
Successful syringe purchases with 
disposal information 30 (34) 
Successful syringe purchases with 
safety information insert provided 18 (20) 
Table 2. Success of Syringe Purchases Grouped by
Tester Demographics
Tester Characteristic % Successful Purchases
Race/ethnicity
Black 70
White 53
Latino 83
Age (years)
≤ 25 71
> 25 66
Gender
Women 72
Men 64
Table 3. Success of Syringe Purchases by
Pharmacy Type and Location
Pharmacy Characteristic % Successful Purchases P Value
All pharmacies 69
Pharmacy location .003a
Bronx 33
Brooklyn 71
Manhattan 83
Queens 67
Staten Island 89
Pharmacy type .809
Chain 67
Independent 70
aSignificant difference at P < .05.
macies visited are representative of those not visited, sterile
syringe purchases would be anticipated in 77%, or 493, of the 640
pharmacies registered in Brooklyn, Manhattan, Queens, and
Staten Island. However, in the Bronx, if the 33% success rate is
representative, then of 97 pharmacies registered in this borough,
customers would be unable to purchase syringes in 65 pharmacies.
Given the small number of visits in the Bronx (18), the inferences
should be considered exploratory rather than definitive.
Discussion
That our study found no statistically significant differences in a
person’s ability to purchase a syringe based on age, gender, or
race/ethnicity is encouraging. Pharmacies did not clearly discrim-
inate based on an individual customer’s attributes. The lack of dif-
ferences between the practices of chain and independent pharma-
cies is also encouraging, as we had hypothesized that because
chains could register from headquarters, individual outlets might
not know about the program.
With respect to neighborhoods, we found no significant differ-
ences between those with low- and high-CNI rankings. We did
find, however, that access in the Bronx is significantly lower than
in the other boroughs. Given that 40% of New York City’s opioid-
related hospital discharges take place in the Bronx, the lack of
pharmacy access in this high-need borough demands attention.
As to cost of syringes, we found widespread variation through-
out the city. Perhaps more important, we found that single syringes
were largely unavailable; in almost two-thirds of successful visits,
testers were required to purchase a 10-pack of syringes with a
modal price of $3.99.
Limitations
The major limitation of the study is the timing of its implemen-
tation (August 2001 through January 2002). The study was con-
ducted within the first 8 months of the new law’s implementation,
and the attack on the World Trade Center disrupted the life of New
York City significantly for much of that time. It would be useful
to repeat the study to ascertain whether some implementation
issues have been resolved.
Other limitations include conducting visits during daytime
hours, precluding evidence about syringe availability at night
(when most exchanges are closed), and speaking English during
visits, precluding evidence about non-English speakers.
Lastly, the random selection from among registered pharmacies
allows generalization only to all registered pharmacies.
Generalization to all pharmacies is not possible because no sys-
tematic study was conducted of the differences between registered
and nonregistered pharmacies.
Recommendations
We have grouped the following recommendations for enhanc-
ing ESAP implementation into those directly related to HIV pre-
vention, those with potential to enhance HIV prevention, and those
related to compliance with ESAP requirements. We suggest that
efforts should be targeted toward enhancing the program elements
that are directly linked with proven HIV prevention strategies.
HIV Prevention
As this study demonstrates, further efforts should be undertak-
en to train pharmacy staff to maximize ESAP effectiveness.
Because the use of sterile syringes is known to prevent HIV trans-
mission, the NYSDOH should focus efforts on strategies to
enhance syringe access. Specifically, NYSDOH should work to
ensure that all of the registered pharmacies sell syringes. Training
should take place with pharmacy staff at ESAP-registered phar-
macies to ensure that they are, in fact, participating in ESAP.
Because the pharmacist is often not the person involved in the
syringe-selling transaction, all pharmacy staff, including weekend
and evening workers, should be included in such training.
To address the access problems identified in the Bronx, target-
ed training should take place in registered pharmacies throughout
this borough. Outreach to nonenrolled pharmacies could enhance
syringe availability. We were encouraged to learn that NYSDOH,
upon receiving our preliminary findings, redirected staff and
resources to contact and offer assistance to ESAP-registered phar-
macies in the Bronx.
Potential for HIV Prevention
Pharmacy staff practices are of concern. Probing customers as
to why they are purchasing a syringe or requiring customers to
sign their names and addresses in a log or registry may deter peo-
ple from accessing syringes at pharmacies. While some testers
received disposal information that was helpful, our results suggest
that most pharmacy staff do not promote proper syringe disposal
and that misinformation about syringe disposal is prevalent.
Training should focus on pharmacy staff interaction with cus-
tomers to prevent interactions that might deter customers from
buying syringes and undermine ESAP’s public health goals.
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Table 4. Success of Syringe Purchases Extended
to All ESAP-Registered Pharmacies 
Brooklyn, Manhattan, Queens, Staten Island (n = 71)
Successful purchases, % 77
Inference to 640 registered pharmacies 493
Bronx (n = 18)
Successful Purchases, % 33
Inference to 97 registered pharmacies 32
ESAP = Expanded Syringe Access Demonstration Program.
Additionally, pharmacy staff should be educated about safe
syringe-disposal options.
Compliance with ESAP Requirements
As this study demonstrates, customers did not routinely receive
the ESAP safety insert. No data exist demonstrating the efficacy of
this insert in preventing HIV transmission, so we suggest NYSDOH
not expend scarce resources enforcing a requirement of questionable
utility. Rather, we suggest considering the elimination of the safety
insert requirement to allow the resources available for ESAP imple-
mentation to be focused on the aspect of the program with proven
public health impact—expanded syringe availability.
Conclusion
Major strides in the implementation of ESAP were made during
its first few months of operation, including registration of one-half
the pharmacies in New York City. As the study demonstrates,
more than two-thirds of registered pharmacies were selling
syringes. However, the study also demonstrates that more time is
needed for complete implementation and targeted assistance may
be needed in specific areas (e.g., the Bronx).
We recommend that the demonstration period of the ESAP pro-
gram be extended before its effectiveness is evaluated and that
more resources be made available for pharmacy training.
Support for this study was provided by the Ford Foundation. None of the
authors has any conflict of interest or financial affiliation with any of the
pharmacies studied. Ruth Finkelstein holds two contracts for unrelated pro-
jects from the New York State Department of Health AIDS Institute, the
agency responsible for administration of the ESAP program. The contracts,
number 001553-02 and 001217-03, fund a series of educational symposia for
HIV providers and an evaluation of adherence support programs.
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Reactions from injection drug users in Atlanta to the prospect of
holding onto syringes to dispose of them safely.
“They’d [the police] catch you with a dirty syringe and you’d go to jail for possession, so people ain’t hardly gonna keep
’em laying around, keep ’em in a container or whatever.”(p 1923)
“That authorities pulling up, ‘Hey, I got you.’ They know they can stop you, and if you come and dispose of them, they got
a case there. You got narcotics in the syringe. You know you gonna have residue in there…”(p 1925)
“Chance of going to jail, I’m not going to risk that. That’s me. I got a probation, so I can’t take the chance at all. I’m so
scared now. Then I’d have to go back and do all that time.”(p 1926)
Springer KW, Sterk CE, Jones TS, Friedman L. Syringe disposal options for injection drug users: A community-based perspective. Subst
Use Misuse. 1999;34:1917–34.
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RESEARCH
Limited Access to Syringes for
Injection Drug Users in
Pharmacies in Denver, Colorado
Stephen K. Koester, Trevor W. Bush, and Beth A. Lewis
Injection drug use continues to be an important risk factor for the
transmission of blood-borne diseases; it is directly or indirectly
responsible for about one-third of all cases of human immunodefi-
ciency virus (HIV) infection and acquired immunodeficiency syn-
drome (AIDS)1 and more than one-half of all hepatitis C virus
(HCV) cases.2 The Centers for Disease Control and Prevention
(CDC) estimates that after 5 years of injecting, 90% of injection
drug users (IDUs) are infected with HCV.2 The transfer of blood-
contaminated needles and syringes (hereafter referred to as
“syringes”) among users, and the use of contaminated syringes in
the preparation and distribution of shared drugs facilitates blood-
borne disease transmission.3–9 If sterile syringes were used every
time an illicit drug was prepared and injected, blood-borne disease
transmission through drug injection could be reduced significantly.
Scarcity of sterile syringes, however, contributes to syringe
reuse by IDUs.10 Structural constraints, including state statutes,
municipal ordinances, and licensing board regulations, may pre-
vent IDUs from obtaining syringes (because of prescription laws
or requirements), discourage IDUs from carrying syringes
(because of drug paraphernalia laws), or restrict the establishment
or operation of syringe exchange programs.11–16
In this study we assessed whether IDUs could purchase syringes
from pharmacies and identified factors that may hinder purchases
in Denver, a city in a state with no prescription requirement or
pharmacy board regulation concerning the sale of syringes.
Because of the failure of repeated attempts to pass legislation per-
mitting syringe exchange programs in Colorado, pharmacies are the
only reliable source of sterile syringes for most Denver-area IDUs.
The only potential legal constraint to pharmacy sale of syringes
in Colorado is a drug paraphernalia statute based on the Drug
Enforcement Agency’s Model Paraphernalia Act of 1979.17 No
pharmacist has ever been cited for violating this statute or a com-
plementary Denver municipal ordinance (Colorado Board of
Pharmacy written communication, 1999). In fact, no pharmacist
has ever been cited for violating paraphernalia statutes of any state
(Scott Burris, written communication, October 2000).
Objective: To determine the availability of syringes for injection drug users (IDUs) from pharmacies in Denver. Design: Single-group,
uncontrolled, noncomparative study. Setting: Denver, Colorado. Patients or Other Participants: 23 randomly selected pharmacies
in the Denver metropolitan area and 3 additional pharmacies located near drug-buying locations. Intervention: Attempt by eight
trained IDU “research assistants” to purchase packages of 10 U-100 insulin syringes without a prescription from pharmacies. Main
Outcome Measures: Successful purchase of syringes; reasons for refusal. Results: Of 26 pharmacies, 4 reported not stocking
syringes, 3 did not sell syringes to any research assistants, 10 sold to some research assistants but not to others, and 9 sold to all
research assistants. Of 206 purchase attempts, 54% were successful. In 37.9% of 95 refusals, the pharmacist reported that syringes were
not sold at the store, and in 28.4% the pharmacist refused to sell because the research assistant did not produce diabetic identification
or answer insulin-related questions. No differences in pharmacy response were found with respect to the racial or ethnic characteris-
tics of the research assistant. Price varied substantially within and among stores. No pharmacies that sold syringes to research assis-
tants were open 24 hours per day. Conclusion: While IDUs who live near a pharmacy that regularly sells syringes and IDUs with a
convincing diabetes story may have adequate access to syringes, others face inconsistent availability. Price fluctuations and limited
hours of those pharmacies that sell syringes may be additional barriers to access to sterile syringes for IDUs in Denver.
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Objectives
Our primary objective was to determine whether sterile syringes
were readily available from Denver area pharmacies. Our secondary
objective was to identify obstacles to access. For example, syringe
surveys done in both St. Louis and Florida suggest that ethnic dis-
crimination limits syringe access for some IDUs,18,19 and in a pilot
study, we noted that among the pharmacies that sold syringes, sig-
nificant differences in the prices charged were identified.
Methods
In 1996, as part of a National Institute on Drug Abuse study, we
conducted a pilot syringe-buying survey of pharmacies located in
northeast and northwest Denver neighborhoods.20 In 1999 we
designed and implemented this buying survey based on that pilot.
Both buying surveys were modeled on a survey conducted in the
metropolitan area of St. Louis.18
IDU Research Assistant Selection
In an effort to simulate actual syringe purchases, a participatory
research methodology was developed. Active IDUs, who had
injected within 30 days of screening and had ongoing relationships
with the project’s qualitative research team, were contracted to buy
syringes. These eight “research assistants” represented both gen-
ders and the city’s three major ethnic groups: African American,
white, and Latino. In addition, we included two young (< 25 years
old), white IDUs to represent a rapidly growing segment of the
IDU population in Denver. Preliminary seroprevalence and ethno-
graphic data from our concurrent intervention study indicated that
while many of these youth are free of blood-borne diseases, they
engage in high-risk sexual and drug-using behaviors. Seven of the
research assistants were daily heroin injectors, and the other was a
methamphetamine injector. The participants had been IDUs for 2
to 30 years.
Sampling
The sampling frame for this study was a list from the Denver
metropolitan area telephone directory of the 65 community phar-
macies located within an approximately 50 square mile area of the
city and adjacent suburbs. Twenty-four of these pharmacies were
randomly selected; one was excluded because it was an herbal
pharmacy that did not sell pharmaceutical medications or syringes.
Three other pharmacies were added because they were located
within walking distance of drug-buying (“copping”) and using
areas where we routinely recruited subjects for the intervention
study. The resulting sample of 26 included 5 pharmacies located
within corporately owned supermarkets, 5 chain pharmacies, 9
independent pharmacies, and 7 independent combination pharma-
cy/liquor stores.
Buying Strategy
Ethnographers (i.e., qualitative researchers) met with research
assistants to discuss the study’s purpose and methods and to devel-
op a standard procedure for how the research assistants would ask
to purchase syringes. A standard script was based on information
from the pilot study, discussion with research assistants, and the
stocking practices of most pharmacies. Research assistants were
instructed to ask, “Could I have a 10-pack of U-100 insulin
syringes?” As our purpose was to determine if IDUs could obtain
syringes without having to prove a “legitimate medical need,” this
standard dialogue was used to lessen the possibility that individu-
al buying strategies would determine whether syringes were sold.
Research assistants, dressed in their typical attire, requested
syringes at the pharmacy counter. If the pharmacist or pharmacy
staff asked for more information (i.e., a diabetic card or specifics
about insulin type or dosage), the research assistant said the
syringes were for a relative. After each attempt, one of the ethno-
graphers and the research assistant discussed the attempt.
All purchase attempts were made on Tuesdays or Thursdays
between 10 am and 2 pm and in the months of January through
May 1999. No pharmacy was visited by more than one research
assistant per day.
Results
Syringe Sales
Of the 26 pharmacies visited during 206 purchase attempts, 4
told all of our research assistants that they did not stock syringes.
Further study determined that 2 of these pharmacies stopped sell-
ing syringes because of their proximity to visible drug buying
sites, a third was in the process of phasing out its pharmacy and no
longer stocked syringes, and the fourth was an otherwise fully
functioning pharmacy that apparently did not stock syringes.
Among the 22 pharmacies that reported carrying syringes, 3 did
not sell to any of our research assistants, 9 sold to all of our
research assistants, and 10 sold to some but not all of our research
assistants (Table 1).
Of 206 purchase attempts, 54% were successful. Unsuccessful
attempts were attributed to a number of factors (Table 2).
Individual research assistants’ success rates ranged from 48% to
57.7% with a mean of 53.9%. Two assistants requested not being
asked to attempt purchases at two pharmacies they regularly visit-
ed for personal items; these pharmacies sold to all other research
assistants, suggesting that had these two assistants visited these
respective stores their success rates might have been higher.
Research assistants reported being asked questions about diabetes
in 28.4% of buy attempts. In these cases, they gave the mutually
agreed upon response that the syringes were for a relative; none of
these attempts was successful.
No significant differences were found between success rates
based on gender or racial/ethnic differences (data not shown).
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Syringe Prices
The price charged for a package of 10 U-100 syringes varied
both within and among stores. Price differences within a store
occurred at eight of the pharmacies and ranged from a difference
of $0.11 to $8.01 per 10-pack of syringes. One chain pharmacy
implemented a price increase midway through the study from $3
to $4 per 10-pack. Two other chain pharmacies and four indepen-
dents varied their prices between participants for no identifiable
reason. One of these chain stores charged $2.89 to the first assis-
tant, $3.00 to the third assistant, and $2.00 to the fifth assistant. At
another independent pharmacy, price variability resulted from tax
being charged to some research assistants and not to others.
Hours of Operation
None of the 19 pharmacies that sold syringes was open 24 hours
per day. Six pharmacies opened before 9:00 am Monday through
Friday, while three opened that early on Saturday. Seven pharma-
cies remained open past 8:00 pm Monday through Friday, but only
three were open that late on Saturdays. Four locations were open
on Sundays.
Discussion
The results of this survey indicate that sterile syringes are incon-
sistently available to IDUs through pharmacy sales without a pre-
scription in the Denver metropolitan area. However, more than
one-half of the successful purchases occurred at the 9 pharmacies
where all attempts were successful. Seven stores refused all sales
and 10 others were variable; 5 of these latter pharmacies sold to 4
or fewer of the 8 research assistants. For IDUs who are able to pur-
chase syringes from a pharmacy that regularly sells to IDUs with
a convincing diabetic story, access may be adequate. However,
among “street” IDUs whose routines are less certain, and who may
be unable to convey a diabetic pretext, the uncertainty about phar-
macy sales may result in high-risk injection episodes.
Our results are similar to those of syringe purchase attempts in
Anchorage, Alaska. That study reported an overall success rate of
54%, with 9 of 22 stores in their sample refusing to sell syringes to
any of 3 research assistants. Of the remaining 13 pharmacies that
sold syringes, only 7 sold to all 3 assistants. That study also did not
find significant ethnic differences in ability to purchase syringes.21
In some cases, the cost of syringes may be a factor in whether
or not they are purchased, particularly in those instances when
IDUs have limited money to purchase them. In one store, the only
pharmacy within a 1.5-mile radius of a well-known drug buying
and using area, clerks routinely charged $6.99 or more for a 10-
pack and $1.50 per single syringe. Syringes at this store were kept
at the front counter and not in the pharmacy. This liquor
store/pharmacy was poorly stocked and only had a pharmacist on
duty a few days a week.
An additional barrier to syringe access is pharmacy hours of
operation. Because heroin addicts cannot stop using opiates with-
out suffering withdrawal symptoms, the limited hours of operation
of most pharmacies in this survey are of concern.
Finally, only nine of the pharmacies surveyed could be consid-
ered “reliable” (selling to every buyer) sources of sterile syringes.
In a geographically dispersed, Western city such as Denver where
the automobile is the dominant mode of transportation, access to
reliable pharmacies may be problematic for IDUs with limited
access to transit. This is particularly troubling because IDUs have
several reasons to inject the drug soon after obtaining it. If caught
with the drug they face a possession charge, and if they are “dope
sick” (in withdrawal) their overwhelming concern is to “get well.”
In such cases, an IDU is unlikely to continue looking for a sterile
syringe after being turned down, particularly if alternative syringe
sources are not nearby.
Limitations
Interpretation of our data is limited by small sample size and the
inability to control for pharmacy staff encountered. We were
unable to verify if a seller was the same individual encountered by
other research assistants or to determine whether the seller was a
pharmacist, technician, or store clerk. Because research assistants
only asked for a 10-pack of insulin syringes, this study did not
assess the availability through pharmacy sales of smaller numbers
or other types of syringes.
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Table 2. Reasons For Unsuccessful Syringe
Purchase Attempts, Denver 1999 (n = 95)
Attempts 
Reason No. (%)
Syringes not sold at storea 36 (38)
Proof of diabetic status required 27 (28.4)
Syringes only sold in boxes of 100 13 (13.7)
Pharmacy closed during posted business hours 10 (10.5)
Not in store computer as a previous customer 6 (6.3)
Store-imposed age requirement 2 (2)
Ignored by store staff 1 (1)
aSix of these attempts were made at pharmacies that sold to other
research assistants.
Table 1. Syringe Sales at Denver Pharmacies
No. Pharmacies 
Syringe-Selling Patterns (n = 26)
Did not stock 4
Did not sell 3
Sold to some 10
Sold to all 9
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Conclusion
The results of the Denver and Anchorage surveys are consistent
with other research that has found wide variation in the ability of
IDUs to purchase syringes through pharmacies,18,19,22–25 indicat-
ing that syringe sales to IDUs is not a clear-cut issue for many
pharmacists. Work by Farley and colleagues23 has shown that a
common fear for pharmacists is that of increasing drug use, while
other researchers have found that pharmacists cite business con-
cerns as a reason for discouraging syringe sales to IDUs.24–26
These concerns must be addressed in public health efforts to
expand syringe availability through pharmacy sales. To accom-
plish this requires collaboration between public health researchers,
practitioners, IDUs, and pharmacists. Pharmacists are a critical
component in comprehensive efforts to prevent the spread of
blood-borne diseases among IDUs, their sex partners, and their
children. Selling syringes to persons who may be IDUs can help to
reduce blood-borne disease transmission.
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Needle Sightings and On-the-
Job Needle-Stick Injuries
Among New York City
Department of Sanitation
Workers
Steven Lawitts
The New York City Department of Sanitation  (DSNY) is
responsible for collecting and disposing of all residential waste in
New York City, collecting and marketing recyclable materials
from all residences, cleaning the city’s 6,200 miles of streets, and
clearing the streets of ice and snow.  Of DSNY’s approximately
9,500 employees, 6,400 are uniformed sanitation workers, whose
primary responsibility is operating almost 4,900 “truck-shifts”
(one truck, with a crew of two sanitation workers, on an 8-hour
shift) per week to collect household garbage and another 2,300
truck-shifts per week to collect residential recyclables. 
In this paper, I describe the problems and processes associated
with improper disposal of used syringes and needles in household
garbage and recyclable materials in New York City.
Sanitation Procedures and Policies
For many years DSNY has made information available to the
public on proper disposal of needles and syringes.  The Digest of
Sanitation Codes,1 which is currently published in five languages,
is a summary of sanitation laws, rules, and regulations applying to
residents, merchants, and owners and managers of residential and
commercial properties.  The Digest of Codes contains clear
instructions on needle disposal.  Beginning in the mid-1990s, with
the department’s increasing use of the Internet, the Digest of
Sanitation Codes was placed online.  In 2001 DSNY added an
interactive “How do I dispose of…?” feature to its home page,
www.nyc.gov/sanitation. The Web site, and the printed version of
the Digest, advise syringe users to  “place needle in a metal con-
tainer such as a coffee can labeled ‘sharps’ or ‘used syringes,’ seal
container with masking tape around the lid, then dispose of the
container as Household Non-Recyclables  [regular garbage].” The
Digest of Codes contains more detailed information, including the
option of using heavy-duty plastic containers for disposal of nee-
dles.  The Digest also lists fines from $50 to $250 for improper
needle disposal.
DSNY follows a standard procedure when sanitation workers
observe improper disposal of needles.  Sanitation workers imme-
diately stop collecting garbage and call the Sanitation Department
Environmental Police Unit, which is responsible for investigating
hazardous-waste incidents.  An environmental police officer
responds, examines, and secures the observed needles.  In addi-
tion, if the sanitation worker first observed the needles in the open
hopper of the collection truck, the environmental police officer
searches the hopper for additional needles.  If the sanitation work-
er first observed the needles in a bag or can placed at the curb, the
officer will inspect that bag or can and nearby containers.  If the
officer can determine who improperly placed the needles for dis-
posal, he may issue a summons for a fine, $50 for a first violation
and up to $250 for repeat violations.  If the officer can determine
the owner of the needles, the officer can instruct the owner how to
properly dispose of them.  When the officer has removed and
secured all needles from the truck’s open hopper or from the curb-
side, he authorizes the collection truck to continue on its collection
route.
The Environmental Police Unit completes an Unusual Incident
Report for each needle-sighting and needle-stick incident, and also
records each incident in the DSNY Hazardous Waste Log. DSNY
maintains a database showing the date, street address, and borough
of every needle-sighting and needle-stick incident.
Needle sightings reported by sanitation workers have decreased
in recent years, from 234 reported needle-sighting incidents in fis-
cal year (FY) 1997 to 90 incidents in FY 2001 and 75 in the first
three quarters of FY 2002 (see Table 1). With approximately 7,200
truck-shifts per week collecting from residential routes, a total of
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Table 1. Needle Sightings and Needle-Stick Injuries 
Fiscal Year
No. Sightings (No. Sticks)
Quarter 1997 1998 1999 2000 2001 2002
July–September 59 (8) 49 (5) 41 (11) 30 (3) 30 (2) 26 (3)
October–December 53 (11) 49 (5) 29 (3) 29 (0) 23 (13) 28 (1)
January–March 59 (5) 66 (6) 39 (2) 25 (1) 14 (6) 21 (3)
April–June 63 (9) 74 (4) 33 (5) 17 (7) 23 (10) —a
Total, first three quarters 171 (24) 174 (16) 109 (16) 83 (4) 67 (21) 75 (7)
Total, year 234 (33) 238 (20) 142 (21) 100 (11) 90 (31) —a
aNo data.
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374,000 truck-shifts operate each year.  The average incidence of
needle sighting was 1 in 1,600 truck-shifts in FY 1997. The nee-
dle-sighting incident rate decreased to 1 in every 4,156 truck-shifts
operated in FY 2001.
Needle-Stick Injuries
Sanitation workers occasionally get stuck by improperly dis-
posed needles.  Sanitation workers were stuck by needles 33 times
in FY 1997, down to 11 times in FY 2000, up to 31 times in FY
2001, and returned to FY 2000 levels during the first three quarters
of FY 2002. Again, with 7,200 collection truck-shifts operated
each week, the frequency of needle sticks was approximately 1 in
every 11,000 truck-shifts operated in FY 1997, decreasing to 1 in
34,000 in FY 2000, returning to 1 in every 12,000 in FY 2001 and
returning to FY 2000 levels in the first three quarters of FY 2002.
Each collection truck has a crew of two sanitation workers, with
one worker being the designated driver and the other the designat-
ed loader.  Since many of the designated drivers also elect to load
to speed up the collection process, the incident rate of needle sticks
per loading sanitation worker shift is lower than the rate per truck-
shift. Finally, comparing the first three quarters of each fiscal year,
the combined total number of needle sightings and sticks declined
from 195 in 1997 to 82 in 2002.
When a sanitation worker is stuck by a needle, the procedure
begins similarly to the procedure for needle sightings described
above.  Concurrent with the environmental police officer’s inves-
tigation, the sanitation worker is transported to a nearby hospital
and given hepatitis B vaccine.  The sanitation worker is subse-
quently referred to an infectious disease specialist and follow-up
vaccinations against hepatitis B. The sanitation worker is encour-
aged to speak with the counselors at the DSNY Employee
Assistance Unit and, if preferred, to outside counselors.  Beginning
6 months after the needle-stick incident, the sanitation worker is
referred for an HIV blood test.  All of the medical procedures, and
any professional counseling, are fully covered by the city as
expenses resulting from a line-of-duty injury.  The employee is
paid for time needed for medical treatment related to the needle-
stick injury.  Fortunately, no sanitation worker has become infect-
ed with a blood-borne infection caused by an on-the-job needle
stick.
Conclusion
The presence of needles and syringes in garbage poses serious
risk to sanitation workers and is expensive because of interruptions
of work. Sightings of needles and syringes in household garbage
and recyclable materials have varied from year to year in New
York City. The frequency of needle-stick injuries among sanita-
tion workers has also varied, with the fewest observed in FY 2000.
Data from the first three quarters of FY 2002 indicate that the fre-
quency could be as low as in 2000.
As part of the evaluation of the New York State Expanded
Syringe Access Demonstration Program (ESAP), which allows
sale, distribution, and possession of syringes without a prescrip-
tion, DSNY is making month-by-month, location-specific needle-
sighting and needle-stick data available to the New York State
Department of Health.  The Department of Health and other orga-
nizations participating in ESAP can use these data to look for rela-
tionships between increased syringe availability and needle inci-
dents involving sanitation workers.
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RESEARCH
State Syringe and Drug
Possession Laws Potentially
Influencing Safe Syringe
Disposal by Injection Drug Users
Scott Burris, Joseph Welsh, Mitzi Ng, Mei Li, and Alyssa Ditzler
Disposal of potentially infectious medical waste has become an
important issue in public health policy. Waste generated in the
health care system is highly regulated at the state and federal lev-
els. Disposal outside the health care setting has received far less
attention and virtually no regulation, yet more than three billion
syringes are used each year outside health care facilities and
deposited in the general waste stream in the United States.1
Discarded needles pose a low risk to the general public. There is,
however, widespread concern about needles discarded in public
places like parks, and discarded needles are a source of injury 
and anxiety to workers in trash disposal, recycling, and related
industries. Most of these syringes come from people administering
medications for conditions such as diabetes, but many are
attributable to injection drug users (IDUs).2 IDUs have been esti-
mated to perform as many as one billion injections of illicit drugs
each year in the United States.3 IDUs are thus an important part of
the syringe disposal picture, and may become more important as
efforts proceed to promote the health goal of a new sterile syringe
for every drug injection.4,5 Pharmacists may well play a key role
in the expansion of community syringe disposal opportunities.6
Unfortunately, IDUs have generally been neglected by commu-
nity sharps disposal programs. There are only a few systems, most
notably syringe exchange programs (SEPs), that provide for safe
disposal of syringes from IDUs.2,7,8 The need to improve disposal
options for IDUs has been recognized in a few recent state laws
authorizing syringe sales to IDUs,9 but the possible role of exist-
ing syringe prescription, drug paraphernalia, and drug possession
laws in deterring IDU participation in safe disposal schemes has
not been thoroughly evaluated. Community disposal programs
take many forms, but those implemented to date usually require
the participant to dispose of syringes in specially designed or
labeled containers placed in regular trash, or to take the needles to
a designated community disposal site (including SEPs).2 In either
case, the participating IDU would have to accumulate used nee-
dles, many of which would contain drug residues, and dispose of
them in a way or in a place that makes concealment difficult. To
Objective: To review state laws and judicial decisions for potential barriers to proper syringe disposal by injection drug users (IDUs).
Design: Using standard legal research methods, this study reviewed drug paraphernalia, syringe prescription, drug possession, and
syringe exchange laws and relevant case decisions in 59 jurisdictions. Main Outcome Measures: Drug paraphernalia, syringe pre-
scription, and drug possession laws. Results: Drug paraphernalia laws prohibit all possession of syringes by IDUs in 31 jurisdictions.
Syringe prescription laws prohibit possession in 7 jurisdictions. In 53 jurisdictions, IDUs may be subject to prosecution for the posses-
sion of drug residue in used syringes. Only two states (HI, RI) have no legal barriers to safe syringe disposal by IDUs. Sixteen jurisdic-
tions that have tried to expand syringe access for IDUs by authorizing SEPs or by deregulating pharmacy sale of syringes continue to
have criminal law provisions that could pose barriers to proper disposal. Conclusion: IDUs are a significant source of syringes dis-
posed of outside the health care system. Involving IDUs in safe community sharps disposal programs is an important public health
goal, but may be frustrated by legal barriers. Although this study looked only at law on the books, and not law as actually applied, ethno-
graphic and survey research indicates that criminal laws do influence the syringe possession behavior of IDUs. The findings of this
study suggest that syringe and drug possession laws could deter IDUs from participating in safe syringe disposal programs.
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the extent that possession or use of syringes for drug use, or pos-
session of trace amounts of illegal drug, is a crime, participating in
safe disposal creates a legal risk for IDUs. As one IDU put it,
“They’d [the police] catch you with a dirty syringe and you’d go
to jail for possession, so people ain’t hardly gonna keep ’em lay-
ing around, keep ’em in a container or whatever.”7(p1923)
Objective
This article reports the results of a national survey of drug para-
phernalia, syringe possession, and drug possession laws intended
to identify potential legal barriers to IDU participation in safe
syringe disposal.
Methods
An earlier study identified state syringe prescription and drug
paraphernalia laws regulating the sale of syringes to IDUs.9,10
These statutes were examined to determine whether they prohibit-
ed possession of syringes by IDUs, and what penalties they pro-
vided upon conviction. Drug possession laws could influence dis-
posal behavior if they prohibit the possession of any amount of
drug detectable through chemical analysis, because syringes used
by IDUs commonly contain a residue of the drug that was inject-
ed. To determine state law with respect to residue possession, we
examined every state’s drug possession law and used standard
legal research techniques to identify court decisions interpreting
their applicability to possessors of minute amounts of illegal drugs.
Data were collected for 50 states, the District of Columbia, and
eight territories. Laws whose applicability was not clear were
interpreted using conventional methods of statutory and case law
analysis. Detailed memoranda explaining these conclusions were
prepared for each jurisdiction, and may be viewed at www.
temple.edu/lawschool/aidspolicy.
Results
Drug Paraphernalia Laws
Drug paraphernalia laws typically prohibit the sale and posses-
sion of any item intended to be used in the consumption of illegal
drugs, including syringes. Only 8 of the states or territories studied
did not have a paraphernalia law (AK, Guam, Marshall Islands,
Micronesia, Northern Marianas, Palau, PR, and Samoa). Six other
jurisdictions regulated only sale, and so did not make the posses-
sion of paraphernalia a crime. In 14 states, paraphernalia laws had
been amended to exclude syringes entirely, in some set amount, or
when obtained from a SEP (see Table 1). Paraphernalia possession
is a misdemeanor in most states, typically punishable by up to a
year in jail and a fine of $1,000. For an IDU already on probation
or parole for a more serious offense such as drug possession, a
paraphernalia conviction can lead to a return to jail for a longer
period on the original charge. In 3 states (AZ, DE, ND) the crime
is a felony. In AZ and DE, however, the conviction still only car-
ries a year in jail. North Dakota is unique in specifying a term of
imprisonment up to 5 years. The fines in these three states are larg-
er than in misdemeanor states, ranging, at least on paper, from
$2,300 (DE) to $150,000 (AZ).
Syringe Prescription Laws
Thirteen jurisdictions have a provision requiring a prescription
for the possession of a syringe under at least some circumstances
(see Table 2). In 7 states, these provisions clearly or may reason-
ably be interpreted to make any possession of a syringe by an IDU
illegal without a prescription. In 6 other states, these laws have
been amended to allow possession of syringes without a prescrip-
tion of a specified number (usually 10 or fewer), or when obtained
through a SEP. Pennsylvania has a Board of Pharmacy regulation
requiring a prescription for the sale of a syringe, but not for pos-
session. With the exception of DE (where it is a felony), violation
of syringe prescription laws is a misdemeanor, typically punish-
able by $2,000 in fines and 1 year in jail.
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Table 1. Applicability of Drug Paraphernalia Laws to Possession of Used Syringes by IDU
Law Could be Applied Law Exempts at Least Some Possession No Prohibition
(n = 31) (n = 14) (n = 14)
IDU = injection drug user; SEP = syringe exchange program.
aSEP clients only.
bSEP law exempts clients only; statute deregulating sale and purchase of syringes for disease prevention purposes did not explicitly allow
possession, but was clearly intended to.
cOrdinances in several communities prohibit paraphernalia possession.
dLaw does not mention syringes or injection, and is limited to items used for consuming “marijuana, hashish, hashish oil, or cocaine.”
AL, AZ, AR, CA, CO, DE, FL, GA, ID, IL, IN,
IA, KS, KY, LA, MS, MO, MT, NE, NJ, NC,
ND, NV, OH, OK, PA, SD, TN, TX, UT, VI
CT, DC,a HI,b ME, MD,a MN, NH, NM,b NY,
OR, RI, SC,d WA, WI
AK,c Guam, Marshall Islands, MA, MI,c
Micronesia, Northern Marianas, Palau, PR,
Samoa, VT, VA, WV, WY
Controlled Substances Laws
All jurisdictions have laws regulating the possession of con-
trolled substances, which include the main drugs of abuse. State
controlled substances laws typically make it a crime “for any per-
son knowingly or intentionally to possess a controlled substance
unless such substance was obtained directly from, or pursuant to,
a valid prescription or order of a practitioner while acting in the
course of the practitioner’s professional practice, or except as oth-
erwise authorized by this chapter.”11 In most states, courts have
interpreted these laws to prohibit the illegal possession of any
amount of drug, no matter how small, that can be detected by
chemical analysis (see Table 3). Typically judges have inferred
from the lack of a statutory minimum amount that the legislature
must have intended to criminalize the possession of any detectable
amount of drug.12 Such an interpretation would encompass the
residue remaining in a syringe after use. Because most judges have
taken this position, the most conservative assumption is that judges
in the 19 jurisdictions without a decision on this issue would reach
the same conclusion. In DC and MD, the syringe exchange law
exempts only SEP clients from prosecution for possession of drugs
in syringes. The penalty for residue possession in jurisdictions
where it is a misdemeanor ranges from $1,000 to $5,000 in fines
and 1 to 5 years in jail. In the 34 jurisdictions where the crime is a
felony, jail terms typically increase to 5 to 10 years, and fines to at
least $5,000 (as high as $50,000 in MT and CT).
Table 4 combines the data presented in the first three tables 
to characterize the degree to which state laws could be acting as 
barriers to IDUs’ participation in safe syringe disposal activities.
Jurisdictions are placed into three categories: those with both syringe
and drug possession provisions that could apply to used syringes;
those with just one type of law; and those with none. Two points are
striking. First, only HI and RI have no legal barriers to syringe dis-
posal by IDUs. Second, 16 jurisdictions that have tried to expand
syringe access for IDUs by authorizing SEPs or by deregulating
pharmacy sale of syringes continue to have criminal law provisions
that could pose barriers to proper disposal. This group includes MN,
NH, and NY, states whose syringe access laws require that pur-
chasers be given information on safe disposal options.
Discussion
IDUs could be generating as much as one-fourth of all syringes
used in the community.2,3 Like other community sharps users,
IDUs commonly lack good alternatives for safe disposal of their
used syringes.2,8 There has been little published research on IDUs’
syringe disposal behavior, though available data suggest they usu-
ally put a used syringe in a sturdy container before throwing it in
the trash.13 (Data presented at the XIV International AIDS
Conference in 2002 reported high rates of improper disposal
among IDUs in Baltimore.14) Providing access to appropriate dis-
posal schemes for IDUs is a sensible part of an overall effort to
deal with the problem of unsafe community sharps disposal. This
study found that serious legal barriers exist, at least on paper, to
IDU participation in safe disposal schemes in the vast majority of
U.S. states and territories. These barriers even exist in jurisdictions
that have otherwise acted to facilitate syringe access to IDUs (and
indeed even in states that have mandated that syringe purchasers
be given information about safe disposal). This suggests that the
legal barriers remain at least in part from a lack of awareness of the
way that syringe access and drug possession laws are tied to dis-
posal. In some states, the failure to remove barriers to disposal may
also reflect the legal and political complexity of syringe access and
drug possession law. In New Mexico, for example, legislation to
ease syringe access removed legal barriers to the sale of syringes
to IDUs, but apparently inadvertently did not legalize their posses-
sion once purchased.15
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Table 2. Syringe Prescription Law Impact on
Possession of Used Syringes by IDUs
No Possession Allowed At Least Some Possession 
Without a Prescription Allowed Without a Prescription
(n = 7) (n = 6)
CA, DE,a IL, NV,b NJ, VA,c VI CT, FL,d ME, MA,e MN, NY
IDU = injection drug user(s); SEP = syringe exchange program.
aPossession illegal even with a prescription.
bPharmacy board has reportedly taken position that syringe sales to
IDUs are legal without prescription to prevent blood-borne disease;
prescription requirement is reportedly not a barrier to purchase of
syringes by IDUs.
cPrescription required for minors only; others must show “written
legitimate purposes” for possession, per pharmacy regulation.
dPrescription required for minors only.
eSEP clients only.
Table 3. Statutes or Judicial Interpretations Regarding Possession of Trace Amounts of Illegal Drugsa
Law Reasonably Interpreted Possession Explicitly Exempted by 
Possession Explicitly Criminalized to Criminalize Possession Law or Judicial Interpretation
(n = 34) (n = 19) (n = 6)
AL, AK, CO, CT,b DC,c GA, ID, IL, IN, DE, FL, Guam, IA, Marshall Islands, AZ, AR, CA, HI, NV, RI
KS, KY, LA, ME, MD,c MI, MN, MS, MO, MA, Micronesia, MT, Northern Marianas, 
NE, NH, NJ, NM, NY, NC, ND, OH, OK, Palau, PA, PR, Samoa, SD, TN, VT, VI,
OR, SC, TX, UT,VA, WA, WI WV, WY
SEP = syringe exchange program.
aBoldface type indicates crime is a felony.
bA federal district court has enjoined enforcement of this law in Bridgeport.
cSEP clients exempt.
Two published U.S. studies have found that fear of legal risk
influences how IDUs think about disposal. Interviews with 26
Atlanta IDUs elicited incredulity at the proposition that IDUs
would retain used syringes in containers at home as part of a
syringe collection system: “That’s the first thing [IDUs] think
about, they gonna go to jail if the police come to their house, they
gonna charge you with possession of narcotics.”7(p1923) Similar
fears were expressed about community drop boxes: “They [the
police] know they can stop you, and if you come and dispose of
them, they got a case there.”7(p1925) Interviews with Baltimore
IDUs found similar views.8
Existing data on the enforcement of syringe and paraphernalia
laws, and their effect on the behavior of drug users, further suggest
that legal barriers could interfere with safe disposal. There is evi-
dence that syringe prescription and drug paraphernalia laws are
vigorously enforced in at least some jurisdictions. Studies con-
ducted in Maine and Massachusetts found significant levels of
syringe law enforcement.16,17 In Rhode Island, whose former
syringe possession law was one of the nation’s most stringent, the
street price of syringes reached $6 each.18 A 1995 study of 466
active IDUs in Baltimore found that 33.9% had been arrested or
hassled by the police for carrying syringes.19 Thirty-eight percent
of active IDUs interviewed in a California study reported a police
stop based on paraphernalia possession; half those stopped were
arrested.20 In 1995, 3 years after Connecticut law was changed to
allow purchase and possession of up to 10 syringes, 7 of 147 IDUs
in the eastern part of the state reported recent paraphernalia
arrests.21 In a recent law suit, a federal judge found that police in
Bridgeport, Connecticut had continued to stop and sometimes
arrest IDUs for possessing syringes or drug residues inside
syringes in spite of the state’s legislation legalizing syringe pur-
chase and possession.22
Ethnographic and survey research among IDUs has repeatedly
found that fear of arrest is a factor in whether or not IDUs carry
their own syringes with them when they are purchasing and using
drugs.19,23–29 Bluthenthal and colleagues found that 35% of 424
IDUs they interviewed were concerned about being arrested while
carrying drug paraphernalia, and that those who were concerned
were more than twice as likely to share syringes.20 In their report
of syringe use practices in Seattle, where syringe purchase is legal,
Calsyn and colleagues observed lower rates of syringe sharing
compared with regions where syringe purchase and possession
was illegal.30 Fear of arrest has also reportedly influenced SEP
attendance31 and may have increased the length of time contami-
nated syringes circulated on the streets.32 Heimer and colleagues
concluded that “among the many structural impediments SEPs
face, none may be more important than their legal status.”32(p171)
Although the reduction of legal barriers to syringe purchase and
possession has had significant effects on IDU behavior, it is impor-
tant to note the evidence that these effects have been reduced by
continuing anxiety about the law among IDUs. Despite the change
in Connecticut state laws, only 30% of IDUs surveyed after the
new law took effect reported that they regularly carried their own
syringes. The majority (65%) cited fear of arrest as their main rea-
son for not carrying syringes in public.21 A Minnesota study com-
paring IDUs’ behaviors before and after syringe access was legal-
ized found that nearly half continued to worry about being stopped
with a syringe. Even months after the new law went into effect, 4%
said they had been stopped by the police for having unused
syringes in the past 30 days. Although IDUs were more likely to
purchase and less likely to share syringes, there were no changes
in the proportions who carried, reused or safely disposed of
syringes.13
Limitations
This study only collected data about law on the books; it did not
investigate how the laws are actually applied or how they actually
influence the behavior of IDUs. Further research is required to
determine whether the potential effects of restrictive syringe and
drug possession laws are actually felt in individual communities in
the various jurisdictions. This study analyzed syringe and para-
phernalia laws as they apply to possession by an IDU. The effect
of these laws on the legality of providing syringes to IDUs is
addressed elsewhere in this issue.33
Conclusion
Significant observational research has found that IDU’s mini-
mize their time carrying syringes in order to avoid legal jeopardy.
Unwillingness to retain or transport used syringes to a safe dispos-
al site would interfere with IDU participation in safe disposal pro-
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Table 4. Legal Disincentives to Safe Disposal of Syringes Used by IDUs
Both Syringe and Drug Either a Syringe or Drug No Syringe or Drug 
Possession Provisions Possession Provision Law Barriers
(n = 31) (n = 26) (n = 2)
AL, CO, DE, DC,a FL, GA, ID, IL, IN, IA, KS, AK, AZ, AR, CA,a CT,a Guam, ME,a Marshall Islands, HI,a RIa
KY, LA, MA,a MD,a MS, MO, MT, NE, NJ, MI,a Micronesia MN,a NV,a NH,a NM,a NY,a Northern
NC, ND, OH, OK, PA, SD, TN, TX, UT, VA, Marianas, OR,a Palau, PR, Samoa, SC, VT,a WA,a WV,
VI WI,a WY
IDU = injection drug user.
aState has authorized SEP, fully or partly deregulated syringes to prevent blood-borne disease, or otherwise acted to enhance syringe access for
IDUs.
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grams, which serve an important public health purpose in the com-
munity. This study has found that the vast majority of states and
territories in the United States continue to criminalize the posses-
sion of used syringes by IDUs, at least on paper. This finding holds
even in states whose public policy has become to afford IDUs
access to sterile syringes, and even in states that affirmatively have
tried to encourage proper disposal by IDUs. While we lack
detailed data for most areas of the country regarding the actual
application of these laws or their effects on IDU behavior, we have
enough information to be concerned that law is a barrier to safe
syringe disposal. Policy steps to address the problem include clear-
ly legalizing IDU possession of syringes and amending controlled
substances laws to specify a specific or usable amount of sub-
stance necessary to create criminal liability. Pharmacists can play
an important role in disposal, both as participants in disposal
schemes and as stakeholders in the political process of revising
laws to promote safer disposal by IDUs.
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RESEARCH
Community Syringe Collection
and Disposal Policies in 
16 States
Wayne L. Turnberg and T. Stephen Jones
Hypodermic needles, syringes, and lancets used outside of
health care settings (hereafter referred to as “community
syringes”) may be used for diabetes care, allergy care, home health
care, animal care, or injection drug use. Estimated use of commu-
nity syringes includes between 0.9 and 1.68 billion insulin injec-
tions1,2 and up to 1 billion illegal drug injections per year.2 Public
health, environment and occupational health laws have historical-
ly focused on disposal of syringes generated in health care settings.
Less attention has been paid to disposal of community syringes
that, when improperly discarded, present a risk of injury and pos-
sible infection.3,4
A 1998 report identified 15 community syringe disposal pro-
grams in the United States, Canada, and Australia,5 which follow
one of three basic disposal strategies: (1) placing used syringes in
common household containers (e.g., bleach or soda bottles) and
then in the trash; (2) placing used syringes in drop boxes located
in the community; and (3) bringing filled sharps containers to a
collection site, such as a pharmacy, for safe disposal as infectious
waste. Many state and local public health agencies, waste man-
agement companies, and other organizations have implemented
community syringe collection and disposal programs to promote
safe disposal practices. Often the goal is collecting all sharps for
safe disposal as infectious waste rather than having them discard-
ed in the trash. Such programs help prevent needle-stick injuries
and possibly infection among waste collectors, operators of solid
waste materials recovery facilities, and the public.
Safe syringe disposal is often difficult for injection drug users
(IDUs) although important to achieve. IDUs have elevated preva-
lence of blood-borne infections.6,7 Human immunodeficiency
virus (HIV) can survive in a syringe for as long as 4 weeks.8,9
IDUs are interested in safe needle disposal10; however, drug para-
phernalia laws and other statutes establishing criminal penalties for
Objective: To review laws, regulations, and guidelines that affect the collection and disposal of hypodermic needles, syringes, and
lancets used outside of professional health care settings (hereafter referred to as “community syringes”). Design: Law and policy anal-
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the community was gathered from federal and state records and state agency personnel. Main Outcome Measure: Legally permis-
sible means of syringe collection and disposal available to persons in the community injecting medical treatments and injection drug
users. Results: Laws, regulations, or guidelines in 13 states allowed community syringes to be legally discarded in household trash;
guidelines for in-trash disposal varied among the states. Only 6 states had laws or regulations that specifically addressed community
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possession of syringes exist in most states.11 Syringe exchange
programs (SEPs), which are intended to prevent blood-borne
infection transmission by providing IDUs access to sterile syringes
for drug injection, also provide a safe syringe disposal option for
IDUs. Because most SEPs require that one used syringe be turned
in for each new syringe provided, SEPs recover millions of used,
blood-contaminated syringes that are disposed of as infectious
waste. In the United States, SEPs reported exchanging 19 million
syringes in 1998.12 The number of discarded syringes decreased in
some areas where SEPs operated.13 However, the fear of arrest for
syringe possession makes many IDUs unwilling to save used
syringes and take them to a SEP or other disposal site.10 A com-
panion study to this one surveyed all the U.S. states and territories
to identify and analyze the laws and regulations affecting IDU
syringe disposal.11
Objectives
This study was conducted as a pilot project for a national sur-
vey. Our purpose was to gather information about federal and state
infectious waste and worker safety-related laws, regulations, and
guidelines and to assess their effect on three strategies of commu-
nity syringe disposal in 16 states.
Methods
We selected 16 states for this review: 13 because of their active
infectious waste programs managed by state agency staff known to
the authors (Alabama, California, Florida, Massachusetts,
Michigan, New Jersey, New York, Ohio, Oregon, Rhode Island,
South Carolina, Wisconsin, Washington), one because of its com-
munity syringe disposal activities associated with a pharmacy-
based syringe access initiative (Minnesota),14 one because of a
community sharps disposal program published in the literature
(Georgia),15 and one because of proposed syringe access legisla-
tion (Hawaii).
From January through December 2001, we gathered informa-
tion about laws, regulations, and guidelines related to solid and
infectious waste disposal for each state and reviewed the informa-
tion to determine the effect on community syringe collection and
disposal. Information was obtained from state Web sites, if avail-
able, or from state agency staff. State agency regulators were asked
how policies were interpreted and implemented in their states.
We also examined federal regulations of the Occupational
Safety and Health Administration (OSHA) relating to blood-borne
pathogen safety and regulations of the United States Postal Service
(USPS) on shipment of syringes through the mail.
We examined (1) which agencies manage infectious waste
(syringe disposal); (2) which form existing policies take (laws,
regulations, guidelines); and (3) what effect policies have on three
disposal strategies (in-trash, collection site, or mailback).
Disposal in household trash can involve (a) loose syringes
placed in garbage, (b) in a container (e.g., commercial sharps con-
tainer, bleach bottle, plastic soda bottle, coffee can), or (c) syringes
with needles physically removed. Unfortunately, many of the con-
tainers currently recommended by state agencies (e.g., coffee cans,
bleach bottles, detergent bottles, and commercial sharps contain-
ers) break and release their contents when compacted. Although
plastic soda bottles have been found to successfully contain most
syringes under the stresses of compaction in the waste stream,16
some syringe-filled containers may be inadvertently recycled, cre-
ating a potential hazard for recycling facility workers.
Syringe collection programs may involve either collection sites or
mailback programs. With collection sites, filled sharps containers are
brought to a collection site such as a pharmacy, nonmedical facility
(e.g., fire station, solid waste transfer station), collection drop box locat-
ed in the community or medical facility (e.g., hospital, public health
clinic, physician’s office). At the collection site, sharps containers may
be handled by facility personnel, who manually place them in a storage
area or placed into the collection container directly by the consumer
without handling by collection site personnel. Collected syringes are
disposed as infectious waste. In mailback programs, sharps contain-
ers meeting legal specifications of USPS are mailed to customers,
who return by mail the full containers to a licensed sharps disposal
company for disposal as infectious waste.
Results
Managing Agencies
Infectious waste is typically managed by one or a combination of
state agencies of public health, environmental protection, and trans-
portation. Among the 16 states reviewed, infectious waste was man-
aged solely by public health agencies in five states (California,
Florida, Michigan, Rhode Island, South Carolina), solely by envi-
ronmental protection agencies in six (Alabama, Georgia, Minnesota,
New Jersey, Ohio, Wisconsin), by both public health and environ-
mental protection agencies in three (Hawaii, Massachusetts, New
York), and by public health, environmental protection, and trans-
portation agencies in two (Oregon, Washington).
Policy Types and Strategies
State Guidelines
In 13 states, the state agencies responsible for infectious waste
management have published guidelines for legal community
syringe disposal options (Table 1).
Household trash—In 11 states, agencies recommended placing
syringes in a container before disposal in household trash,
although the type of disposal container and labeling and sealing
instructions varied (Table 2).
Syringe collection and mailback programs—In six states,
agency guidelines recommended and assisted in identifying a
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community syringe collection site (Table 1). Only two states iden-
tified the syringe mailback service as a disposal option. Guidelines
in California were under development. Earlier guidelines in
Washington recommending six disposal options expired in 1994
following passage of state legislation conditionally restricting dis-
posal of syringes in trash.16
Federal Guidelines
Since the 1991 expiration of the 1988 Medical Waste Tracking
Act (H.R. 3515 One Hundredth Congress), the United States
Environmental Protection Agency (EPA) has had no direct authority
over infectious waste disposal. However, EPA has developed guide-
lines on disposal of community syringes. EPA container recommen-
dations before trash disposal are presented in Table 2. Two EPA
brochures recommended placing community syringes in hard plastic
or metal containers with screw-on or tightly secured lids prior to dis-
posal in the trash.17,18 Another booklet was developed for children
with insulin-dependent diabetes and their parents.19
State Laws and Regulations
Household Trash
State laws or regulations in 11 states allowed community
syringes to be legally discarded in household trash (Table 3).
Florida infectious waste regulations encouraged home users to
segregate and package their syringes, but did not address disposal.
New York regulations did not specifically address the legality of
community syringe disposal in the trash, although state agency
policy allowed home users to dispose of syringes in the household
trash. Washington law allowed trash disposal of syringes only in
those communities in which no “sharps collection service” was
available.16
In two states (Oregon, Wisconsin), disposal in the trash of
sharps from any source, including community sources, was specif-
ically prohibited. This prohibition also extended to jurisdictions
that send solid waste to these states for disposal. For example, the
city of Seattle, which ships its solid waste to an Oregon landfill,
must comply with the Oregon statutory ban on syringes in the
trash.
Syringe Collection Programs
In 10 states, community syringe collection sites were not specif-
ically addressed in state infectious waste laws or regulations
(Table 3). In these states, a conservative interpretation of laws and
regulations could require that syringe collection sites such as phar-
macies be regulated as infectious waste generators and that they
meet standards required of health care facilities. However, state
regulatory agencies in 2 of these states (Rhode Island, South
Carolina) have adopted less restrictive interpretations. In these
Policies in 16 States    SYRINGE DISPOSAL
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Table 1. State Agencies with Community Syringe Disposal Guidelines: Recommendationsa
State
Disposal Strategy Recommended AL FL HI MA MI MN NJ NY OH OR RI SC WI
In household trash • • • • • • • • • • •
Community syringe collection site / • • • • • •
location assistance
Community syringe mailback service • •
AL = Alabama; FL = Florida; HI = Hawaii; MA = Massachusetts; MI = Michigan; MN = Minnesota; NJ = New Jersey; NY = New York; OH =
Ohio; OR = Oregon; RI = Rhode Island; SC = South Carolina; WI = Wisconsin.
aNo state agency guidelines in CA, GA, and WA.
Table 2. State Agency and Environmental Protection Agency (EPA) Syringe Container Guidelinesa,b
State/Agency
Recommended Syringe Container
For Trash Disposal AL FL HI MA MI MN NJ NY OH RI SC EPA
Clear plastic soda bottle N N Y Y Y Y N Y
Glass bottle N N N N N
Detergent/soap bottle Y Y Y Y Y Y Y Y Y
Plastic bleach bottle Y Y Y Y Y Y Y Y
Metal coffee can Y Y Y N Y Y Y
Commercial sharps container Y Y
AL = Alabama; FL = Florida; HI = Hawaii; MA = Massachusetts; MI = Michigan; MN = Minnesota; NJ = New Jersey; NY = New York; OH =
Ohio; OR = Oregon; RI = Rhode Island; SC = South Carolina; WI = Wisconsin.
N = No; Y = Yes.
aNo state agency guidelines in CA, GA, and WA.
bCommunity syringe disposal in trash illegal by statute in OR and regulation in WI.
states, syringes from private residences were not considered to be
a regulated waste, and therefore collection facilities receiving such
waste were not regulated as infectious waste generators.
Collection sites were specifically mentioned in infectious or
solid waste laws or regulations of six states (Table 3). California
and Wisconsin simplified the infectious waste disposal require-
ments for collection sites. Florida regulation and Washington
statute exempted collection sites from solid or infectious waste
facility permitting requirements. The New Jersey infectious waste
regulation allowed community syringe collection only by permitted
regulated infectious waste generators such as hospitals. New
York’s infectious waste statute required that community sharps
must be accepted by hospitals and residential health care facilities.
Its syringe access statute required that eligible providers of syringes
such as pharmacies register with the state health department to
either sell or accept community syringes for disposal, and that these
facilities must meet the state’s infectious waste disposal standards.
Mailback Programs
Mailback for community syringes was mentioned in law only in
California. Under California’s infectious waste statute, mailback
systems were required to submit to the California Department of
Health Services a list of all infectious waste generators serviced by
the company and to update the list every 3 months.
Federal Regulations
OSHA’s blood-borne pathogen standard (29 CFR Part
1910.1030) required that workers be protected in all occupations
where exposure to blood or other potentially infectious materials
may occur. In an OSHA blood-borne pathogen regulation inter-
pretation for community syringe collection programs in New
York, collection sites such as pharmacies in which users placed
sharps containers directly into a drop box or kiosk that was main-
tained by an infectious waste transporter were not required to meet
the standard. However, collection sites in which staff received and
handled sharps containers from customers or who were involved
with emptying a drop box or kiosk had to comply with the OSHA
blood-borne pathogen standard.20
Shipping of used syringes through the mail is regulated under
federal regulations (39 CFR Part 111.1) for syringes mailed via
USPS. The federal regulation, which incorporated Section 8.0 of
USPS Domestic Mail Manual, established specific packaging,
labeling, and tracking requirements for syringes mailed through
USPS. Distributors or manufacturers of sharps mailing kits, which
are used to mail sharps to storage or disposal facilities, are required
to obtain USPS authorization. Before obtaining authorization, each
type of mailing kit must be tested and certified by an independent
third party to ensure that it meets durability standards.
Discussion
Infectious waste laws, regulations and guidelines in the 16 states
we reviewed had many differences and, in many cases, did not
mention or support community syringe disposal except for dispos-
al in trash. We found substantial inconsistencies and conflicts
between the state laws, regulations, and guidelines, particularly in
the recommendations for disposal in trash.
Only six states had laws or regulations related to infectious
waste disposal that specifically addressed community syringe col-
lection. In at least five of these states (California, Florida, New
York, Rhode Island, Wisconsin), the state government has played
an active role in promoting the development of community syringe
collection programs.21–25 It appears that states that formally recog-
nize syringe collection programs invest more staff time and
resources in developing such programs.
Ideally, no syringe should be disposed in the trash. Community
syringe programs that involve segregating syringes from the trash for
disposal as infectious waste help to attain that goal.22–25 However,
collection programs may involve direct and indirect costs to users
(i.e., cost of transporting, mailing, and part or all of the cost of sharps
containers). Collection programs must have trained staff and space at
the collection site. The major program costs are usually purchasing of
sharps containers and infectious waste disposal. The costs of trans-
porting and treating the collected syringes are increasing.26
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Table 3. Community Syringe Collection and Disposal Addressed in Solid or Infectious Waste-Related
Statute and/or Regulation
AL CA FL GA AI MA MI MN NJ NY OH OR RI SC WA WI
Trash disposal allowed • • •1 • • • • • • •1 • P • • •2 P
by statute and/or regulation
Collection programs addressed • • •3 •3 • •
in statute and/or rule
Mailback programs •
addressed in statute
AL = Alabama; FL = Florida; HI = Hawaii; MA = Massachusetts; MI = Michigan; MN = Minnesota; NJ = New Jersey; NY = New York; OH =
Ohio; OR = Oregon; RI = Rhode Island; SC = South Carolina; WI = Wisconsin.
•1 = Trash disposal not specifically addressed in rule or statute; allowed under state agency guidelines.
•2 = Trash disposal conditionally allowed by statute in regions not serviced by a “sharps collection service.”
P = Trash disposal prohibited by statute or rule.
•3 = Only collection by licensed medical facilities addressed by statute or rule
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Even so, some communities have met the costs of collection
programs by developing partnerships among local health depart-
ments and solid waste agencies, solid waste companies, pharma-
cies, diabetes organizations, infectious waste companies, and med-
ical facilities.20–28 Another collection approach is placing sharps
containers in public places. For example, the bathrooms of the
Houston Bush–Intercontinental Airport are equipped with sharps
containers.29
Designing programs and policies that will increase safe commu-
nity disposal options for IDUs is a high priority. The major barrier
to IDU participation is legal; the fear of prosecution for possession
of syringes and/or traces of drug in the syringes substantially
reduces IDUs’ willingness to participate in safe disposal.10,11 New
laws increasing IDU syringe access seem to spur development of
community syringe disposal programs and IDU participation.14,23
In our view, containment and disposal in the trash, the least cost-
ly and most convenient option for the syringe user, should be con-
sidered only if community syringe collection programs are unavail-
able or too costly, and only if legal to do so. Although placing
syringes in containers before disposing in the trash would reduce
needle-stick hazards for residential waste collectors, containers
may rupture, potentially exposing waste handlers to loose needles.
An action taken in August 2002 should result an increased avail-
ability of safe disposal options. Six national professional organiza-
tions called for the formation of state-level groups to “to review and
improve the current options for safe disposal of used sharps gener-
ated in the community by patients and IDUs and to plan public edu-
cation efforts on safe disposal.”30 Another positive step is the recent
creation of the Coalition for Safe Community Needle Disposal.31
Limitations
The findings of this study are subject to several limitations.
First, because this survey was based on a convenience sample of
only 16 states, it is not generalizable to the entire United States.
Second, this study did not gather data on either local ordinances or
the behaviors and activities of individuals or community syringe
collection programs. Both factors may lead to de facto differences
from the state and federal policies. Third, this study presents lim-
ited information on the policies and programs to increase IDUs’
safe needle disposal options. Policies relating to legal issues for
IDUs who want to safely dispose of their syringes have been
reviewed by Burris et al.11
Conclusion
Unsafe discarding of community syringes can cause needle-stick
injuries and can potentially transmit blood-borne infections.
Workers in the solid waste industry are most at risk. In our view,
the national goal should be no community syringes discarded in
trash or the community in locations such as parks, buildings, or
other public areas. To achieve this goal, communities need to
develop low-cost, easy-to-use systems in which community syringe
users place their used syringes and other sharps into containers that
are then collected for treatment as infectious waste. Such systems
include community syringe collection sites (e.g., at pharmacies,
medical facilities, or fire stations), syringe mail-back programs, and
SEPs. If community syringe collection programs are unavailable or
too costly for users, then syringe containment before disposal in the
trash should be considered provided that the practice is not prohib-
ited by law or regulation.
Our survey findings suggest that states with state government
leadership and a wide partnership of interested parties (including,
pharmacists, diabetes educators, physicians, HIV/AIDS preven-
tion programs, persons with diabetes, solid and infectious waste
companies, local health departments, and local solid waste agen-
cies) make greater progress in increasing the number of syringes
diverted from trash.22–25 States should consider amending laws,
regulations, and guidelines to promote community syringe collec-
tion programs and other safe disposal methods. Policy changes
should improve the disposal options and incentives for both IDUs
and persons using syringes for medical indications. A national
effort is needed to achieve consistent community syringe disposal
laws and guidelines for all states.
Pharmacists and others establishing community syringe collec-
tion programs should contact state and local government authori-
ties to determine laws, regulations, and guidelines that apply.
Pharmacists can play a key role in promoting safe disposal by edu-
cating their syringe-purchasing patients, providing sharps contain-
ers, and accepting used syringes for safe disposal. Pharmacists can
join other interested groups in advocating clarification of disposal
laws and regulations that favor community programs designed to
keep syringes out of the trash so that they can be disposed of as
infectious waste.
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Promoting Safe Syringe
Disposal Goes “Hand in
Hand” with Expanded Syringe
Access in New York State
Susan J. Klein, George R. Estel, 
Alma R. Candelas, and Hope A. Plavin
Safe disposal of hypodermic needles and syringes (hereafter
referred to as “syringes”) used outside of health care settings is a
critical public health concern for which options are limited in
many communities.1,2 Safe disposal options for people who need
home health care, people who inject insulin,3 and people who are
injection drug users (IDUs) are often inadequate.4 Access to sharps
containers for syringe disposal may be a barrier for persons with
limited incomes.5
When the New York State Legislature authorized sale of
syringes without a prescription as a demonstration program to pre-
vent blood-borne pathogen transmission, it emphasized proper dis-
posal of syringes.6 We review syringe disposal options in place
before the January 1, 2001, start of the New York State Expanded
Syringe Access Demonstration Program (ESAP), and summarize
actions taken in conjunction with ESAP to enhance safe disposal.
Safe Disposal Options Before ESAP
Thirteen New York State Department of Health
(NYSDOH)–authorized syringe exchange programs (SEPs) have
accepted used syringes for safe disposal since 1992.7 In 1993, the
New York State Public Health Law was amended to require certain
types of health care facilities to accept used sharps, including
syringes, originating from private residences for disposal.8 Each
facility established its own program, including location, days and
hours of operation, policies and procedures, designation of staff,
and training. These facility-based options exist in all but one coun-
ty in the state. Residents may also dispose of syringes in household
trash in accordance with local laws. Since 1995 NYSDOH has
made available a brochure containing guidance on safe disposal of
sharps in household trash.
Recent Initiatives
The amendments establishing ESAP set forth specific require-
ments for safe disposal. To qualify for registration to sell or furnish
syringes under ESAP, pharmacies, health care facilities, and health
care practitioners must “cooperate in safe disposal of used hypo-
dermic needles and syringes.” This was defined in regulation to
mean that each time syringes are sold or furnished under ESAP, a
safety insert must be provided that addresses safe disposal, among
other topics. In addition, the independent evaluation of ESAP must
include an analysis of its impact on safe disposal.9
Disposal at Pharmacies
Pharmacies in many areas of the country accept used sharps for
disposal,10–13 a practice supported by the American Pharmaceutical
Association policy statement on syringe disposal.14
Pharmacies enrolled in ESAP are not required to accept used
syringes for disposal. To promote safe disposal of used syringes
and other sharps used outside of health care settings, pharmacies
can voluntarily participate in any of the following:
■ Distribute copies of the ESAP safety insert that discusses safe
disposal (required for ESAP-registered pharmacies).
■ Make available the NYSDOH brochure, Household Sharps—
Dispose of Them Safely.
■ Refer individuals to sharps disposal programs in the communi-
ty.
■ Educate the public about safe disposal.
■ Sell or furnish puncture-resistant personal sharps containers or
sharps disposal by mail systems. 
■ Accept syringes and other sharps used by individuals for safe
disposal.
Although pharmacy acceptance of used sharps for safe disposal
is not widespread in the state, a July 2000 NYSDOH survey of
pharmacies revealed that many pharmacies were interested in
accepting sharps in the future.15 We examined NYSDOH and
Department of Environmental Conservation (DEC) policies to
assess the potential role of various types of providers, such as phar-
macies, clinics, and community-based organizations, in safe dis-
posal (Table 1).16 Although NYSDOH had a procedure in place to
register pharmacies and clinics to accept used syringes since
January 1, 2001, as of April 2002, few had done so. Barriers to
accepting used syringes for safe disposal included: regulatory
requirements (i.e., Occupational Safety and Health Administration
blood-borne pathogen standards); lack of space on site; lack of
resources for disposal of syringes collected; and lack of broad avail-
ability of puncture resistant sharps containers.15,17
NYSDOH developed guidance for pharmacies interested in
offering sharps collection by either (1) installing a tamper-proof
sharps collection kiosk for direct deposit of contained sharps by
customers, or (2) allowing staff to receive contained sharps from
customers for placement into a receptacle.18 Sharps collected at a
pharmacy must be transported to a DEC-approved storage, treat-
ment or disposal facility.16 NYSDOH purchased personal sharps
containers, ESAP “Contains Sharps” stickers, and facilitated
placement of kiosks at pharmacies willing to accept used sharps.
Disposal at Health Care Facilities
In November 2000 NYSDOH mailed a survey to all New York
State health care facilities (n = 930) required to operate sharps dis-
posal programs. The survey requested contact information, drop-
off locations, days and hours of operation, program requirements
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(e.g., requirements for specific types of puncture-resistant contain-
ers), and other information. Responses were used to compile a
statewide directory, and it was widely disseminated. Some county
health departments and other local agencies prepared county-spe-
cific directories of facility-based sharps disposal programs as well
as fliers and brochures promoting these programs.
Disposal in Trash
While New York state law does not prohibit disposal of used
sharps in household trash, we attempted to determine whether local
laws had such provisions. We contacted DEC, trade organizations
representing the solid waste industry, the New York City Department
of Sanitation, and local health departments. We found no evidence of
local laws prohibiting disposal of sharps in household trash.
NYSDOH’s brochure, Household Sharps — Dispose of Them Safely,
was updated, reprinted in both English and Spanish, and placed on
the NYSDOH Web site. This brochure was made available to ESAP-
registered pharmacies as well as health and human service providers.
Develop Community Coalitions to Promote
Safe Disposal
NYSDOH sponsored development of Community-Based
Syringe Access and Safe Disposal Demonstration Projects that
engage a wide range of local partners.  The demonstration projects
produce materials to inform community members of the impor-
tance of safe disposal and about existing sharps disposal programs,
create new sharps collection programs, and distribute personal
sharps containers at no charge to individuals. New sharps collec-
tion programs include placement of kiosks at local pharmacies,
diabetes centers, clinics, and community-based organizations in
addition to local partnerships that address pick up, transport, and
disposal of collected sharps.
Additional Safe Disposal Options
Based on information gathered, NYSDOH is considering alter-
native approaches for syringe disposal,2,10–13,19,20 Options for
expanding the availability of puncture-resistant sharps containers,
kiosks, and drop boxes are also being explored.
Public Education
The ESAP safety insert contains detailed guidance on safe dis-
posal. The safety insert is available in both English and Spanish
and is also accessible on the NYSDOH Web site. In calendar year
2001, more than 170,000 copies of the safety insert were distribut-
ed to pharmacies and other providers. Of these, 78% were in
English and 22% were in Spanish. Safe disposal was highlighted
in a statewide videoconference program and in numerous meetings
and presentations.
A new consumer brochure was developed for persons with dia-
betes and their families. This brochure provides instructions on
safely disposing of sharps in household trash. A generic safe
sharps disposal poster, suitable for display in diabetes clinics,
pharmacies, and other locations, was developed. A videotape and
a trainer’s guide for diabetes educators addressing safe disposal of
sharps in household trash are being developed.
Conclusion
In August 2002, several national organizations, including the
American Medical Association and the American Pharmaceutical
Association, called for renewed attention to safe syringe disposal
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Table 1. Syringe Disposal Options Identified for Providers in New York State
Syringe Community-
Involvement in safe Nursing Health Care Exchange Based 
disposal activities Hospitals Homes Clinics Practitioners Pharmacies Programs Organizations
Already handle Y Y Y Y — Y —
regulated medical waste
Required to accept sharps  Y Y — — — — —
since 1996 under Public
Health Law 1389 dd(4)
Approved by NYSDOH to accept — — — — — Y —
sharps for safe disposal
Can voluntarily register for — — Y Y Y — —
ESAP and accept sharps
Can work with an ESAP- — — — — — — Y
registered provider that
accepts sharps
Can promote safe disposal Y Y Y Y Y Y Y
and refer individuals 
to safe disposal sites
ESAP = Expanded Syringe Access Demonstration Program; NYSDOH = New York State Department of Health; Y = Yes.
outside of health care facilities.1,21,22 In New York State, ESAP
provided added impetus for NYSDOH and others to expand the
options for and availability of safe syringe disposal options.
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Community Needle Collection
and Disposal Programs in
Florida
Wayne L. Turnberg, Edith Coulter, Jan Rae Clark,
and Robert G. Vincent
In June 2001 sharps collection and disposal programs (referred
to as “community needle collection programs” in this article) were
operating in at least 29 (43%) of the 67 counties in Florida.1 This
article reports on the development of these community needle col-
lection programs. We examined laws, regulations, and guidance
documents on this topic and a statewide survey of community nee-
dle collection programs.
Establishing the Model Program and
Regulations
In the early 1980s, the Florida Department of Environmental
Protection (DEP) began to address the management of special
waste streams such as household hazardous waste (HHW). During
1983 to 1985, DEP funded statewide “amnesty days” collections
for HHW. In 1986 DEP began providing grants to local govern-
ments to fund local HHW take-back centers. Some HHW collec-
tion centers accepted community-generated needles. As a result,
the take-back center concept became the model for needle collec-
tion programs.
In 1988, in response to reports of needles on the beaches and
accounts of needle-stick injuries among garbage collectors,
Florida enacted a biomedical waste statute. The biomedical waste
rules, adopted in 1989, covered medical waste from health care
facilities. At that time, disposal of needles generated in the com-
munity (i.e., outside health care settings) was not addressed by
either statute or rule.
County health departments and municipal governments were
instrumental in starting community needle collection programs.
Although the Florida DEP was not directly involved in organiz-
ing local needle collection efforts, it facilitated the process by
easing regulatory barriers for county health departments and
municipal governments starting such programs. Between 1989
and 1994, the Florida DEP required both a storage permit and
permit fee for each needle drop-off site. In 1995, to encourage
the growth of these programs, the Florida DEP simplified regu-
lations covering collection programs by requiring only one gen-
eral permit and permit fee for each program that was open to the
public regardless of the number of drop-off sites.2
Streamlining Needle Collection
In 1996 the Florida legislature transferred responsibility for
biomedical waste to the Florida Department of Health (DOH). The
statutory revisions in Section 381.0098(4)(h), Florida Statutes,
included language authorizing the DOH to develop “a streamlined
process for permitting biomedical waste storage facilities that
accept and store only sharps collected from the public, which may
include the issuance of a single permit for each applicant that
develops or sponsors a sharps collection program.” In response,
the Florida DOH developed a simplified biomedical waste needle
collection program permit application and waived the fee for non-
profit needle collection programs.
Needle collection programs are operated by county govern-
ments, county health or environmental health departments, clinics,
fire departments, county utilities, or combinations of these institu-
tions (Table 1). Loose needles are not accepted. Properly con-
tained needles are collected at locations such as county health
departments, clinics, hospitals, pharmacies, fire stations, or drop
boxes.3,4 Consumers can obtain new sharps containers, at minimal
or no cost, from a collection site. When a sharps container is filled,
the consumer takes it to a collection site and receives a new con-
tainer. Filled containers are removed from collection sites by
licensed biomedical waste transporters. The containers are 
transported to a treatment facility and disposed of as biomedical
waste. The Florida DOH has developed news releases and posted
collection program information on their Web site
(www.doh.s ta te . f l .us /envi ronment / fac i l i ty /b iomed/
sharpsprograms.htm). The collection programs develop and dis-
tribute brochures at locations such as pharmacies, clinics, and hos-
pitals.
The operating costs for Florida community needle collection pro-
grams include purchasing sharps containers, promotion and public
education (brochures, news releases, public service announce-
ments), and biomedical waste transport and treatment. The pro-
grams are supported by funding or in-kind donations from program
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Table 1. Types of Organizations Directing Florida
Community Needle Collection Programs, 2001
Florida 
Counties
(n = 67)
Type of Organization No. (%)
County government 8 (12)
Environmental health/county health department 13 (19)
Nursing/county health department 2 (3)
Solid waste 2 (3)
Clinic/county health department 2 (3)
Fire department 1 (1.5)
County utilities 1 (1.5)
Counties without identified programs 38 (57)
Source: Reference 1.
◆
sponsors. The sponsors include county health departments, county
or municipal governments, hospitals, pharmacies, and commercial
biomedical waste transport and treatment businesses.
Conclusion
In a study of 16 states in the United States, 12 states (75%) did
not have biomedical waste laws and/or regulations designed to
encourage community syringe collection programs.5 Florida is a
good example of how supportive regulations and policies can
favor the development of community needle disposal programs. In
Florida, state and county governments recognized the value of
community programs to collect needles for safe disposal. As a
result, Florida state government simplified the administrative pro-
cedures and first reduced and then eliminated fees for community
needle collection programs. In addition, the Florida DOH Division
of Environmental Health assigned biomedical waste coordinators
to assist local and county community needle collection efforts. The
local programs were designed to provide sharps containers and
collection of needles at no or limited cost to the public. An in-
depth study of these programs would be useful in assessing the
success of the programs in “capturing” needles and other sharps,
such as lancets, generated outside of health care settings and in
preventing occupational and nonoccupational needle-stick injuries
in the community.
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Eureka—Implementing Safe
Community Needle Disposal
in Rhode Island
Paul F. Caranci, Rita Farmanian, Dona Goldman,
Cherie M. Kearns, Karen LeBoeuf, Richard
Nicholson, Richard Sands, and Mona Scheraga
In 1999 concerns about worker needle-stick injuries and plant
operation interruptions at the state landfill and materials recovery
facility (MRF) led to the development of Rhode Island’s statewide
residential needle disposal program, Eureka Sharps Disposal
System (“Eureka”; called “SharpSmart” from 1999 to 2001).
Rhode Island Resource Recovery Corporation (RIRRC) staff, who
run the landfill and MRF, had observed an apparent substantial
increase in the number of loose needles in residential trash and
recyclable materials.
Sharps in Trash and Recyclables
At MRF, workers manually sift through waste to remove recy-
clable materials to reduce the volume of solid waste going to land-
fills. When a loose needle is observed in the MRF line, RIRRC
temporarily stops operations, at a cost of approximately $1,800 per
hour. In 1999 and 2000 more than 400 pounds of loose sharps
were removed from the MRF line; in the first 8 months of 2000,
35 to 40 incidents of loose syringes led to a total of 65 hours of
MRF interruptions at an estimated cost of $120,000. During 18
months in 1999 and 2000, five RIRRC workers suffered acciden-
tal on-the-job needle-stick injuries, complicated by concerns about
the potential risk of infectious disease.
Program Design
Because of these concerns, RIRRC staff contacted the Diabetes
Foundation of Rhode Island (DFRI) to discuss how to reduce the
number of needles discarded in residential trash and recyclables.
DFRI offered to help create a safe community needle disposal pro-
gram in Rhode Island. DFRI staff found that 14 pharmacies had
sharps collection tubs to collect used needles, but the requirement
that the person collecting the used needles must be trained under
the Blood-Borne Pathogen Standard of the U.S. Occupational
Safety and Health Administration (OSHA) limited the utility of
this option. To simplify needle disposal, DFRI staff worked on
needle kiosk designs that limited potential exposure to the used
needles. Having patients place used needles through a “one-way”
door into a locked kiosk substantially reduces the potential blood-
borne pathogen exposure for staff in the facility (e.g., pharmacy)
where the kiosk is located.
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The initial kiosk design, funded by the Champlin Foundation,
was a mailbox-like metal bin approximately 5-feet high. The
model was designed to accept commercial sharps containers,
bleach bottles, and other tape-sealed plastic containers or coffee
cans. Depositing sharps in glass containers was not permitted.
Eureka kiosks were placed at 14 pilot sites in fall 2000. As of
August 2002, kiosks have been placed at 42 sites around Rhode
Island, including 35 pharmacies, 4 fire stations, 2 police stations,
and the DFRI office. The number of kiosk locations will increase
to 50 by December 2002. Although the kiosk is designed for both
indoor and outdoor use, all have been placed inside facilities (e.g.,
in pharmacy waiting areas).
DFRI informed the public of Eureka through a public relations
campaign using radio, print, and television media, Web site post-
ings, and posters and brochures for display in physicians’ offices.
The campaign was designed to reach sharps users, state agencies,
municipalities, physicians, pharmacists, nurses, and health educa-
tors. Through the campaign, sharps users have been encouraged to
place their properly contained sharps in a Eureka kiosk. When a
full sharps container is placed in the kiosk, staff at the site provide
a new sharps container free of charge. The sharps containers were
donated to Eureka by the Rhode Island Department of Health,
RIRRC, and Stericycle. Stericycle, a medical waste company, has
sponsored the pick-up from the Eureka bins and delivery of sharps
to a medical waste treatment plant and, from there, to American
Refuel, Inc., where they are burned.
Experiences with Eureka
Between October 2000 and February 2002, more than 7,500
pounds of sharps and sharps containers have been collected
through Eureka. Since March 2002, the average monthly collec-
tion has been 750 pounds, or more than 1 million  syringes col-
lected annually. 
DFRI and its Eureka partners are using multiple measures to
evaluate Eureka operations and impact. The evaluation measures
include  weight and estimated number of sharps collected for indi-
vidual sites and the overall program, number of needles found on
the MRF line, and RIRRC worker injuries. Initial findings at
RIRRC are promising, with no worker needle-stick injuries since
the start of Eureka and a 50% decrease in the weight of loose nee-
dles and sharps found on the MRF line (from 400 pounds of sharps
in 2000 to 200 pounds in 2001). Eureka has been most successful
at those sites where staff and/or local fire departments strongly
promoted the program.
Eureka implementation costs have varied, depending on avail-
able community resources and sponsorship. The total start-up
implementation cost in Rhode Island was $130,000 (a large por-
tion of the start-up funds went to design the materials and to design
and build the kiosk), the majority of which was supplied through
in-kind donations, cash sponsorship, and grants. For Eureka sites,
the average annual cost was $1,500 (for sharps containers, litera-
ture for the local community, maintenance, and disposal).
In August 2001, the Rhode Island General Assembly passed
legislation to establish a commission to evaluate needle disposal
laws and methods, examine the outcomes of the Eureka Sharps
Disposal program, and obtain long-term funding for the Eureka
project. The commission is publishing a status report in December
2002.
The DFRI plans to begin a national expansion of Eureka in late
2002. DFRI and Walgreens have formed a partnership to place
kiosks nationwide in Walgreens pharmacies that have adequate
space. A second partnership was formed with Medical Waste
Solutions, LLC, to develop Eureka into a comprehensive and repli-
cable residential sharps disposal program.
Conclusion
The preliminary success of Eureka demonstrates the feasibility
of a statewide residential needle disposal program developed
through collaboration among consumer groups, the solid waste
industry, state agencies, health care providers, and corporations.
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How Wisconsin Promotes
Household Sharps Collection
Barbara B. Derflinger and Jean K. Druckenmiller
An estimated 2 to 3 billion syringes annually are generated out-
side of health care settings in the United States.1 Discovery of nee-
dles and syringes (hereafter referred to as “sharps”) on beaches and
other public places have led to widespread concern about sharps in
the environment and extensive laws and regulations of sharps gen-
erated in health care settings. However, sharps discarded in munic-
ipal waste have largely been ignored. Sharps in waste can injure
waste handlers and recycling facility workers. Even the suspected
presence of sharps can prevent recyclable materials from being
recycled.
In the early 1990s, Wisconsin’s health care providers, waste
handlers, environmentalists, and state government collaborated to
write rules that both require and enable all generators to dispose of
sharps safely. The goals were as follows:
■ To reduce risks of injury and disease.
■ To include all who generate or encounter small amounts of
sharps, including the public, waste handlers, injection drug
users, pet owners, farmers, and small businesses.
■ To foster sharps collection programs, which are safe, conve-
nient, inexpensive, flexible, and anonymous.
Wisconsin Forbids Sharps in Solid
Waste
Wisconsin’s rules about sharps2,3 can be summarized as fol-
lows: All sharps must either be disinfected and broken or be incin-
erated before being put in a landfill; sharps generated outside of
medical facilities, known as “household sharps,” are not exempt
from the above requirement; all sharps generators must keep
sharps separate from other wastes, use proper containers, and dis-
pose of sharps safely; generators may take household sharps to
“sharps collection stations,” locations whose owners or managers
agree voluntarily to collect sharps from the public.
Wisconsin has identified three key components to successful
and safe disposal of household sharps. First, minimal but effective
regulation lays the groundwork for easy-to-implement programs.
In addition to the rules mentioned above, Wisconsin requires
sharps collection stations to operate at or below cost, to follow
safety requirements and, if they are not themselves generating
sharps, to register with the state by writing a simple letter.
Registration exempts collectors from red tape such as licenses and
reports, and enables the state to provide a list of collection sites to
the public. Supporting provisions, such as definitions of terms,
treatment standards, enforcement and exemptions, were carefully
drafted to enable and not to discourage people from collecting
sharps. Finally, unlike most states, Wisconsin has no legal penal-
ties for possession of syringes and needles, a situation that
enhances use of syringe exchange programs by individuals who
are injection drug users (IDUs) (S. Stokes, AIDS Resource Center,
Milwaukee, Wisc., oral communication, August 1998).
Most Wisconsin Counties Have
Sharps Collection Sites
Second, local initiatives respond best to local needs.
Pharmacies, health care providers, local governments, waste
haulers, and groups of persons with diabetes have all initiated col-
lection programs. These local efforts range from a single collection
site to groups of 30 or more sites. All collection sites are designed
to be convenient and low cost or free to the user. As of September
2002, more than 500 stations had registered with the state. In addi-
tion, numerous health care providers, who do not have to register,
accept their patients’ sharps. More than 90% (66/72) of
Wisconsin’s counties have at least one registered sharps collection
station.
Third, education enables everyone to know what to do. The
state publishes generic educational materials and trains health
workers; local organizers train people in greater detail.
Specifically, the Wisconsin Department of Natural Resources3
(WDNR) publishes guidance for generators, educators and sharps
collectors. WDNR maintains the list of collection sites and dis-
tributes it with help from the Wisconsin chapter of the American
Diabetes Association and the Wisconsin Veterinary Medical
Association. The state health department has trained more than
175 public health nurses and 250 infection control workers who in
turn train staff in their facilities. The health department also pro-
vides updates in its infection control and AIDS/HIV newsletters
and works closely with trade organizations such as the Association
for Professionals in Infection Control and Epidemiology (APIC).
Local organizers develop their own training videos and outreach
materials, such as press releases, public service announcements,
brochures and Web pages (for example, Oneida County4 and City
of Madison5).
Together, these three components foster safe sharps disposal.
As a result, fewer sharps are seen in the environment, more waste
can be recycled because it is free of sharps and, where many sharps
are collected, waste handlers have fewer injuries, fewer health
risks, and less emotional trauma. While the state does not have
statistics because it deliberately exempted collectors from keeping
records, some local programs do track amounts collected, costs,
and sharps injuries.6,7
Progress is enhanced where local ordinances establish fines for
improper disposal and education is frequent and ongoing (T.
Gansluckner, Pierce County Department of Solid Waste, Wisc.,
oral communication, August 1998) and where community leaders
champion the idea (G. Lester, West Allis Memorial Hospital, West
Allis, Wisc., oral communication, August 1998). Progress is
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impeded where collection sites are inconvenient and where no one
volunteers to collect sharps. In Wisconsin, progress is still needed
in the hospitality sector and among persons who are homebound,
those who are not fluent in English, and those who inject animals,
such as livestock producers and pet owners.
Conclusion
Wisconsin has responded to real public health risks posed by
household sharps in waste by requiring everyone to separate
sharps from other waste and encouraging a wide variety of volun-
tary sharps collection programs. Wisconsin has found that minimal
but effective state and/or local regulation, local initiatives and pub-
lic education are all vital to successful sharps collection programs.
With numerous health care providers serving their patients and
more than 500 registered collection sites serving the public,
Wisconsin is reducing risks of injury and disease from sharps both
in the environment and in waste.
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Importance of substance abuse treatment in preventing HIV
transmission among injection drug users.
These recommendations must be viewed in the overall context of the drug epidemic. Comprehensive responses to this threat
to public health are critical: most critical is the expansion of drug treatment to make it more available.(p 8)
Indeed, the appropriate legislative bodies should enact legislation (and should appropriate monies) to increase drug treatment
capacity and establish better links between treatment and AIDS prevention programs that target injection drug users. (p 8)
Normand J, Vlahov D, Moses LE, eds. Preventing HIV Transmission: The Role of Sterile Needles and Bleach. Washington, DC: National
Academy Press, 1995. www.nap.edu/catalog/4975.html. Accessed November 5, 2002.
F R O M  T H E  L I T E R A T U R E
Household Sharps Collection
Program in Brown County,
Wisconsin
Joseph P. Van Rossum and Judy Friederichs
In 1994 Wisconsin State Administrative Code NR526 made it
illegal to dispose of untreated sharps (needles, syringes, finger
stick lancets) in landfills in the state.1 The new code prohibited
placing used sharps in residential trash for curbside pick-up. This
report describes the program for safe disposal of home-generated
sharps developed by Brown County.
Program Development
In 1995 the Brown County Departments of Health and Solid
Waste organized a work group to develop the new sharps dispos-
al program. Ideally, the new program would be as convenient and
inexpensive as disposal in the trash and be easily accessible to the
212,000 residents of Brown County. The work group included
sharps users, pharmacists, physicians, infection control providers,
and staff from the Wisconsin Department of Natural Resources,
other health departments, hospitals, and regional diabetes and
hemophilia associations. The work group took more than 1 year to
evaluate other sharps disposal programs and to develop and imple-
ment the new county program. While the new program was being
developed, consumers were advised to store used sharps in punc-
ture-resistant containers.
Implementing the Program
The Brown County Household Sharps Program began operating
in June 1996. The program operates at sharps collection stations,
where staff provide sharps containers to the public and accept
filled sharps containers, both free of charge. Each collection sta-
tion has one or more 39-gallon collection bin to store returned
sharps containers. When collection bins are filled, station staff call
a contracted medical waste hauler for pick up. There are currently
31 sharps collection stations located in local pharmacies (19),
health care clinics (9), and hospitals (3). Thus, the majority (61%)
of the collection stations are pharmacies. Twenty-eight stations are
located in Green Bay.
The program currently distributes two sizes (1 and 5 quarts) of
sharps containers that are compliant with Occupational Safety and
Health Administration (OSHA) regulations. A small number of
larger sharps containers (8 gallons) are provided to people with
hemophilia.
Brown County Solid Waste Department (BCSWD) staff man-
age the program. The county contracts with a medical waste com-
pany to distribute sharps containers to collection stations, pick up
filled collection bins, and dispose of them as medical waste.
Sharps collection station personnel were required to participate
in a 30 to 40 minute training session before the station opened.
BCSWD staff visit new collection stations 6 weeks and 6 months
after they open.
The program staff developed a variety of materials including:
brochures, collection station staff training sheets, an operational
guide, a logo decal identifying collection stations, instruction
stickers for sharps containers, videos for sharps users and collec-
tion station personnel, and a plastic bag to make it easier to place
filled sharps container in the bin. The program maintains a Web
site at www.co.brown.wi.us/Solid_Waste/sharps_medwaste.htm.
Experiences with the Program
Program data for the period 1996 through 2001 are shown in
Table 1. Program costs have increased substantially since start-up
primarily because of an approximate 60% increase in the cost of
sharps containers. In each year from 1999 through 2001, the pro-
gram distributed sharps containers with capacity for an estimated
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Table 1. Brown County Household Sharps Program
Pounds of
Sharps and Sharps
Syringe Capacity of Sharps Cost per Quart Containerb Cost of Programc Containers Collected
Year Containers Distributeda $ $ No.
June—December 1996 638,000 0.71 9,035 815
1997 694,600 0.74 10,555 8,655
1998 861,050 0.77 13,128 8,519
1999 1,023,450 0.83 16,937 7,121
2000 908,100 1.11 19,993 5,063
2001 977,000 1.38 27,000 6,276
aEach 1-quart container holds an estimated 50 syringes. The estimate of number of syringes is calculated by multiplying the total number of
quarts of sharps containers distributed for the year by 50. In 2001, the program distributed 1,760 1-quart, 3,524 5-quart, and 5 8-quart containers.
bTotal cost of purchasing, collecting, and disposing sharps containers divided by the number of quarts distributed.
cProgram cost is primarily the cost of purchasing, collecting, and disposing sharps containers. Salaries are not included.
◆
0.9 to 1.0 million syringes.
In 1998 Brown County started a hospitality sharps program, pri-
marily intended to be used in hotels and restaurants. A mailing was
sent to all establishments that had a County Health Department
license. Only eight businesses participate in the hospitality program.
Because of the limited response, the hospitality program will be
gradually phased out.
The major program costs are the purchase of sharps containers and
collection bins and charges for the collection and disposal of used
sharps as infectious waste. County staff salaries are not included in
cost estimates. A public–private partnership funds the program.
Partnership sponsors include 16 municipalities, the Brown County
Health and Solid Waste Departments, 3 local hospitals, a national
waste hauler, a national medical waste contractor, and the county
landfill contractor. In April 2002 all but one of the partners commit-
ted to sponsor the program for 3 more years. No systematic data are
available on needle stick injuries or needles found in the trash.
Conclusion
A statewide ban on placing household-generated sharps in com-
munity solid waste and landfills prompted the development of the
Brown County Household Sharps Program. The program was
developed and implemented through a collaboration of pharma-
cies, local governments, county health and solid waste depart-
ments, health care providers, and others, and it currently keeps as
many as 0.9 to 1.0 million sharps per year out of solid waste and
disposed of as medical waste. Participation by local pharmacies
has been an important element in the program’s success.
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San Francisco Safe Needle
Disposal Program, 1991–2001
Brad Drda, Jose Gomez, Ruth Conroy, Mel Seid,
and Jacob Michaels
In the late 1980s, the San Francisco Department of Health
(SFDH) received multiple reports of discoveries of discarded nee-
dles and syringes. Although the large majority involved residential
trash and trash workers, needles were found in San Francisco parks,
mailboxes, and street excavations. Because the San Francisco
syringe exchange program (SEP) was assumed to provide disposal
services to injection drug users (IDUs), SFDH staff worked to set up
a disposal scheme for people with diabetes and other non-IDU nee-
dle users. Over a period of about 2 years, SFDH staff brought
together diabetes organizations, the solid waste haulers, the major
pharmacy chains, syringe manufacturers, and medical waste dispos-
al companies. As a result, in 1991 the San Francisco Safe Needle
Disposal Program (SFSNDP) was created to provide free, safe, and
convenient needle disposal to San Francisco residents to reduce the
risk that garbage workers and city workers would be injured or
infected by used needles.1–3 SFSNDP has become one of the largest
community-based programs to keep needles, syringes, and other
sharps out of residential solid waste.1 Multiple community groups
including the San Francisco garbage companies, community phar-
macies, and local health officials contribute to sustaining SFSNDP.
Free-of-Charge Pickup and Collection
of Sharps Containers
San Francisco resident needle users can pick up a free 2-liter
(previously 1-quart) sharps container at more than 50 locations
throughout San Francisco. When the container is full, the customer
turns it in to any of these locations for free disposal. Full sharps
containers are stored and picked up in covered plastic tubs called
medical waste boxes. People using the program are not required to
show any identification, except at one site, the San Francisco
Household Hazardous Waste Collection Facility.
Most Sites Are Pharmacies
As of June 2002, 56 participating container pick up and drop-off
locations are in San Francisco. Of these, 50 (89%) SFSNDP pro-
grams are located in pharmacies including: 42 Walgreens, 4 Kaiser
Foundation Health Plan, University of California at San Francisco
(UCSF) Parnassus Heights, Stadtlander’s, Veterans
Administration (VA) Hospital, and San Francisco General
Hospital (SFGH). In addition, 6 SFDH clinics participate in the
program.
SFSNDP was originally funded almost entirely through donat-
ed products, time, and effort. However, those donations slowly
declined and, in 2002, the program became fully based on paid ser-
vices. Most of the current funding for SFSNDP comes from the
San Francisco residential solid waste charges. Sanitary Fill
Company, one of the San Francisco solid waste companies, con-
tributes funding from these solid waste charges. Additional fund-
ing comes from the $200 annual fee paid by each participating
pharmacy. See Table 1 for additional cost and program activity
data.
Pharmacists contact SFSNDP to request additional sharps con-
tainers. All sharps collected by the program are disposed of as
infectious waste, currently by Stericycle, at $40 per scheduled pick
up. The UCSF, the VA Hospital, and SFGH pharmacies and the
six SFDH clinics, dispose of the sharps containers through their
medical waste disposal systems.
When the program started, with a 6-month pilot from July 1
through December 31, 1991, the City and County of San Francisco
Solid Waste Management Program handled publicity. At a 1991
news conference, a garbage collector who had been stuck by a nee-
dle told his story. SFSNDP received excellent media coverage,
including an article that appeared in Newsweek in 1991. SFSNDP
has mailed informational flyers approximately twice a year to peo-
ple with diabetes and to physicians who are likely to prescribe nee-
dles in San Francisco. Letters are also sent to residences where
garbage workers have seen needles in the trash. Program posters
with the SFSNDP logo have been displayed in buses, bus shelters,
and participating pharmacies. The program developed a sticker on
how to dispose of the full container which was originally placed on
sharps containers when distributed, but this procedure was stopped
in 1993 because of the added labor; since then SFSNDP has relied
on pharmacists to instruct consumers in proper disposal. In the late
1990s, SFSNDP increased outreach efforts mostly through flyers
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Table 1. Program Activity and Estimated Costs for 2000–2001
Sharps Medical
Containers Waste Boxes Weight of
Distributed Picked-Up Sharps Waste Estimated Program Costs ($)a
Year No. No. (Pounds) Containers Disposal Administration Total
2000 14,760 284 6,611 32,000 10,000 25,000 67,000
2001 13,630 269 4,538 32,000 10,000 25,000 67,000
aBased on 1999 figures.
and presentations about disposal at health fairs to people with dia-
betes, the gay community, non-English-speaking Chinese and
Hispanic communities, and substance abuse counseling organiza-
tions. In 1999, SFSNDP gave out 14,120 sharps containers, and
removed an estimated 2 million needles from the residential waste
stream. Since then, use of SFSNDP has been stable (see Table 1).
Sanitation Worker Needle-Stick
Injuries Decreased
Although we cannot attribute the changes to SFSNDP, the num-
ber of needle-stick injuries to garbage collectors declined steadily
from 21 sticks in 1989 to 3 in 1995 and remained low, with a total
of 6 needle sticks in 2001, according to Occupational Health and
Safety Administration logs. Anecdotal reports from garbage col-
lectors and agency administrators also suggest a substantial
decline in the frequency of needles sightings in the garbage since
the program began.
Although community-generated needles continue to be dis-
posed of in the solid waste stream of San Francisco, SFSNDP has
made a substantial contribution to both removing needles from the
waste stream by collecting sharps and ensuring that others can be
placed in sharps containers distributed by the program, Prevention
Point, the San Francisco syringe exchange program, collects
approximately 2 million needles per year from IDUs who use the
program.4 Together, SFSNDP and Prevention Point recover and
safely dispose of as many as 4 million needles per year from com-
munity needle users. This success has depended upon active col-
laboration between garbage companies, pharmacies, city govern-
ment, and other health providers.
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Community Sharps Disposal
Program in Council Bluffs,
Iowa
Donn Dierks and Dick Miller
An alarming increase in needle sightings and six needle-stick
injuries in autumn 1991 and spring 1992 in Council Bluffs, Iowa,
led its contracted solid waste handling company, Browning Ferris
Industries, Inc. (BFI), to seek help from the Council Bluffs Health
Department (CBHD). BFI requested that CBHD establish a com-
munity sharps disposal program to reduce the number of used nee-
dles, syringes, and other sharps (hereafter referred to as
“syringes”) entering the residential solid waste stream.
In collaboration with BFI and local pharmacies, and with finan-
cial support from a local foundation, the Dodge Foundation, CBHD
designed and implemented the Council Bluffs Sharps Disposal
Program. Initiated in May 1992, the program distributed free of
charge, wide-mouth, 1-gallon plastic bottles with screw-on lids to
be used as containers for used syringes. Initially, new containers
were distributed to the local pharmacies by health department
employees. Local pharmacies and the CBHD provided the contain-
ers to patients whose medical care required injections. A pamphlet
describing the program was given to anyone receiving a container.
When a container was filled, residents were to return it, in exchange
for a new container, to the CBHD office or to one of several par-
ticipating local pharmacies. CBHD collected filled containers from
pharmacies and consolidated the containers for pickup by a medi-
cal waste transportation company (Bio-Hazardous). BFI, the city’s
solid waste collection contractor at that time, paid the costs of trans-
porting and treating the syringes as infectious waste.
Pharmacy-Based Program
Initial pharmacy participation in the program was low (6 of 15
local pharmacies participated). The main concerns voiced by phar-
macists were limited space in their pharmacies and potential lia-
bility in accepting the filled containers. In response to the concern
about space, the program allowed pharmacists to take as few or as
many boxes holding four empty 1-gallon containers as they
wished. CBHD also made a commitment to deliver and/or collect
containers within 24 hours of notification from participating phar-
macies. In response to the concern about liability, the program has
provided pharmacies that will not accept filled containers with
new containers to distribute to their customers. The flexibility of
the program, combined with the efforts of one of the authors, a
local pharmacist and Board of Health member, led to 13 of the 15
local pharmacies participating in the program since 1999.
Between 1992 and 2002, CBHD paid approximately $9,180 for
containers, labeling, and pamphlets (Table 1). Because CBHD per-
sonnel delivered and collected containers while doing other envi-
ronmental health work, there were no direct personnel costs. The
population of Council Bluffs is approximately 60,000 people. The
direct program costs over 10 years totaled $0.15/person. The cost
of the new containers have been offset by the Dodge Trust grant
and the budget of the Solid Waste Management Division of
CBHD. In addition, during the same time period, the solid waste
collection contractor paid $17,290 for biohazard waste disposal of
program containers, leading to a total estimated cost for the pro-
gram of less than $27,000. The cost of the disposing of the col-
lected syringes as infectious waste is now included in the Council
Bluffs solid waste collection contract.
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Table 1. Estimated Number of Syringes Collected through the Council Bluffs Syringe Disposal Program,
1992–2002
Estimated No. Biohazard 30-Gallon 
Calendar Year Estimated No. Syringes Collecteda Containers Collected
1992 8,640 4
1993 38,880 18
1994 56,160 26
1995 62,640 29
1996 77,760 36
1997 95,040 44
1998 84,240 39
1999 84,240 39
2000 105,840 49
2001 84,240 39
2002 (January 1 – June 30) 54,000 25
Total 751,680     348
aBased on estimate of 120 needles per gallon container and 18 1-gallon containers per 30-gallon biohazard box.
Conclusion
In 10 years (1992–2002) of program operation, there were only
two needle-stick injuries among solid waste workers. The program
appears to have helped make the work environment safer for
employees of solid waste handling companies and to have helped
prevent employee injuries and medical expenses resulting from
needle sticks. As a means of diverting community-generated
syringes from the solid waste stream, the Council Bluffs Sharps
Disposal Program may serve as a model for other municipalities.
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Safe Sharps Disposal in
Public Restrooms, Bush
Intercontinental Airport,
Houston, Texas
Julie E. Myers, Susan Eppes, Danni Lentine, and
T. Stephen Jones
With 35 million passengers, Bush Intercontinental Airport in
Houston, Texas, was the eighth busiest airport in the United States
in 2001 (T. Bartlett, deputy director of aviation, Bush
Intercontinental Airport, personal communication, September 12,
2002). The Houston Airport System (HAS) owns and manages the
airport, which includes 63 public restrooms and employs approxi-
mately 700 maintenance and custodial workers (T. Bartlett, per-
sonal communication, September 12, 2002).
In March 1998, the custodial staff started reporting to HAS that
they were encountering needles and syringes (hereafter referred to
as “syringes”), primarily in the public restrooms at Bush
Intercontinental Airport. Staff reported that syringes were most
commonly found in the toilet seat cover dispensers and feminine
products disposal units inside the restroom stalls. Syringes were
sometimes seen protruding through the plastic bags.
These unsafely discarded syringes put custodial staff and solid
waste workers at risk for needle-stick injuries and blood-borne
infections. Although no needle-stick injuries had occurred, HAS
and the airport safety and health director, decided to place sharps
containers in all public restrooms. The containers were installed in
November 1998. The goal was to protect the health and safety of
the employees and travelers in the public restrooms. 
Operation
In these 63 public airport restrooms, heavy plastic sharps dis-
posal units measuring approximately 10" × 12" × 5" are mounted
on the wall outside the restroom stalls no higher than 48 inches
above the floor with unobstructed access in compliance with the
Americans with Disabilities Act requirements. Each unit holds a 1-
gallon sharps disposal insert and locks it in place. The sharps dis-
posal insert has an opening for a horizontal drop (i.e., flip-top lid),
similar to sharps containers used in health care facilities. This
design makes it difficult to remove syringes from the container.
When the insert is full, the top displays a “full” message, and no
more syringes can be introduced.
To discourage unsafe syringe disposal, bright orange decals with
the program’s logo (a syringe with a universal “no” sign) are affixed
to the toilet seat cover dispensers. The decal states, “Please use con-
tainer provided for your convenience” in English and Spanish.
Because they are considered to be at risk for biohazard expo-
sure, all 200 HAS custodial employees received training about
blood-borne pathogens, biohazard spill cleanup, and proper use of
personal protective equipment (PPE; i.e., gown, mask, goggles,
and gloves). HAS produced and uses a training video about blood-
borne pathogens. Only three specially trained employees are
allowed to remove full sharps disposal inserts and replace them
with empty ones. Only one appointed syringe disposal employee
carries out the routine maintenance of the restroom disposal units.
This employee checks the containers and records the percentage
full; all containers are checked at least once a month. All custodi-
al staff are asked to report full sharps containers to the syringe dis-
posal employee. When a container insert is full, one of the spe-
cially trained employees dons PPE, unlocks the metal unit, and
places the syringe disposal insert into a red, labeled, biohazard bag,
which is later transferred to a large cardboard collection box (with
a volume of 3.1 cubic feet) in a designated storage facility at the
airport. A biomedical waste management company picks up the
cardboard storage boxes and disposes of them as infectious waste.
The cardboard storage box holds approximately eight biohazard
bags. Each bag contains one sharps container insert and each full
sharps container insert holds approximately 200 syringes. Most
sharps container units are changed once or twice a year, more fre-
quently in some locations.
Cost
The major cost of the program was for purchasing and mount-
ing the 63 containers (one mountable sharps disposal container
with key plus one sharps disposal insert container) at $30.35 each.
Each new sharps disposal insert container costs about $1.50. The
physical plant maintenance staff of the HAS mounted all of the
containers, absorbing the labor cost of installation. It is difficult to
calculate the cost of the training program because most of the
training is identical to the biohazard preparedness training required
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for all employees. It is similarly difficult to calculate staff time for
this program because the monthly inspections of the sharps con-
tainers take place in the course of other routine activities.
Emptying each container takes about 5 to 10 minutes for an annu-
al total of 5 to 10 manpower hours devoted to this program. The
airport is charged for disposal by the storage box and not by
weight. In 2002, the biomedical waste management company
charged $25 to $30 to dispose of each box, making the entire cost
of disposal for each of the past 2 years approximately $225 to $270
per year. The annual cost of the entire program can be estimated at
$12.42 to $13.07 per restroom.a Charges for staff time maintaining
the program are not included.
Evaluation
In 1998, the first year of operation, the program disposed of
three of these cardboard collection boxes of biomedical waste
(approximately 4,800 syringes). In 1999 and 2000, they disposed
of five boxes each year (approximately 8,000). In 2001 and 2002,
they disposed of nine boxes each year (approximately 14,000). 
The program has not collected data for impact evaluation.
Reports of sharps “sightings” continued after the program began
but at what is believed to be a much lower frequency. One occupa-
tional needle-stick injury was reported since the start of the pro-
gram (compared with none reported before the program). This 2001
injury occurred while a HAS custodial employee was removing a
full, plastic trash bag from a trash receptacle in a restroom. No
problems with the sharps container in this restroom were found.
Obstacles
During the 4 years of the program operation, HAS received
about five telephone calls and letters about the program. All
expressed concern that the airport was supporting injection drug
users and condoning drug use.
Tampering with the equipment has occurred. Custodial staff
report that some program decals have been removed and that
objects other than needles and syringes have been found in the
sharps containers.
Some syringe users may be deterred from using the containers
placed so that they are accessible and easily seen because of con-
cerns that using the container will identify them as a person who
has diabetes or who uses illegal drugs.
Expansion
In 2000, six staff restrooms were added to the program, bring-
ing the total number of restrooms with sharps containers to 69.
Any future HAS contracts for building expansions will require that
all new restrooms have wall-mounted sharps disposal containers.
New Airport Security Measures
After September 11, 2001, the Transportation Security
Administration increased the requirements for manual inspection
of passenger baggage, thereby increasing the risk of needle-stick
injuries to security personnel.1 New civil and criminal penalties
have been established for persons in airports possessing unde-
clared syringes without specific evidence of needing them for
medical purposes.
Conclusion
The HAS program is a model of a program to place sharps con-
tainers in airports and other public places. The program has been
inexpensive and easy to operate. It appears to have reduced the
number of sharps unsafely discarded in trash or hidden in restroom
stalls. It has recovered a relatively small but increasing volume of
sharps. Seeing these sharps disposal containers probably has an
important public health and educational impact—making passen-
gers more aware of the concept of safe syringe disposal.
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aTo estimate the per restroom annual cost, we depreciated the cost of
the wall-mounted sharps container over 4 years ($30.35 per wall-mount-
ed sharps container divided by 4 years equals $7.59), added the cost of
changing the insert 1.04 times a year per restroom (approximately 72 dis-
carded inserts divided by 69 restrooms times $1.50 per insert equals
$1.57), and added the approximate per restroom disposal cost of the bio-
hazard boxes (between $225 and $270 to dispose of 9 boxes, divided by
69 restrooms).
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